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With 250 million reported chronic infections globally, Hepatitis B Virus (HBV) is a major 
human health issue, linked to increased risk for development of hepatocellular 
carcinoma (HCC). Current treatments to control chronic HBV infection remain 
ineffective. New and effective therapies that target the persisting viral molecules are 
needed in order to clear infection. 
 My research aims to understand the role of hepatitis B virus (HBV) in inducing HCC and 
identify novel host molecules that are targeted by HBV. Understanding how HBV 
modifies and manipulates host cellular pathways is critical for the development of 
mechanism based therapeutics.  
Here, I provide a review for the HBV core protein (HBc), its function and the host 
molecules it usurps during infection and pathogenesis. I also identify Polo-like-kinase 1 
(PLK1) as a proviral factor in HBV pathogenesis. I demonstrate by loss of function as well 
as gain of function approaches that PLK1 inhibition suppresses viral replication both in 
vitro and in vivo. I also show that HBc is a phosphorylation substrate for PLK1 in vitro 
and I mapped the PLK1 phosphorylation sites to HBc residues S168, S176 and S178. 
Finally, I used a global proteomics approach to study human HBc interactome identifying 
xvi 
 
potential interacting partners with interesting links to viral pathogenesis. Collectively, 
my research expands our understanding of the role of HBc in HBV pathogenesis and the 




CHAPTER 1. INTRODUCTION 
1.1 Hepatitis B  
The seminal discovery of the Hepatitis B virus by the Nobel Prize winner Baruch 
Blumberg in 1965 marks the birth of the field of HBV virology 1. We have since 
witnessed major breakthroughs in the study of HBV epidemiology, diagnosis, 
pathogenesis, oncogenicity and treatment. These efforts have culminated in the 
development of the HBV vaccine in 1969 by Blumberg and his colleagues which granted 
them a well-deserved Nobel Prize in medicine. Soon afterwards, Dane and his colleagues 
obtained the first electron microscope images of Dane particles, a 42 nm infectious viral 
particles with a distinct inner core 2. Yet with over 5 decades of breakthroughs in HBV 
research, chronic HBV infection claims over 600,000 death annually from the ensuing 
cirrhosis or hepatocellular carcinoma 3.     
1.1.1 Pathogenesis 
Despite these original discoveries, the mechanisms for establishment and 
maintenance of HBV infection remain poorly understood. HBV is one of the most 
efficacious human pathogens having infected over 2 billion people 4. This is due to the 
unique genomic organization of HBV which allows the virus to ‘disguise’ as a 




host’s innate immune response 4. Additionally, the ability of HBV to hijack the cellular 
transcription machinery to replicate efficiently enables the virus to sustain chronic 
infection. HBV is not directly cytopathic and the ensuing liver damage is a side effect of 
the repeated-yet inefficient- attempts of the host’s immunity to suppress the chronic 
infection 5. Based on clinical markers such as serum levels of HBV DNA and HBsAg, 
chronic carriers of HBV are classified into different phases. While the natural history 
varies among chronic carriers, the different stages/phases of infection usually start with 
an immune-tolerant phase, followed by an immune-reactive phase, immune-control and 
finally immune-escape 5. These phases do not necessarily occur sequentially. Factors 
such as patient’s age, gender and immune status collectively dictate if infection would 
be cleared or if it will chronically persist leading to liver fibrosis, cirrhosis and eventually 
hepatocellular carcinoma (HCC). 
1.1.2 Carcinogenesis 
HCC is a major disease ranking 5th among males and 7th among females overall 
cancer 6. Chronic HBV infection has been long described as a major oncogenic agent in 
liver cancer pathogenesis. While the oncogenic role of HBV remains unclear, the 
combination of chronic liver inflammation, apoptosis and regeneration, the 
accumulation of genetic and epigenetic alterations is thought to induce transformation 
7,8. Additionally, HBV DNA integrations into host DNA and the oncogenic co-factor X 
protein provide more direct effectors of transformation 7. While the vaccine against HBV 




to the World Health Organization, with the risk of developing HCC. New and effective 
therapies targeting chronic HBV infection are needed.  
1.1.3 Treatment and prevention 
Current anti-HBV therapies are not sufficient to control chronic infection thus the 
risk for cancer development remains high. Successful and sustained suppression of viral 
replication is essential in order to prevent disease progression and prolong patient 
survival 9. The last decade has witnessed major advances in HBV therapy with the 
introduction of nucleoside analogs as well as interferon-alpha as anti-HBV therapeutics. 
Limitations to the available treatments arise from the side effects associated with 
prolonged interferon treatment and the resistance developed against nucleoside 
analogs in long-term therapy 10,11. Such limitations drive the ongoing research efforts to 
develop novel therapeutics with more sustained suppression of viral replication and 
enhanced viral clearance. Understanding the molecular mechanisms of HBV replication 
is therefore essential for successful treatment. The core protein stands as an important 
target for the next generation of antivirals as it plays multiple roles in the viral life cycle. 
 
1.2 Hepatitis B virus 
1.2.1 Genome organization and structure 
Like other hepadnavirus viruses, HBV is a small encapsidated DNA containing 
virus with a 3.2 kb partially double stranded genome. HBV has a relatively small genome 
with only 4 open reading frames that encode 7 viral proteins. This simplicity of the virion 




several of which have been shown to have pleiotropic roles in the life cycle of the virus 
12,13. The compact nature of HBV also dictates that HBV would adapt to its host’s 
environment by hijacking or mimicking host proteins in order for it to efficiently 
complete its life cycle as well as to evade the immune system. Such mechanisms of 
molecular mimicry and deregulation are common to other viruses 5,14. 
The compact genome of HBV displays a certain degree of complexity with 4 
overlapping open reading frames, a poly-adynelation signal, an encapsidation signal, 2 
enhancers and 4 promoters all tightly regulating viral transcription and replication 15. Of 
the 4 open reading frames of HBV: one encodes the viral polymerase, the preS/S 
encodes the 3 different envelope proteins, the preC/C encodes the core (HBc) and e 
antigens, and finally the smallest one encodes the regulatory X protein 15.  
 
1.2.2 HBV Life cycle 
HBV is a hepatotropic virus that specifically infects liver cells 8. Entry into 
hepatocytes is mediated by the binding of the viral envelope proteins to the human 
sodium taurocholate cotransporting polypeptide (NTCP) receptor (Fig. 1) 16. In the 
cytoplasm of infected hepatocytes, nucleocapsids are released and the HBV genome is 
transferred to the nucleus. Once inside the host cell nucleus, the viral genome is 
converted into covalently closed circular DNA (cccDNA) which serves as a template for 
the transcription of viral RNAs 15. Inside the nucleus of infected cells, the cccDNA 
associates with nucleosomes and assumes chromatin structure 17. Reverse transcription 




site. Pre-genomic RNA (pgRNA) is the largest RNA species transcribed from cccDNA. It 
encodes for all viral proteins by alternative splicing. pgRNA also serves as template for 
reverse transcription of the viral genome. The other viral transcripts encode three viral 
surface proteins, and the small regulatory X protein. HBV replicates through reverse 
transcription 12. Viral reverse transcription takes place in the cytoplasm within the viral 
capsids, a process mediated by the virus-encoded reverse transcriptase in the presence 
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Figure1: HBV life cycle, (Courtesy of Watashi et al., 2014) attachment to the NTCP 
receptor allows HBV entry into hepatocytes. Viral transcription takes place in the 






CHAPTER 2. HEPATITIS B VIRUS (HBV) CORE ANTIGEN (HBC): FUNCTION IN VIRUS 
BIOSYNTHESIS AND HOST GENE REGULATION 
2.1 Introduction 
Hepatitis B virus (HBV) is a major human pathogen that infects the liver, with at 
least 2 billion people infected today, according to World Health Organization 1. While 
90-95% of infected adults clear the infection, the remaining develop chronic infection, 
which increases the risk for developing liver cancer 2. The reason that HBV infection 
persists in 5% of infected adults and over 80% of those infected at birth is still not 
understood 3. In the nuclei of infected hepatocytes, HBV DNA persists as a covalently 
closed circular DNA molecule (cccDNA) which assumes chromosome-like structure, 
serving as template for viral transcription. The HBV genome is small, 3.2 kb, expressing 
four overlapping RNAs, with open reading frames encoding viral polymerase (P), 
regulatory X protein (HBx), surface (S) and core (HBc) antigens. In this review, I focus our 
discussion on the function of HBc protein. HBc is viewed classically as a structural 
protein since it self-assembles to form the viral capsid. Significantly, accumulated 
evidence supports that HBc function extends beyond its structural role, having a role in 
nearly every step of HBV replication. Indeed, HBc has been implicated in subcellular 
trafficking, reverse transcription as well as epigenetic regulation of viral and host 




review aims to highlight how the unique structure as well as post-transcriptional 
modifications of HBc help explain its multilayer roles in HBV biosynthesis and host gene 
expression. 
2.2 HBc structure 
HBc is a 21 kDa protein with distinct N- and C-terminal domains connected by a 
hinge region 6,7. HBc assembles into dimers forming icosahedral capsid particles 8. Each 
capsid is composed of 120 HBc dimers, and interestingly capsid formation takes place in 
the absence of other viral proteins 8. The full-length protein consists of 183 amino acids. 
The N- terminal domain of HBc, spanning amino acid residues 1-140, is the capsid 
assembly domain, and indeed truncated HBc 1-140 is sufficient for self-assembly into 
particles 8. On the other hand, the C-terminal domain (CTD) of HBc, spanning amino 
acids 141-183, is dispensable for viral assembly. Interestingly, capsids lacking the last 34 
amino acids maintain assembly capacity in vitro but do not support genome replication 
9, suggesting a role for the CTD in this process. Of the 34 amino acid residues that 
comprise the CTD, 14 are arginines and at least 7 other residues are serine/threonines, 
putative phospho-acceptor sites.  
Studies to understand the role of the HBc CTD in HBV replication have led to the 
proposal that electrostatic interactions between the highly basic CTD in assembled 
capsids and the viral RNA/DNA regulate reverse transcription of HBV DNA 10. Charge-
driven destabilization of capsids, either by relaxed circular DNA (rcDNA) maturation 
and/or changes in post-transcriptional modifications of CTD, for example by 




other hand, studies by Lewellyn et al favor the interpretation that the HBc CTD serves as 
a nucleic acid chaperone, i.e., CTD mediates changes in nucleic acid structure that 
enable pregenomic RNA (pgRNA) reverse transcription and rcDNA biosynthesis 15 . 
However, these two models are not mutually exclusive, since the chaperone function of 
HBc may be dependent on the overall charge of CTD. 
A recent study employing cryo-EM scanning has determined a high-resolution 3D 
structure of assembled HBV capsids 16. It was proposed that the HBc CTD shuttles 
between the interior and exterior of capsids, evidenced by the presence of CTDs on the 
exterior of some capsids, and RNA-bound CTD to the interior of other capsids 16. This 
model is attractive because it provides a mechanism of how HBc can be accessible to 
interact with proteins involved in intracellular trafficking, capsid maturation, and 
envelopment, thus addressing the many roles of HBc. In this model, the positively 
charged CTD tail interacts transiently with the negatively charged Asp2 and Glu43 that 
line the local three-fold channel that presumably allows movement of CTD tails in and 
out of capsids 16. Studies supporting the presence of CTD in the capsid exterior include 
the cryo-EM study 16 as well as biochemical binding assays that demonstrate a nucleic 
acid sensitive and transient exposure of the CTD tails 17,18. Specifically, RNA filled capsids 
failed to bind serine arginine protein kinase  (SRPK), a host chaperone that binds full 
length HBc capsids but not HBc 1-149 capsids 17, suggesting dynamic exposure of CTDs are 
mediated by CTD-nucleic acid interactions. These results also agree with biochemical 
studies showing that the CTD tails of assembled capsids were sensitive to proteases, and 




remains unknown, although a role of phosphorylation has been suggested by site 
directed mutagenesis of HBc 18. However, a more detailed analysis of the effect of CTD 
phosphorylations and dephosphorylations in CTD shuttling is needed. 
2.3 HBc, a nucleic acid chaperone 
Nucleic acid chaperones are proteins that catalyze structural rearrangement of 
genetic material into a proper conformation 21. Binding of nucleic acid chaperones to 
their targets is characteristically weak, transient, lacks sequence specificity, and requires 
no ATP hydrolysis 21,22. A wide array of viral proteins display nucleic acid chaperone 
activity, for example, nucleo-capsid proteins of viruses including HIV 23, Dengue virus 24, 
and Hepatitis Delta virus 25. The CTD of HBc contains an arginine-rich domain that 
resembles histone tails with more than 50 % of the residues being arginines 15. The CTD 
binds to nucleic acids in vivo due to its positive charge 9,26. In addition to the 
characteristic positive charge, the CTD is also structurally disordered 16,27, another key 
feature of nucleic acid chaperones 28. Notably, the CTD has also been mapped to the 
interior of assembled capsids by cryo-EM 29. The localization of CTD to the interior of 
capsids and its ability to bind nucleic acids in vivo support the model that CTD works as a 
nucleic acid chaperone. The nucleic acid chaperone activity of HBc CTD was recently 
confirmed in vitro using recombinant full length HBc as well as CTD synthetic peptides 27. 
HBc CTD facilitated annealing and unwinding of DNA and enhanced hammerhead 
ribozyme cleavage in vitro, rendering HBc CTD a bona fide nucleic acid chaperone 27. 




difficult to demonstrate the nucleic acid chaperone activity of HBc in vivo, without 
disturbing the other HBc functions. 
2.4 HBc localization 
Studies investigating the subcellular localization of HBc showed that its 
subcellular localization is cell-cycle dependent 30,31. The amount of core protein in the 
nucleus increases in G1 phase, diminishes in S phase and increases again to detectable 
levels in non-proliferating cells 30. HBc shuttles between cytoplasm and nucleus rapidly 
and continuously 32. Although HBc is 21kDa, suggesting passive transport to and from 
the nucleus, it is unknown whether in infected cells HBc that is not assembled into 
capsids exists as a monomer. Thus, the signals that modulate HBc import and export 
from the nucleus are probably distinct from those that guide transport of assembled 
HBc into viral capsids.  
Accumulating evidence suggests the CTD tail is responsible for directing HBc 
subcellular localization 32–34. Several studies have attempted to map the nuclear 
localization sequence (NLS) to the arginine repeats of CTD, however the results are 
conflicting probably due to the redundancy of arginine repeats in the CTD 34–36. 
Recently, an exhaustive mutagenesis analysis of the CTD localized the NLS sequence to 
the 1st and 3rd arginine repeats, while the 2nd and 4th repeats contained the cytoplasmic 
retention signals (CRS)- highlighted in Fig. 1 32. The presence of more than one NLS in a 
protein is known to maximize the import efficiency 37,38. However, one must consider 




assembled HBc in viral capsids. Other viral proteins such as the ICP27 of herpes simplex 
virus type 1 (HSV-1) 38 and the NS1 of Influenza 39 also contain multiple NLS sites. 
The dynamic positioning of HBc CTD in assembled capsids makes it quite 
challenging to identify the different signals regulating HBc transport. Nuclear export of 
HBc resembles ICP27 of HSV-1 and EBNA1 of Epstein Barr virus (EBV) in that they all bind 
to the protein and RNA export factor TAP, and all contain the characteristic arginine rich 
domains (Fig. 1) 40. Since the subcellular localization of ICP27 and EBNA1 are regulated 
by arginine methylation 41,42, it is intriguing to propose that HBc localization is driven by 
a similar mechanism. However, it is not yet known how the arginine repeats of CTD 
contribute to its subcellular localization, a hypothesis worthy of future investigation.  
The contribution of the HBc CTD to capsid localization is still not well 
understood. The ambiguity is based on the long-standing notion that the CTD localizes 
to the interior of capsids based on cryo-EM studies 29. Furthermore, CTD binds nucleic 
acids and has a well-documented role in pgRNA packaging 9. However, more recent 
studies point towards a dynamic model where the HBc CTD shuttles between the 
interior and exterior of the capsid 17,18,32. According to this model, exposure of the CTD 
to the capsid exterior would then allow interaction with cellular factors to direct the 
subcellular localization of capsids. Transport of cargo across the nuclear envelope is 
often facilitated by regulatory phosphorylation/ dephosphorylation of specific residues 
43. Earlier studies reported that phosphorylated HBc was only observed in the 
cytoplasm, based on subcellular fractionation of in vivo 32P-radiolabed cell lysates 30. 




vs. assembled HBc in capsids remains to be understood. The contribution of HBc 
phosphorylation to the nuclear import of capsids likely recapitulates known import 
mechanisms for other viral proteins, including EBNA-1 41,44 and SV40 T-antigen 45. 
Specifically, phosphorylation of EBNA-1 increases its affinity for the import adaptor 
importin alpha 5 which mediates the nuclear transport via interaction with importin 
beta 44. SV-40 large T antigen has the best characterized NLS, and phosphorylation 
upstream of the classic NLS enhances nuclear import 45. Thus, the phosphorylation 
status of HBc CTD could facilitate interaction with nuclear pore complex components. 
Indeed, in pulldown experiments using HBc CTD-GST fusion proteins, serine to alanine 
substitution at the three serine/proline (S/P) sites (Fig. 2) showed increased binding to 
importin alpha 46. While the in vivo relevance of such observations remains to be 
determined, other groups have reported that HBc phosphorylated in vitro by PKC in 
assembled capsids preferentially bound importin beta 12,47. However, the 
phosphorylation sites of HBc required for interaction with importin beta had not been 
mapped47. Furthermore, it is unresolved whether PKC is the in vivo kinase that 
phosphorylates HBc CTD 48,49. Thus, more detailed studies are needed to address this 
issue, employing well-characterized and functionally documented mutants of HBc. 
Alternatively, as shown by Schmitz et al, capsid maturation could be the driving 
force of HBV nuclear import 50. At the nuclear pore, HBc capsids dissociate into dimers 
followed by entry into the nucleus 11. Mature capsids directly interact with nucleoporin 
153 (Nup153), an essential component of the nuclear basket that facilitates nuclear 




disintegration followed by release of viral genomes into the nucleus 50. Interestingly, 
capsids with immature genomes (i.e., RNA- filled capsids) were halted at the nuclear 
pore. Recently, it was reported that serine to glutamate substitutions at the 3 S/P sites 
of the HBc CTD (Fig. 2) reduced CTD exposure to the exterior of capsids suggesting a role 
for these phosphorylations in directing CTD exposure inside or outside of the capsid 18. 
However, the mechanism responsible for distinguishing mature capsids vs. RNA-filled 
capsids is not fully understood. Phosphorylation of HBc, shuttling of the HBc CTD to the 
interior vs. exterior of capsids, and maturation of the genome may regulate exposure of 
different localization signals to host transport machinery. Such a multilayer and dynamic 
regulation network can best explain the difficulty in deciphering the mechanism of HBc 
subcellular localization during the HBV life cycle. To understand these dynamic 
regulatory networks, it is essential to gain better understanding of HBc structure, HBc 
interacting partners, and HBc post-translational modifications. 
2.5 HBc phosphorylation 
Since the HBV genome does not encode a protein kinase, endogenous kinases 
could mediate post-translational HBc modifications 51–53. Protein kinase C (PKC)54,55, 
serine arginine protein kinase 1 (SRPK1) 48 and cyclin-dependent kinase 2 (CDK2)56 have 
been suggested as endogenous kinases that associate or packaged within viral capsids. 
The robust phosphorylation of HBc has been demonstrated in vivo by 
phosphoproteomic approaches 17 and in vivo labeling with 32P-orthophosphate 57. The 
HBc CTD contains multiple serine/threonine phosphoacceptor sites which are 




have identified at least 7 conserved serine and threonine sites that are phosphorylated 
in vivo 17. Notably, proline-directed serine (S/P) sites at positions 155, 162 and 170 are 
highly conserved and several S/P kinases have been reported to phosphorylate these 
sites (Fig. 2) 48,56. Putative kinases include SRPKs 48, Glyceraldehyde-3-phosphate 
Dehydrogenase protein kinase (GAPD- protein kinase)58, PKC 54, and an unknown kinase 
of 46 kDa 59 . Yet none of those studies have mapped the phosphorylation to specific 
sites, with the exception of SRPK1 and 2 at the 3 S/P sites 48. However, the exact 
contribution of the SRPK-mediated phosphorylation to viral replication is not 
understood, because although overexpression of SRPK1 or SRPK2 impaired HBV 
replication, this effect was independent of kinase activity 60. These results support that 
the SRPK-mediated phosphorylation of HBc observed in vitro is due to promiscuous 
substrate specificity of these kinases 56, and that SRPKs exert other functions affecting 
viral replication. For example, SRPKs could act as non-canonical chaperones in capsid 
assembly17. Regarding PKC-mediated HBc phosphorylation, inactivation of PKC led to 
defective capsid envelopment but had no effect on genome maturation 55. There is 
however lack of consensus on PKC being the candidate host kinase since specific 
inhibition of PKC had no effect on CTD phosphorylation 48,49.  Recently, CDK2 was shown 
to phosphorylate the core protein of HBV both in vitro and in vivo 56. Intriguingly CDK2 
inhibitors had no observable effect on viral replication 56. The absence of such effect 
could be due to lack of specificity of the chemical inhibitors or more likely due to 




other kinases via expression of shRNAs could potentially elucidate their contribution to 
HBc phosphorylation and viral replication.  
Although the kinases that phosphorylate HBc are still to be determined, 
phosphorylations of HBc do regulate its function at many levels 47,57,61–63. Specifically, 
phosphorylation and de-phosphorylation of the HBc protein is required for capsid 
maturation as demonstrated by mass spectrometric analysis and site-directed 
mutagenesis studies of HBc 13,14. Phosphorylation of different serine residues of HBc CTD 
regulates reverse transcription, pgRNA encapsidation, DNA synthesis, subcellular 
localization  and virion secretion 13,14,61,64. HBc phosphorylation is also required for the 
chaperone activity of the CTD 27. It was also reported that HBc phosphorylation status 
can influence capsid stability (17), since capsids with glutamate phospho-mimetic 
substitutions at the 3 S/P sites (S/P to E/P) were more stable than wildtype capsids. It is 
likely that during various stages in the life cycle of HBV or as a function of the metabolic 
and proliferative status of the infected hepatocyte distinct kinases target HBc 
phosphorylation, perhaps in an overlapping manner. The identification of those kinases 
and the mechanisms by which they regulate HBV replication is of great significance and 
will provide valuable targets for mechanism-based therapeutics.  
Our studies have identified the mitotic Polo-like-kinase 1 (Plk1) as another 
cellular kinase that phosphorylates HBc in vitro (Diab et al 2016). Plk1 substrates are 
usually primed by phosphorylation at S/P directed sites mediated by CDKs, including 
CDK1 or 2 65. Recombinant HBc as well as immuno-purified HBc from transfected 




mapped the phospho-acceptor sites to the S168, S176 and S178 (Fig. 2) (Diab et al 
2016), all of which have been identified as in vivo phosphor-acceptor sites by an 
unknown kinase 57. Remarkably, inhibition of Plk1 by specific chemical inhibitors or 
siRNA-mediated knockdown of Plk1 suppressed viral replication, suggesting that HBc 
phosphorylation by Plk1 is functionally important in virus biosynthesis (Diab et al 2016). 
Significantly, I made the interesting observation, in accordance with the known 
substrate preference of Plk1 that alanine substitutions at the 3 S/P sites (S/P to A/P) 
lead to loss of Plk1 phosphorylation in vitro. By contrast, Plk1 phosphorylation was 
robustly recovered in phospho-mimetic mutants, containing serine to aspartic acid 
substitutions at all three S/P sites (Diab et al 2016). This suggests that CDK2 functions as 
the priming kinase for HBc, mediating the phosphorylation of the S/P sites which in turn 
enables the subsequent phosphorylation by Plk1 65. Based on our results that Plk1 is a 
positive effector of HBV replication, a mechanistic understanding of the role of Plk1 
phosphorylation of HBc in HBV replication promises a great therapeutic potential. So far, 
Plk1 is the sole host kinase whose chemical inhibition results in impaired HBV replication 
in vivo at concentrations comparable to direct acting agents, including interferon- and 
entecavir (Diab et al, 2016). 
2.6 HBc and interaction with host factors 
 Almost every stage of the HBV life cycle is modulated by HBc. With such intricate 
function, HBc has evolved to interact and modulate several host proteins. For example, 




vitro and in vivo 66. On the other hand, the host HSP40 protein also binds but de-
stabilizes HBc by accelerating its degradation 67. The binding of HBc to other cellular 
factors such as NIRF, an E3 ubiquitin ligase, is implicated in HBc degradation 68. Thus, 
dynamic interactions of HBc with host chaperones regulate both HBc stability and capsid 
assembly 66–68.  
Viruses hijack host RNA processing machinery 69,70 and HBV is no exception. HBc 
utilizes the nuclear export factor 1 (NXF1/p15) and transcription export (TREX) 
machinery for nuclear export as ribonucleoprotein complex along with the viral pgRNA 
40; however, TREX mediated export of HBc and pgRNA are independent of each other 40. 
Other virus that hijack the NXF1/p15 pathway for mRNA processing and export include 
EBV 71 and HSV- 1 72. However, depletion of different TREX components has no apparent 
effect on accumulation of viral DNA, suggesting redundancy among host factors utilized 
by the virus.  
Another class of host proteins commonly targeted by viruses is serine, arginine 
rich-proteins 73 which, along with the kinases (SRPKs) that phosphorylate them, play 
central roles in alternative RNA splicing 74.  Intriguingly, HBc CTD resembles serine, 
arginine-rich proteins and it is not surprising that SRPKs associate HBc 17,48,60. 
Interestingly, mass spectrometry analyses of HBc interacting proteins identified SRPK1 
as well as several known SRPK1 interacting partners, including SRSF1, SRSF9, DHX9, 
CDKN2A, DDX21 and DDX50 (Diab et al unpublished results). The functional significance 
of these HBc interactions for the viral life cycle is unknown and worthy of investigation. 




processing and production of its own viral RNA. It is also likely that such interactions 
might allow HBc to interfere with host gene expression. This has been evident in the 
case of the E1^E4 protein of the human papilloma type 1 virus which not only binds to 
SRPK1 but also inhibits phosphorylation of its host serine arginine substrates 75. A yeast 
two-hybrid screen of a human liver cDNA library identified the human protein GIPC1 as 
another HBc interaction partner 76, but the significance of such interaction remains to be 
determined. GIPC1 contains a PDZ domain, a protein-protein interaction domain 
reviewed in 77. PDZ-containing host proteins are commonly targeted by viral proteins; 
examples include the Tax protein of the T-cell leukemia virus type 1 78 and the E6 
protein of the human papilloma virus type 18 79. 
It is reasonable to speculate that HBc exerts its various roles by interacting with 
specific host factors at different stages of the viral life cycle in a phosphorylation 
dependent manner. Indeed, phosphorylation of HBc has been reported to dictate some 
of HBc-host interactions. For example, binding of HBc to the nuclear pore complex is 
dependent on HBc phosphorylation 47,50,63. Phosphorylation of HBc is required for the 
interaction with importin beta47, whereas only the alanine substitution mutant at the 
S/P sites of HBc CTD showed specific binding to importin alpha 46. Moreover, un-
phosphorylated HBc was found to preferentially bind host proteins B23 and I2PP2A, 
while phosphorylation diminished these interactions 63. A better understanding of the 





2.7 HBc as a regulator of transcription 
In chronically infected patients, HBc is detected both in cytoplasm and nucleus of 
hepatocytes 80,81. In vitro models of HBV infection also show nuclear as well as 
cytoplasmic localization of HBc. Nuclear localization of HBc has been linked to high 
viremia and deficient immune response in biopsies from HBV infected patients 81–83. 
These results prompted investigations on the nuclear function of HBc, both in terms of 
virus biosynthesis and effects on host gene expression.  
In the nucleus of infected cells, the viral cccDNA assumes chromatin-like 
structure in association with histone and non-histone proteins, along with viral HBx and 
HBc proteins 84,85. Association of HBc with the cccDNA mini-chromosome was reported 
to alter nucleosome spacing 84. Furthermore, it was reported that HBc preferentially 
associated with CpG island 2 of the HBV genome that overlaps enhancers (Enh) I and II 
involved in viral transcription; HBc binding to CpG island 2 positively correlated with the 
rcDNA/cccDNA ratio and serum levels of HBV DNA in infected patients 86. HBc also acts 
as transcriptional activator of the HBV pre-Core promoter by enhancing binding of NF-kB 
upstream of viral Enh II 87. However, how HBc modulates the functions of the cccDNA 
mini-chromosome is not yet understood. Since HBc is also essential for viral DNA 
replication, a definitive genetic approach involving mutagenesis or depletion of HBc is 
not feasible to delineate its role in cccDNA mini-chromosome functions.  Therefore, 
novel approaches are needed to specifically target nuclear HBc, influencing its capacity 





In terms of effects of HBc on host gene expression, HBc enhanced cAMP-
Response-Element (CRE)-mediated transcription via the CRE/CREB/CBP pathway 88 in a 
manner similar but weaker to previously reported HBx-mediated CRE activation 89,90. 
HBc may also function as a transcriptional repressor of host genes. For example, binding 
of HBc to E2F1 reduced the DNA-binding ability of E2F1 at the p53 promoter, thereby 
inhibiting p53 transcription 91. In hepatoma cell lines expressing the core protein, HBc 
blocked the human death receptor 5 (DR5) by repressing its promoter, and inhibition of 
DR5 desensitized hepatocytes to TRAIL-induced apoptosis 92. These results suggest a 
role for HBc in the development of chronic infection by preventing hepatocyte death via 
blocking DR5 expression. The gene regulatory function of HBc may have evolved as an 
attempt by the virus to evade host immunity. HBc has been shown to downregulate IFN-
induced host antiviral responses in hepatoma cell lines, by interacting with the 
promoter of MxA, an INF-inducible gene widely implicated in antiviral response 93,94. 
However, these conclusions must be further confirmed by determining in vivo 
association of HBc with MxA promoter, in physiological cellular contexts of HBV 
infection. Interestingly, MxA has been recently shown to inhibit HBV replication by 
direct interaction with HBc, preventing capsid formation 95, yet another example of 
antagonism between viral and host proteins. 
In continuing effort to understand the effect of HBc on host gene expression, recent 
studies have generated the genome-wide profile of HBc in HBV-infected hepatocytes 
employing chromatin immunoprecipitation microarray studies (ChIP-on-chip). These 




binding to HBc 96. However, further studies are necessary to understand the functional 
significance of HBc binding to the host genome in effecting HBV-mediated disease 
pathogenesis. Toward this goal, Lucifora et al recently demonstrated interaction of 
nuclear deaminases APOBEC3A and APOBEC3B with HBc-bound cccDNA in host nucleus, 
leading to cccDNA deamination and degradation 97. Whether HBc recruits these nuclear 
deaminases to host genes is unknown and of great importance, given the role of 
APOBEC proteins as cancer driver genes in humans 98–100. 
2.8 Unanswered questions and future directions 
The core antigen (HBc) is involved in various aspects of HBV biosynthesis: formation 
of the viral capsid, pregenomic RNA (pgRNA) encapsidation followed by its reverse 
transcription, and as a component of the viral mini-chromosome contributing to its 
chromatin structure. The unique structure of HBc CTD and its modifications, mainly 
phosphorylation, are essential for viral biosynthesis. Therefore, HBc seems to be an 
excellent target for mechanism-based therapeutics. Yet many questions remain 
unanswered when it comes to HBc biology. A definitive answer on the identity of the 
kinase/kinases responsible of HBc phosphorylation in vivo is yet to be determined. 
Additionally, systematic investigation of HBc-host interactions both in the context of 
physiologic infection as well as a single molecule will expand our knowledge not only of 
how HBc is regulated by post-translational modifications, but also how HBc regulates 
host genes. Moreover, given the unique structure of the CTD, the seemingly 
promiscuous affinity of HBc for RNA, and the observed interaction of HBc and 




interactions between HBc and host RNAs. Thus I propose that HBc, as an RNA-
interacting protein associates and regulates host RNAs and in particular long non-coding 
RNAs (lncRNA). Accumulating evidence supports the regulatory role of lncRNAs in 
cellular gene expression 101; whether HBc/ lncRNA interactions also exert a role in 
hepatocyte physiology and virus biosynthesis is presently unknown 102 and the topic 
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Figure 2: Arginine rich motifs of different viral proteins are characterized by the 
abundance of arginine residues within short 10-20 residues. The arginine rich domain of 
the HBc protein has distinct nuclear localization and cytoplasmic retention signals. 
 
 
Figure 3: HBc C-terminal domain (CTD) is a phosphorylation substrate for CDK2 and Plk1 




CHAPTER 3. MATERIALS AND METHODS 
3.1 Cellular models 
3.1.1 HepaRG cell lines 
3.1.1.1 HepaRG cell culture:  
- Proliferating HepaRG cells were maintained in complete William’s medium 1 
containing: 
 William’s E medium GIBCO (500ml bottle, stored @4°C) 
 50ml of HighClone FetalClone II, U.S. Origin, (10% final), stored and aliquoted @-
20°C, 
 Add 5ml of penicillin/streptomycin GIBCO (100 units/ml penicillin, 100 µg/ml 
streptomycin, aliquoted and stored @-20°C) 
 5ml of GlutaMax 100X GIBCO (stored @4°C) 
 250µl of human insulin solution (5 µg/ml final, I-9278, 5ml SIGMA) stored @4°C 
 500µl of hydrocortisone (50 µM final conc.) 
 
Note: Hydrocortisone hemisuccinate (Sigma H2270-100MG or Stem Cell Technologies 
07904) hydrocortisone hemisuccinate is prepared in sterile PBS (resuspend in 4ml of 
PBS), 500µl aliquoted and stored @-20°C. 
- To differentiate HepaRG cells, cells were not passaged for 2 weeks and media 
was changed twice a week. After 2 weeks, cells were supplied with proliferation 





- A healthy monolayer of differentiated cells was obtained following this 
procedure and was evaluated using phase-contrast microscope.   
  
3.1.1.2 HepaRG-TR-PLK1 cell lines:  
HepaRG cell lines stably expressing the tetracycline repressor (TR) in an inducible 
manner were obtained as described 2. HepaRG-TR cell lines over expressing wild type 
PLK1, HepaRG-TR-PLK1WT, and constitutively active (CA) PLK1, HepaRG-TR-PLK1CA, were 
constructed by transducing HepaRG-TR cells with a lentiviral vector (pLenti4/TO) 
conferring zeocin resistance and containing either version of PLK1. PLK1WT or PLK1CA 
transgenes were cloned into pLenti4/TO vector under the control of the tetracycline-
regulated (tet-on) promoter. Protein expression was confirmed by western blotting 
using PLK1 antibody and following standard protocol.    
Note: For modified HepaRG, add corresponding antibiotic for selection (Zeocin 
INVITROGEN 200µg/ml or Blasticidin INVITROGEN 20µg/ml). 
3.1.1.3 Infection in HepaRG cells and Primary Human Hepatocytes 
This protocol was used to carry out HBV infection in differentiated HepaRG cells as well 
as primary human hepatocytes. 
- Calculations are for a single well of 12-well plate with an MOI of 100 and could 
be scaled up based on the surface area to fit other platforms. 
- For each well, 500 L of complete Williams medium containing 5% FBS and 2% 




- For mock infection, 500 L of medium without virus were used. 
- Calculations of the required amount of virus were made according to Table 1 
-  For inoculation, diluted virus was added to the cells and incubated overnight 
(16h max) at 37°C incubator. 
- The following morning (Day1) the inoculum was removed and the cells were 
washed 3x with wash buffer and fresh complete William’s medium 
supplemented with 5% FBS and 2% DMSO was added. 
- Day 4 after infection, the medium was changed. 
Day 7 infection reaches plateau and viral parameters could be analyzed using standard 
protocols. 
 
3.1.2 HepG2-NTCP cell line and infection 
- HepG2hNTCP cell line (A3 clone) was obtained from Prof. Dr. Urban 3. HepG2hNTCP is 
derived from HepG2 cell line and has been stably transduced by lentivirus 
encoding human sodium taurocholate co-transporting polypeptide (NTCP) under 
puromycin selection rendering them susceptible to HBV infection 3. Cells were 
cultured in culture medium (DMEM 4.5g/L glucose +Glutamine, 10% FBS and 100 
units/ml penicillin, 100 µg/ml streptomycin) and supplemented with 5µg/mL of 





- After infection, cells were maintained in replication medium (culture medium 
supplemented with 2.5 % DMSO. 
- For infection, cells were inoculated with desired MOI of concentrated HBV (MOI 
100 to 500 to achieve 20% to 100% infection efficiency) in presence of 4% PEG in 
culture medium (alternatively replication medium). 
- Inoculum was removed after 16 hours incubation and cells were washed 3x in 
wash buffer and finally were kept in replication medium. 
- Fresh replication medium was added every 2 days. 
- Viral replication was measured by ELISA for HBe after day 7 of infection following 
standard protocol. 
3.2 Production of HBV inoculum in HepG2.2.15 cells: 
3.2.1 Materials 
- HepG2.2.15 cells 4 
- Collagen I (Gibco, A10483-01) 
- DMEM 4,5 g/L glucose (Gibco, 11965126) 
- FBS 10% final  
- Pen/strep (Gibco) 
- Na pyruvate (Gibco) 
- DMSO for cell culture (Sigma) 
- G418  
- PEG8000 (Sigma) at 40% in PBS. 
 
3.2.2 Protocol 
- HepG2.2.15 cells, a hepatoblastoma cell line with 4 integrated copies of HBV 
genome (PMCID: PMC304350) under G418 selection, were grown in growth medium 




penicillin, 100 µg/ml streptomycin, 250 g/mL G418), on pre-collagenated cell 
culture flasks. Cells were passaged with 1/3 dilutions for propagation and 
maintenance. 
- Multiples of 175 cm2 cell culture flasks were grown to 90% confluence in growth 
medium before switching to production medium. 
- When cells reached confluence, cells were washed and replenished with 
production medium (DMEM, 2% FBS, 2%DMSO, 1mM Na pyruvate, 100 units/ml 
penicillin, 100 µg/ml streptomycin, without G418 as selection is no longer 
necessary at this step). 
- Cells were replenished with production medium every 3-4 days and old medium 
was collected for concentration of virus and kept at 4°C until sufficient amount 
was secured (1 L).  
- Cells were maintained in production medium for 2-3 weeks or until cells started 
to detach from the monolayer. 
- Collected media was filtered (0.45 micron) to get rid of cell debris and 1x sodium 
bicarbonate (Gibco) was added to stabilize pH. 
- Virus titer before concentration is approximately 10^8 vge/mL. 
- 40 % PEG8000 (sigma) stock was prepared and filtered (0.2 micron), collected 
media with final conc. 8% PEG was incubated overnight at 4°C while shaking 
gently to facilitate the concentration of the virus. (Each 50 mL falcon tube had 




- A pellet of virus/PEG is obtained by centrifugation at 5000 g for 45 minutes at 
4°C 
-  Pellets were re-suspended in 500 L of OptiMEM media, and were left to 
dissociate overnight at 4°C. 
- The following morning, the re-suspended pellets were passed through 200 L 
filter tips several times until completely re-suspended.  
- All aliquots were aggregated and re-aliquoted into 500 µL and stored at – 80 °C. 
- An aliquot of 25 L was used for titration of virus. Viral DNA was extracted from 
the sample using High Pure Viral Nucleic Acid Kit (Roche, 11858874001) 
following manufacturer protocol.  
- 5.0 and 0.5 L of eluted DNA were used in qPCR reaction using primers for HBV 
genomic DNA to estimate viral genome equivalents. Ct values were compared to 
another virus DNA sample with a pre-determined concentration.  Alternatively, a 
standard curve was generated by serially diluting HBV DNA vector starting with 1 
ng, 0.1 ng, 0.01 ng etc…. (1 ng of genomic HBV DNA contains approximately 10^8 
copies). 
- Number of HBV molecules in 5L (vge) X dilution (5x) 
                                                             = concentration (in vge) in the 25 L of purified inoculum 
X 40 
= concentration in vge per mL 






cell) x # cells /well
[ ] in vge/ml of inoculum
=  volume in mL  x 1000 if you want it in µL 
- Only virus titer of 2x 10^9 or higher were used for infection assays. 
- A functional assay was performed to evaluate the titer of the generated virus by 
infecting HepG2-NTCP cell with 2, 5, 25, 50, 100 L of the newly concentrated 
virus. Infection efficiency was evaluated by ELISA (for HBe) and qPCR (for 




Table 1: Calculating MOI 100 for a single well in a 12 well plate 
Mix for 12 wells 
Estimated number of cells= 1x106 cell/well 
MOI 100= 1.108 vge/well 
Final concentration Cf = 2.108 vge/mL 
Vf = 0.5 ml (per well) 
Vp = … mL 
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CHAPTER 4. POLO-LIKE-KINASE 1 IS A PROVIRAL HOST-FACTOR FOR HEPATITIS B 
VIRUS REPLICATION: THERAPUTIC IMPLICATIONS 
4.1 Abstract 
Background and aims:  Chronic Hepatitis B Virus (HBV) infection is a major factor in 
hepatocellular carcinoma (HCC) pathogenesis, with nearly 250 million people chronically 
infected with HBV. Current treatments for HBV infection and HCC are ineffective. 
Herein, I identified cellular Serine/Threonine Polo-like-kinase 1 (PLK1) as a positive 
effector of HBV replication. The aim of this study is to demonstrate the proviral role of 
PLK1 in HBV biosynthesis and explore PLK1 as an antiviral target. 
Methods: To determine the role of PLK1 in HBV biosynthesis, I employed physiologically 
revenant HBV infection models of Primary Human Hepatocytes (PHH) and differentiated 
HepaRG cells, in conjunction with pharmacologic PLK1 inhibitors, siRNA-mediated 
knockdown of PLK1, and overexpression of constitutively active PLK1(PLK1CA). In 
addition, humanized liver FRG mouse model was used to determine antiviral effect of 
PLK1 inhibitor BI 2536 on HBV infection in vivo. Lastly, in vitro PLK1 kinase assays and 
site-directed mutagenesis were employed to demonstrate HBV core antigen (HBc) is 
PLK1 substrate. 
Conclusions. I demonstrate HBV infection activated cellular PLK1 in physiologically 




50nM) or siRNA-mediated knockdown of PLK1 suppressed, whereas overexpression of 
PLK1CA increased HBV DNA biosynthesis, supporting PLK1 effects on viral biosynthesis 
are specific and PLK1 is a proviral cellular factor. Significantly, BI 2536 administration to 
HBV-infected humanized liver FRG mice suppressed HBV infection, identifying PLK1 as a 
novel antiviral target. Although how PLK1 regulates virus biosynthesis remains to be 
further delineated, our studies identified HBc as a PLK1 substrate in vitro, and mapped 
PLK1 phosphorylation sites. 
4.2 Introduction  
Chronic hepatitis B virus (HBV) infection is an independent risk factor for 
development of hepatocellular carcinoma (HCC)1,2. Liver cancer is the 5th and 7th most 
common cancer worldwide according to gender, and the 3rd in terms of death. With 
approximately 250 million people chronically infected with HBV, according to the latest 
World Health Organization (WHO) estimation, many patients with chronic hepatitis B 
(CHB) are expected to progress to HCC, despite existing therapies1. Although a 
prophylactic vaccine is available, new infections still happen because vaccination 
campaigns are not always well-implemented, and the vaccine it is not always 100%2. 
Furthermore, children born of infected mothers still become chronically infected in 
endemic areas2. Current treatments include use of Peg-IFN and/or antiviral nucleoside 
analogs; the latter require life-long administration, which can result in viral resistance 
when drugs with low genetic barrier are used3. New and effective therapies are urgently 
needed3. In particular, drugs that target both viral replication and prevent neoplastic 




Replication of HBV within hepatocytes involves both nuclear and cytoplasmic 
events4. Following viral entry, nucleocapsids are transported to the nucleus, releasing 
the viral DNA and core/capsid protein (HBc) into the nucleoplasm. There, the viral 
genome, initially a relaxed-circular partially-double-stranded DNA (rcDNA), is converted 
into covalently-closed-circular dsDNA (cccDNA), responsible for viral persistence. This 
nuclear form of the genome serves as template for viral RNA transcription, including of 
pre-genomic RNA (pgRNA)4. In the cytoplasm, pgRNA interacts with HBV polymerase, is 
packaged into capsids where it is reverse-transcribed to generate newly synthesized 
rcDNA4. HBc plays an essential and dynamic role in HBV biosynthesis, including selective 
binding to pgRNA in association with viral polymerase, encapsidation and reverse-
transcription of pgRNA, transport of mature capsids to the site of viral envelopment for 
virion generation, and transport to the nucleus for recycling5. Recent studies 
demonstrated this dynamic interplay between HBc structure and viral pgRNA reverse-
transcription 6,7. Although, the mechanism by which HBc and capsid assembly regulate 
viral DNA synthesis is not fully understood, it is well established that phosphorylation of 
HBc has an important role in various aspects of pgRNA reverse-transcription8. Kinases 
that mediate HBc phosphorylations include CDK2 (Cyclin-Dependent Kinase 2), which 
phosphorylates serine/proline (SP) sites located at the C-terminus of HBc, including 
S155, S162 and S170 5,9. Another study has identified additional S/T sites as having a role 
in regulating all aspects of HBV replication, and SRPK1 (Serine/Arginine Protein Kinase 1) 




Our earlier studies, aiming at understanding the mechanism by which the HBV X 
protein (HBx) mediates oncogenic transformation of hepatocytes 11–13, led us to the 
study of Polo-like-kinase 1 (PLK1), a S/T kinase involved in cell cycle regulation14,15. In 
physiologic conditions, PLK1 is required for checkpoint recovery, mitotic entry and 
progression, whereas it is overexpressed in many human cancers, including HBV-
mediated liver cancer14,15. Andrisani lab  has shown that HBx activates PLK1 
prematurely, allowing propagation of DNA damage to daughter cells by attenuating 
both DNA repair and p53 apoptosis 12,13. In a cellular model of HBx-mediated 
transformation and in liver tumors of animals modeling HBx- and HBV-mediated 
hepatocarcinogenesis, expression of PLK1 is elevated12,13,16,17. However, whether PLK1 is 
activated during physiologic HBV infection of normal hepatocytes, and whether it has a 
role in establishment and maintenance of infection is unknown. To address this issue, in 
this study, I used HBV infection models of non-transformed primary human hepatocytes 
(PHH) and dHepaRG, a bipotential human de-differentiated hepatocyte cell line that 
upon differentiation supports HBV infection. In this study I demonstrate the cellular 
PLK1 enzyme acts as a proviral host-factor for HBV replication in vitro, by favoring 
nucleocapsid formation and subsequent reverse transcription. Furthermore, I have 
identified the viral core protein HBc, as a PLK1 substrate in vitro, and mapped putative 
sites of PLK1 phosphorylation. Moreover, I provide evidence that PLK1 inhibitors serve 
as a novel class of anti-HBV molecules in vitro, and validated the antiviral effect of PLK1 




4.3 Results  
4.3.1 PLK1 is activated by HBV infection in non-dividing/differentiated 
hepatocytes 
Our earlier studies demonstrated that i) HBx activates the mitotic S/T kinase 
PLK1, in a conditional HBx-expressing cell line12, ii) PLK1 activation initiates proteasomal 
degradation of chromatin modifying nuclear proteins SUZ12 and ZNF15811, and iii) 
SUZ12 downregulation in HBV replicating hepatocytes results in expression of hepatic 
cancer stem cell markers and pluripotency genes18. Andrisani lab has also shown 
activation of PLK1 in HBV replicating HepAD38 cells11, further suggesting a link between 
HBV infection and PLK1 activation. However, it remained to be determined whether 
PLK1 activation occurs in the context of physiologic infection of non-dividing, 
differentiated, and non-transformed hepatocytes. To this end, primary human 
hepatocytes (PHH) and differentiated HepaRG (dHepaRG) were infected with HBV, and 
expression and activation of PLK1 was quantified. Upon infection of dHepaRG cells, PLK1 
mRNA increased by15-fold 24hr post-infection (p.i.), followed by a constant level of 
expression of 3-to 5- fold from 48h to 168h p.i. (Figure 1A). This resulted in a transient 
increase in PLK1 protein levels (Fig. 1B). More interestingly, an increase in PLK1 
phosphorylation on S137 and T210, indicative of PLK1 activation, was detected as a 
function of HBV infection by immunoblots (Fig. 1B), and immunofluorescence 
microscopy (Fig. 1C) employing phospho-specific PLK1 antibodies. Remarkably, this 
activation of PLK1 by HBV infection was also detected by immunoblots of lysates from 





4.3.2 PLK1 inhibitors, including BI 2536, suppress HBV DNA accumulation in 
persistently HBV-infected hepatocytes 
To test whether PLK1 activation has a proviral effect, dHepaRG cells were 
infected with HBV virions and on day-7 post-infection (7 d.p.i.), when infection had 
reached a “plateau” in terms of viral replication, cells were treated with various PLK1 
inhibitors. Specifically, increasing concentration of ATP competitive (i.e. BI 2536 and BI 
6727) or non-ATP competitive (i.e. MLN 0905 and ON 01910) PLK1 inhibitors were 
added for 3 days; accumulation of intracellular HBV DNA was measured by Southern 
blot and qPCR (Supplementary Figure 1A and 1B). Amongst all drugs tested, BI 2536 
was the most active and selected for further studies, after monitoring batch-to-batch 
stability (Sup. Fig. 2). HBV infected dHepaRG treated with BI 2536 on day-7 p.i., 
exhibited no effect on levels of secreted HBe and HBs antigens, or intracellular viral RNA 
(Fig. 2A). Interestingly, BI 2536 significantly inhibited synthesis of total HBV DNA, with 
an effective concentration at 50% (EC50) of approximately 4 nM (Fig. 2A), in the absence 
of any toxicity (cytotoxic concentration at 50%, CC50) of ~10 M; Fig. 2B). Interestingly BI 
2536 reduced the level of capsid (i.e. assembled HBc/core protein) detected by 
immunofluorescence microscopy with an antibody recognizing only capsid assembled 
HBc, and not monomeric or dimeric forms of HBc (Fig. 2C), and capsid migration assay 
(Fig. 2D). These results suggest that inhibition of PLK1 by BI 2536 affects the assembly of 
HBV capsids, thereby inhibiting rcDNA synthesis. Similar results were also obtained in 




significant increase in intracellular viral RNA was observed, thus inversely correlating 
with total DNA decrease. This corroborates the hypothesis that rcDNA synthesis is likely 
inhibited by an impaired assembly of capsids around pgRNA.  
4.3.3 Loss-of-function of PLK1 suppresses HBV DNA accumulation in infected 
hepatocytes 
To conclusively establish that PLK1 is a proviral factor, I investigated effect of loss 
of function of PLK1 on HBV replication by siRNA-mediated knockdown of PLK1 (siPLK1). 
As controls, I employed siRNA targeting HBV transcripts (siHBV; positive control), and 
siRNA against HCV (siHCV) serving as negative control. The effectiveness of PLK1 
knockdown by siRNA transfection was determined by quantification of PLK1 mRNA 
levels as a function of time after transfection (data not shown). Transfection of siPLK1 
reduced by nearly 90% endogenous level of PLK1 mRNA at 72hr after transfection, while 
all non-targeting siRNAs had no effect on PLK1 mRNA levels (Fig. 4A). Transfection of 
increasing amounts of siPLK1, ranging from 5 to 25 nM in HBV-infected dHepaRG cells, 
resulted in a progressive reduction of 50 to nearly 70% in the accumulation of 
intracellular HBV DNA (Fig. 4A). By contrast transfection of 25nM siHCV had a minimal 
effect, while transfection of 25nM siHBV reduced HBV DNA by nearly 80% (Fig. 4A). 
With siPLK1, I again observed a decreased accumulation of assembled HBc within 
infected cells by IF, using an antibody recognizing assembled capsids (Fig. 4B), thus 
confirming the potential relationship between proviral action of PLK1, formation of HBV 
capsids and resulting decrease in neo-synthetized rcDNA. Similar results were also 




HBV or an irrelevant target (Fig. 4C). Specifically, Southern blot analyses demonstrated a 
50% reduction in HBV DNA by transfection of siPLK1, a 10% reduction with siHCV and 
65% reduction with siHBV (Fig. 4D).  
4.3.4 A modest gain-of-function of PLK1 is associated with an increased HBV 
replication 
To investigate the effect of gain-of-function of activated PLK1 on HBV replication, 
I generated a HepaRG cell line expressing a constitutively active form of PLK1 (PLK1CA) in 
a tetracycline inducible manner (i.e. HepaRG-TR-PLK1CA) (Sup Fig. 4A). HBV infected 
dHepaRG-TR-PLK1CA cells were induced to express PLK1CA on day-7 p.i. by addition of 
increasing amount of tetracycline (0, 16, 80, and 400 ng/ml) for 3 days. Quantification of 
viral DNA and secreted antigens was carried out day-10 p.i. Under these conditions of 
established infection, a modest expression of PLK1CA enhanced HBV replication by 1.5- 
to 2- fold, whereas no effect on HBeAg secretion was observed (Sup Fig. 4B). This result 
suggests that active PLK1 enhances formation of new viral genomes by reverse-
transcription of pregenomic RNA (pgRNA), i.e., it exerts a positive effect on capsid-
assisted reverse transcription of pgRNA.  
4.3.5 Reduction of HBV viremia in liver-humanized infected FRG mice treated 
with BI 2536 
To demonstrate the effect of BI 2536 on inhibition of HBV replication in vivo, I 
employed liver-humanized FRG mice36 infected with HBV (5x108 vge/mouse). Once 
serum viremia reached 7 log10 vge/mL, antigenemia 5 log10 IU/mL for HBsAg and 2,500 




peritoneal injection of 10 mg/kg of BI 2536 (or same concentration of DMSO diluted in 
saline) bi-weekly for 4 weeks. Serum viremia and antigenemia were monitored at the 
end of weeks 1, 2, 4, 6, 7 and 8, while weeks 6, 7, and 8 were those under treatment. 
Treated mice exhibited at week-8 a mean reduction of 1.406 log10  0.26 in viremia (Fig. 
5C), whereas minimal effect was observed on antigenemia (Fig. 5A and B). It is worth 
noting that similar duration treatment with IFN- (25 g/kg/tw; 5 mice treated) or 
entecavir (ETV; 2.5g/mouse/day in drinking water; 3 mice treated) in liver-humanized 
FRG mice led to a viremia reduction of 0.668 log10  0.18 or 1.919 log10  0.23 
respectively (data not shown). These results indicate that a mean reduction of 1.406 
log10  0.26 in mono-therapy obtained with BI 2536 was relevant and in between 
performance of IFN- and ETV in this model.   
4.3.6 Effect of the combination of BI 2536 with approved or investigational 
anti-HBV molecules 
Our in vitro and in vivo data demonstrated that PLK1 inhibitors could be used as 
efficient and safe anti-HBV drugs. PLK1 inhibitor, including BI 2536 seems to target the 
capsid-associated reverse-transcription of pgRNA into rcDNA. Other drugs also target 
this step of the viral life cycle, including nucleoside/nucleotide analogues (NA) and core 
inhibitors (also called core protein allosteric modulators; CpAM). But all these drugs do 
have different molecular targets, and therefore could be theoretically used in 
combination to enhance the inhibitory phenotype. In order to establish whether BI 2536 
could be used in combination with NA or CpAM without leading to antagonistic effect, I 




and IFN- was also included. As expected only BI 2536 + IFN- treatment led to a 
reduction in HBeAg secretion (Fig. 6A), whereas all other combinations led to a sharp 
reduction of intracellular HBV DNA (Fig. 6B). No obvious antagonism was evidenced for 
all combinations tested, thus suggesting that these drugs could be further considered 
for combination studies.  
4.3.7 HBc is a substrate for PLK1 in vitro 
During established infection, inhibition of PLK1 by treatment with BI 2536 
suppressed only viral DNA synthesis (Fig. 2A, 3A, and 3B), suggesting that PLK1 may 
have a role in capsid-associated reverse-transcription of pgRNA into rcDNA. Conversely, 
inhibition of PLK1 could prevent these processes, based on capsid assembly. Since HBc 
has an essential and dynamic role in this process of capsid assembly, pgRNA 
encapsidation, and rcDNA biosynthesis, I investigated whether HBc is a PLK1 
phosphorylation substrate. 
To determine whether HBc is a direct target of PLK1, I performed in vitro kinase 
assays with purified recombinant HBc and PLK1 (Fig. 7). I observed in vitro PLK1 
phosphorylation of HBc using either recombinant HBc or HBc isolated from HepaRG-TR-
HBc cells (Fig. 7A); furthermore, addition of BI 2536 at 500 nM inhibited this 
phosphorylation (Fig. 7A, left panel). The C-terminal domain of HBc (CTD), spanning 
amino acids 143 to 183 (Fig. 7B) contains eight S/T residues. I performed in vitro PLK1 
kinase assays with GST-CTD fusion peptide isolated from transfected cells and featuring 
either wild type or mutated CTD sequences at all S/T sites. This approach was validated, 




exhibited absence of PLK1 phosphorylation (Fig. 7C). PLK1 requires a priming 
phosphorylation of its substrate, usually by CDK1 or CDK2 kinases at S/P sites. 
Interestingly, HBc is known to be phosphorylated by CDK2 at three SP phosphorylation 
sites (Fig. 7B). Accordingly, I tested whether HBc proteins containing S/A and S/D 
substitutions at all three SP positions (labeled as 3AP or 3DP) could serve as PLK1 
substrates. Interestingly, only the phosphomimetic substitutions, i.e., S/D at positions 
155, 162, and 170 (referred to as 3DP), exhibited phosphorylation by PLK1 (Fig. 7C). 
Next, I observed that S168A exhibited significantly reduced phosphorylation in the 
context of the phosphomimetic substitutions at SP sites, whereas no difference in the 
phosphorylation by PLK1 was detected by T146A and T147A substitutions (Fig. 7D). 
Single point mutations at residues 168, 176 and 178 all resulted in significant reduction 
of HBc phosphorylation by PLK1 (Fig. 7E). Therefore, I conclude that S168, S176 and 
S178 are PLK1 phosphorylation sites in vitro. 
4.3.8 S/A substitution of in vitro PLK1 phosphorylation sites diminish HBV 
replication 
To assess the in vivo significance for the identified in vitro Plk1 phosphorylation 
sites, I employed a trans-complementation assay for HBV replication. HuH7 cells were 
co-transfected with a plasmid that provided the HBV genome that had a point mutation 
in the HBc gene, inactivating the latter. Another plasmid provided WT or mutant 
variants of HBc. Co-transfection of HBc WT and the HBV genome lacking HBc resulted in 
successful HBV replication reflected in the production of cccDNA (Fig. 7F). Co-




3SP sites did not result in observable change in cccDNA production (Fig. 7F). 
Interestingly, alanine substitutions at the 3 identified in vitro PLK1 phosphorylation sites 
(168, 176 and 178) in the 3DP background resulted in almost 50% decrease in cccDNA 
production (Fig. 7F).  
4.4 Discussion 
The hepatitis B virus (HBV) is one of the most important human oncogenic virus 
1,2,19. Approximately 250 million individuals worldwide are chronically infected by HBV, 
having increased risk for developing hepatocellular carcinoma (HCC)19. If clinicians 
dispose of several anti-HBV drugs, they have limited chemotherapeutic options for HCC. 
It is thus crucial to identify novel molecules that target both virus biosynthesis and 
neoplastic transformation. In this study I provide evidence that the polo-like-kinase 1 
(PLK1), a kinase already demonstrated to be involved in HCC, could represent a potential 
target to tackle both HBV replication and liver oncogenesis. 
Earlier studies demonstrated that HBx activates PLK1 in a hepatocyte model cell 
line12, and that PLK1 was activated in the HepAD38 cellular model of HBV11. However, 
this cellular model of viral replication does not model physiologic infection. In this study, 
using physiologically relevant HBV infection models comprised of primary human 
hepatocytes and the HepaRG cell line, I show that indeed, HBV infection leads to early 
activation of PLK1. Here, I show that PLK1 phosphorylation occurs upon HBV infection in 
non-dividing and differentiated cells; the mechanism of PLK1 activation during HBV 
infection is yet to be determined.  HBx protein, which is expressed very early after HBV 




activation via the p38MAKP12,20. Here I provide evidence of the functional advantage to 
the viral life cycle of this early activation of PLK1 by HBV infection.  
Employing PLK1 pharmacological inhibitors and an RNA interference approach, I 
have shown that PLK1 enzymatic activity is crucial for maintenance of HBV replication in 
non-dividing hepatocytes. Indeed, BI 2536, an ATP-dependent PLK1 inhibitor, drastically 
inhibited HBV replication in vitro in both HepaRG cells and PHH, as well as in vivo, in liver 
humanized FRG mice, without toxicity. Interestingly, the antiviral activity of BI 2536 was 
very potent with an EC50 ranging from 5 and 50 nM, depending on cell type used; such 
an antiviral efficacy is rarely obtained with host targeting agents (HTA) and corresponds 
to the efficacy of direct acting agents (DAA; such as nucleoside analogues or assembly 
inhibitors). Accordingly, an in vivo antiviral activity was also obtained with BI 2536 in 
HBV-infected liver humanized FRG mice, and this antiviral activity was comparable to 
that obtained with entecavir or IFN- in the same model. The RNAi approach confirmed 
the PLK1 specificity, as kinase inhibitors are often non-specific. The antiviral phenotype 
obtained by RNAi targeting PLK1 was also very strong in vitro. The use of such an 
approach in vivo using siRNA that could be specifically targeted to infected hepatocytes 
could represent an interesting alternative to pharmacological inhibitors, which may be 
quite toxic when administrated systemically. Recently, it has been shown that RNAi 
nanoparticles in complex with PLK1 siRNA, administered systemically, efficiently delivers 
PLK1 siRNA to the liver with no observable toxicity21.  
The molecular mechanism underlying the proviral role of PLK1 has not been 




the capsid/core protein (HBc), responsible for capsid assembly around the pregenomic 
RNA, and indirectly pgRNA reverse-transcription, as the latter occurs only within 
capsids. PLK1-mediated phosphorylation requires prior phosphorylated “primed” 
substrates22. Here I presented evidence that HBc is a direct target of PLK1 in vitro, and 
importantly, efficient phosphorylation of HBc required prior phosphorylation at 
positions S155/S162/S170, sites shown to be phosphorylated by CDK25,9. Our studies 
identified S168, 176 and 178 as potential sites for PLK1 phosphorylation in vitro, 
dependent on prior phosphorylation of S/P sites at positions S155, S162 and S170. Thus, 
PLK1-mediated phosphorylation of HBc in a sequential phosphorylation process could 
directly mediate the dynamic events associated with capsid formation, pgRNA 
encapsidation and reverse transcription. Indeed, substitution of serines at these sites 
with alanines resulted in major reduction in cccDNA production. Further mechanistic 
studies and molecular tools (phospho-specific antibodies) are required to fully delineate 
this mechanism of PLK1 involvement. 
Many other viral proteins are directly phosphorylated by PLK1, including the non-
structural 5A protein from HCV23, the mump virus nucleoprotein24, and the 
parainfluenza virus 5 (PIV5) P protein25. PLK1-mediated phosphorylation of the target 
can either lead to its degradation or change in function; therefore, PLK1 can either act 
as a proviral or antiviral factor. For HCV, PLK1 seems to be a proviral factor, as it 
contributes to the hyper-phosphoryaltion of NS5A23, which is a crucial event to switch 
from a replicative cycle (i.e. amplification of viral RNA) to a productive one (i.e. 




only limited value to inhibit HCV replication, because the virus replicates better in vitro 
in dividing cells, thus precluding non-toxic PLK1 inhibition. But in the case of HBV, this 
framework for a potential use of PLK1 targeting drugs does exist. Indeed, HBV only 
replicates in non-dividing and highly differentiated cells. Although I have shown here 
that an anti-HBV phenotype could be obtained in vivo, more experiments are warranted 
to further demonstrate the safety of such an HTA-based approach. Many PLK1 
pharmacological inhibitors as well as strategies based on PLK1 silencing are in current 
development for treating several cancers26,27; a repositioning of such drugs for the 
treatment of CHB patients could be foreseen. The fact that PLK1 inhibitors could 
reinforce the inhibition of the neo-synthesis of encapsidated rcDNA, as nucleoside 
analogues already do, represent an excellent framework for the potential development 
of combination therapies. 
4.5 Materials and Methods 
4.5.1 Chemicals, antibodies, and others reagents 
All chemicals were purchased from Sigma Aldrich unless otherwise specified. PLK1 
inhibitors (BI 2536, BI 6727, MLN 0905 and ON 01910) were from Selleckchem. 
Polyclonal HBc28, and commercially available HBc antibodies were used for 
immunofluorescent staining and immunoblots. Rabbit polyclonal anti-HBc was from 
Dako, and monoclonal anti-HBc from Abcam (Clone C1). PLK1 antibodies used: rabbit 
polyclonal (Abcam 21738-100) for detection of phospho-PLK1-S137 in WB and IF; rabbit 
monoclonal (Ab115095) for detection of phospho-PLK1-T210 in WB and IF, and rabbit 




sequence designed) were purchased from Dharmacon, transfected into dHepaRG or 
PHH using Darmafect-1 reagent, following manufacturer’s instructions. Tenofovir and 
HBV capsid assembly inhibitors Bay41-410929 were kindly provided by Gilead Sciences 
and Novira Pharmaceutics, respectively. IFN- (i.e. Roferon) was from Hoffmann-La-
Roche.  
4.5.2 HepaRG cells and primary human hepatocytes & infection by HBV 
 Human liver progenitor HepaRG cells30 were cultured for 2 weeks in complete William’s 
medium (Gibco) supplemented with 10% FCS Fetal Clone II serum (Thermo scientific), 50 
U/mL penicillin/streptomycin (Gibco), 2 mM glutaMax (Gibco), 5 μg/mL human insulin 
(Sigma), and 5 × 10−5 M hydrocortisone hemisuccinate (UpJohn, SERB) at 37°C in 
humidified CO2 (5%) incubators and differentiated into hepatocyte-like cells by a 
treatment with 1.8% DMSO (Hybrid-max, Sigma) for two weeks as described31. 
Engineered HepaRG cell lines were also used. HepaRG-TR-PLK1CA cell line enabling 
tetracycline-inducible expression of a constitutively active form of PLK1 (i.e. T210D 
mutant 32) was constructed as  described  for HepaRG-TR-HBc cell line 33.  Primary 
human hepatocytes (PHHs) were from surgical liver resections, after informed consent 
of patients (kindly provided by Pr. Rivoire (CLB, Lyon); agreement numbers DC-2008-99 
and DC-2008-101). PHH were prepared as previously described34 and cultured in 
complete William’s medium supplemented with 1.8 % of DMSO.  
4.5.3 HBV infection and analysis of viral parameters during replication 
Differentiated HepaRG cells (dHepaRG) and PHH were infected as previously described 




accumulation of viral RNA and DNA, secretion of HBe and HBs antigens were monitored 
by qPCR, RTqPCR, southern blotting, and ELISA, as described35. Briefly, HBeAg and 
HBsAg were quantified in culture medium by ELISA, using a chemiluminescence 
immunoassay kit (Autobio, China) following manufacturer’s instructions. Total DNA was 
purified from infected cells using MasterPure™ Complete DNA Purification Kit 
(Epicentre). Southern blot analysis of HBV DNA was performed using equal amounts of 
total DNA, electrophoresed on 1.1% agarose gels, hybridized to HBV DNA radiolabelled 
with [α-32P]CTP 31 and analyzed by autoradiography. Total RNA was extracted from 
infected cells using NucleoSpin® RNA (Macherey-Nagel) and transcribed into cDNA using 
SuperScript III reverse transcriptase (Invitrogen, Carlsbad, USA). Real-time PCR for total 
HBV DNA and cccDNA was performed using LightCycler 96 (Roche) as described35.  
4.5.4 Transfections, plasmids and siRNAs  
Transient transfections in HEK293T cells were carried out employing Lipofectamine 2000 
(Invitrogen) as described by manufacturer. HBc-WT (EL43), HBc-3A (EL113) and HBc-3D 
(EL114) were kindly provided by Dr. D. Loeb, derived from EL43 plasmid 7. The CTD-GST 
fusion protein plasmids: GST-HCTD141 (CTD WT) and, the GST-HCTD141-AAAAAAA (CTD 
7A) 5 were a kind gift from Dr. Hu. SiRNAs (Smart pool grade; Dharmacon) for PLK1, HBV 
and HCV (5-25nM) were transfected in HBV-infected HepaRG or PHH using Dharmafect I 
(Dharmacon) following manufacturer’s protocol.  
4.5.5 Humanized FRG mouse model and HBV infection 
All animal studies were reviewed and approved by a local ethical committee. The highly 




were used 36 and maintained in pathogen-free facility. High quality, cryopreserved 
human hepatocytes were purchased (BD, Biosciences) and injected via an intra-splenic 
route into 2 to 3 month old mice as described previously 36. Liver humanized Fah-/-/Rag2-
/-/Il2rg-/- mice featuring serum production of human albumin, at least 5 mg/mL, were 
infected with 200 μl of HBV inoculums (1.108 veg to 1.109 veg in PBS) via intra-peritoneal 
route 37.  
Mice were treated by intraperitoneal injection of BI 2536 (10mg/kg/twice a week) for a 
month. Serum was harvested every week by retro-orbital bleeding and stored at -80°C 
in aliquots for further antigenemia and viremia analysis. Mice were sacrificed at week 8 
post-infection and hepatic tissues were frozen and processed for virologic parameter 
analyses or fixed in formalin and embedded in paraffin for immune-staining.  
4.5.6 In vitro PLK1 kinase assays  
Assays were performed as previously described 11using recombinant PLK1 (BPS 
Bioscience, Protein One). Core protein was immuno-purified from HepaRG-TR-HBc cell 
line or purchased from Meridian Life Science, Inc. Site-directed mutagenesis of putative 
PLK1 phosphorylation sites in HBc-WT and HBc-3D was performed employing the Quick-
change Lightning site-directed mutagenesis Kit (Agilent). Point mutations in the GST-
CTD-WT and GST-CTD-7A plasmids were introduced following the same procedure. 
Mutations were confirmed by DNA sequencing. For protein staining, PageBlue™ Protein 




4.5.7 Trans-complementation assay  
HuH7 cells were grown in DMEM media, 10% FBS and 50 U/mL penicillin/streptomycin 
(Gibco). Transient transfections in HEK293T cells were carried out employing 
Lipofectamine 2000 (Invitrogen) as described by manufacturer. DsRed-HBV1.1-∆HBc 
plasmid provided 1.1 copy of HBV genome lacking HBc expression due to a point 
mutation introducing a stop codon. (DsRed-HBV1.1 plasmids were kindly provided by Dr. 
Tsai-Yu Lin. cccDNA was measured by qPCR, HBeAg and HBsAg by ELISA 2-3 days after 
transfection.  
4.5.8 Statistical analysis  
Statistical analysis was performed using two-way Anova, t tests, or nonparametric 
Mann-Whitney tests using the GraphPad Prism software. For all tests, p-value ≤0.05 (*), 
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4.8 Figure legends  
Figure 1: HBV infection activates PLK1. dHepaRG cells (A, B and C) or PHH (D) were 
infected with low dose (100 vge/cell) or high dose (1000 vge/cell) HBV. A) Cells were 
harvested at indicated time points, RNA extracted and subjected to RT-qPCR. Fold 
induction of mRNA expression level of PLK1 and HBV were normalized to housekeeping 
genes, compared to mock infection. B) Immunoblot of PLK1 and phosphorylated PLK1 
(S137 and T210) using whole cell extracts (WCE) of mock- or HBV-infected dHepaRG 




chemiluminescence was done with a ChemiDoc XRS+ system (Biorad). C) 
Immunofluorescence microscopy of indicated proteins +/- HBV infection in dHepaRG 
cells at different time p.i. Cells were fixed by 2% PFA and stained with indicated 
antibodies. D) Immunoblots of PLK1 and phosphorylated PLK1 using WCE from mock- or 
HBV-infected PHH cells. 
 
Figure 2: Effect of BI 2536 on HBV replication in non-dividing and non-transformed 
dHepaRG. Differentiated HepaRG cell (A, B, C, and D) were infected with 100 vge/cell of 
HBV for 7 days followed by treatment with increasing concentration of PLK1 inhibitor BI 
2536, as indicated, for 3 days. A) Secreted antigens HBsAg and HBeAg quantified by ELISA 
from supernatants of HBV infected dHepaRG cells, day-10 p.i. Total RNA and DNA 
extracted from infected cells, day-10 p.i., were analyzed by HBV-specific RT-qPCR or qPCR, 
normalized to housekeeping genes and compared to mock-infected cells. Results are 
presented as fold change in expression or secretion, compared to untreated controls and 
are mean ± SEM of at least 3 independent experiments. B) Cell viability of HepaRG cells 
measured using Cell Titer Glo One Solution Assay, with increasing concentration of BI 
2536, as indicated. DMSO and puromycin were used as controls. C) Immunofluorescence 
microscopy of indicated proteins, +/- BI 2536 in infected dHepaRG cells. D). 
 
Figure 3: Effect of BI 2536 on HBV replication in non-dividing and non-transformed PHH. 
PHH (A, B, and C) were infected with 100 vge/cell of HBV for 4 days followed by treatment 




Quantification of secreted HBsAg and HBeAg by ELISA using supernatants of HBV infected 
PHH on day 7 p.i. Total RNA and DNA extracted from HBV infected cells, day-7 p.i., were 
analyzed by HBV-specific RT-qPCR or qPCR, normalized to housekeeping genes, and 
compared to mock-infected cells. Fold change in expression or secretion quantified 
relative to untreated controls represent mean ± SEM of at least 3 independent 
experiments. B) A representative Southern blot is shown (n=3). Total DNA extracted from 
cells on day-7 p.i., was analyzed by agarose gel electrophoresis, transferred onto nylon 
membrane, and hybridized to radioactive HBV probe as previously described31. 
 
Figure 4: Effect of PLK1 knockdown on HBV replication in dHepaRG and PHH. PHH or 
dHepaRG cells infected with 100 vge/cell of HBV for 7 days were transfected with siRNA 
(5 or 25 nM) targeting PLK1(siPLK1) or HBV (siHBV) or HCV (siHCV), as indicated. A and C) 
Total RNA and DNA were extracted and subjected to RT-qPCR or qPCR with PLK1 or HBV 
primers. Quantification of PLK1 mRNA and HBV DNA is relative to absence of siRNA 
transfection (no siRNA). Results represent the mean ± SEM of at least 3 independent 
experiments. B) Immunofluorescence microscopy of indicated proteins, +/- siPLK1 
transfection in HBV infected dHepaRG cells. Cells were fixed by 2% PFA at day 10 p.i. and 
stained with indicated antibodies. D) A representative Southern blot is shown. DNA was 
extracted from infected PHH transfected by indicated siRNA. 
 
Figure 5: Effect of BI 2536 on HBV replication in liver humanized HBV-infected FRG mice. 




vge/mouse). On week-4 p.i., treatment was initiated as indicated. BI 2536 (10mg/kg) was 
injected twice per week intraperitoneally (IP) for 4 weeks. Blood was collected at the end 
of week-1, 2, 4, 6, 7, and 8 and antigenemia (A and B) and viremia (C) monitored by ELISA 
and qPCR. D) E) 
 
Figure 6: Combination treatment of BI 2536 and tenofovir, IFN-a, or Bay41-4109. 
Differentiated HepaRG were infected with 100 vge/cell of HBV for 7 days, followed by 
treatment with indicated concentration of drugs for 3 days. A) HBeAg secretion in 
supernatant was monitored by ELISA. B) Intracellular HBV DNA was quantified by qPCR. 
 
Figure 7: HBc is a phosphorylation substrate of PLK1 in vitro. In vitro PLK1 kinase assays 
of HBc and site-directed mutants. A), recombinant HBc or immune-affinity purified HBc 
isolated from HepaRG-TR-HBc cells, and PLK1 were used in in vitro PLK1 kinase assays. 
Reactions were performed with (+) or without (-) PLK1 inhibitor BI 2536 (500nM), as 
indicated, in the presence of γ32P-ATP and analyzed by SDS-PAGE and autoradiography. 
B) Amino acid sequence of C-terminal domain (CTD) of HBc. S/T residues are numbered 
1-8; CDK2 SP sites, and putative PLK1 phosphorylation sites are indicated. C, D and E) In 
vitro kinase assays of WT HBc and site-directed mutants, as indicated. Commassie blue 
staining shows the same gel used for autoradiography. Relative intensity quantified by 
ImageJ software is ratio of signal from in vitro kinase reaction versus corresponding 





4.9 Supplementary figure legends  
Supplementary Figure 1: Dose response effect of competitive and non-competitive PLK1 
inhibitors on HBV replication in non-dividing hepatocytes. PHH were infected with 100 
vge/cell of HBV for 7 days followed by treatment with different concentration (0, 5, 50, 
500 and 5000 nM) of indicated PLK1 inhibitors for 3 days. A) Total intracellular HBV DNA 
was extracted and analyzed by Southern blot. B) Infected dHepaRG cells on day-7 p.i. were 
treated with 500 nM of different PLK1 inhibitors for 3 days; total HBV DNA was extracted 
and quantified by qPCR. Results are expressed as fold change normalized to housekeeping 
genes and are from 3 independent experiments.  
 
Supplementary Figure 2: Comparison of batches of BI 2536. Differentiated HepaRG cells 
infected with HBV (100 vge/cell) were treated with increasing concentration of BI 2536 
(0, 0.5, 5, 50, 500 and 5000 nM) on day-7 p.i., for 3 days. Total DNA was extracted and 
HBV DNA was quantified by qPCR relative to housekeeping genes. Results are shown as 
fold change in HBV DNA, compared to mock- treated. Two different batches of BI 2536, 
from different providers were used as indicated. Results are represented as the mean ± 
SEM from at least 3 independent experiments.  
Supplementary Figure 3: Effect of BI 2536 on establishment of HBV infection in 
dHepaRG. A) Diagram of infection and treatment protocol. B) Differentiated HepaRG cell 
were treated with increasing concentration of BI 2536 for 3 days, then infected with 100 
vge/cell of HBV for 7 days. Secreted antigens HBsAg and HBeAg were quantified by 




DNA extracted from infected cells on day-10 p.i. were analyzed by HBV-specific RT-qPCR 
or qPCR, normalized to housekeeping genes, and compared to mock-treated cells. Fold 
change in expression or secretion was quantified relative to untreated controls, and are 
mean ± SEM of at least 3 independent experiments. C) Immunofluorescence microscopy 
of indicated proteins, +/- transfection of siPLK1 in HepaRG cells. siRNA was transfected 
for 3 days prior to infection and cells were fixed on days-3 or 7 p.i. 
Supplementary Figure 4: Limited over-expression of PLK1 leads to an increase of HBV 
replication in dHepaRG. A) Differentiated HepaRG-TR-PLK1CAcells were induced by the 
addition of tetracycline (0, 16, 80 400, 1000 or 2000 ng/mL) for 72 hours and PLK1 levels 
analyzed by immunoblotting. B) dHepaRG-TR-PLK1CA cells were infected with 100 
vge/cell of HBV for 7 days followed by induction of PLK1 by the addition of indicated 
amount of tetracyline for 3 days. HBeAg secretion was analyzed by ELISA. Total DNA was 
extracted and HBV DNA was measured by qPCR. Results are shown as fold change in 
HBV DNA as compared to control cell line. Results are represented as the mean ± SEM of 
2 independent experiments.  
 
Supplementary Figure 5: Effect of IFN-α and entecavir on HBV replication in liver 
humanized HBV-infected FRG mice. Eleven mice, engrafted with human PHH for two 
months, were infected with HBV (5.10e8 vge/mouse). At week-4 post infection 
treatment was started in 8 mice and 3 other mice were mock treated. IFN- (25 g/kg) 




administrated in drinking water. Blood was taken at the end of weeks 4 and 8 and 




















































CHAPTER 5. HOST CELL INTERACTOME OF HBV CORE PROTEIN REVEALS A NOVEL LINK 
TO PARASPECKLE COMPONENTS 
5.1 Introduction 
Studies of virus-host interactions continue to provide critical insights into host 
pathobiology upon infection. Viruses manipulate specific host pathways to allow 
efficient viral amplification and/or evasion of host immune defenses. Due to genomes 
size constrains, the HBV genome is only 3.2KB, HBV proteins such as the X protein (HBx) 
and the core antigen (HBc) have evolved various functional roles beyond their 
contribution to viral replication 1,2. For example, previous studies have demonstrated 
how HBx activates host mitogenic pathways eventually leading to liver cell 
transformation3,4. The viral HBc protein, which forms the viral capsids, plays many roles 
in viral replication beyond its structural function. Notably, several biochemical studies 
have demonstrated the interaction between HBc and host cell components that help 
facilitate efficient viral replication (reviewed in chapter 2). HBc has a unique C-terminal 
domain, which is characteristically rich in arginine and is capable of binding viral and 
host RNAs 5 with similar levels of cooperativity 6. Arginine rich domains with nucleic acid 
binding ability are commonly shared features among several viral proteins 7. Such motifs 
enable viral proteins like the human immunodeficiency virus-1 (HIV-1) Rev to interact 




splicing machinery. Given the structural similarity, HBc may interact with host proteins 
in a similar fashion and accordingly, I employed proteomics-based approaches as well as 
biochemical assays to investigate this hypothesis. 
Affinity purification of viral proteins combined with mass spectrometry-based 
proteomics is a powerful tool to study virus-host interaction, as it helps identify putative 
host partners and likely cellular pathways deregulated by the virus. Aided by affinity 
purification/mass spectrometry (AP/MS) researchers were able to study systematically 
protein complexes hijacked by several viruses including human immunodeficiency virus 
1 (HIV-1)8, hepatitis C virus (HCV)9 and Kaposi’s sarcoma-associated herpesvirus 
(KSHV)10. As for HBV, HBx remains the best-characterized protein in terms of global 
host-interaction partners. Proteomic- based approaches identified several novel host 
factors hijacked by HBx in HBV replication and infection models, including the 
interferon-inducible phospholipid scramblase 1 (PLSCR1), apolipoprotein A-I (apoA-I) 
and the apoptosis induced factor (AIF) 11–14. The role of HBx as a week oncogene is well-
established, and the cellular pathways manipulated by HBx during transformation are 
well-studied15. When it comes to HBc, the global host interactome map remains an 
unexplored territory. Aside from text-mining studies to catalogue HBc-host interactions 
16 and traditional yeast-two-hybrid screens of human liver cDNA library 17, no 
comprehensive analysis of global HBc-host interactions has been reported to date. In 
this study, I employed affinity purification of epitope-tagged HBc protein from the 
human bipotential progenitor liver cell line (HepaRG) 18.  To provide a comprehensive 




based proteomics to identify novel physical in vivo interaction partners of HBc. This 
analysis identified previously reported as well as novel putative HBc interacting 
partners.  
Interestingly, HBc interacting proteins include components of the nuclear speckle 
and paraspeckle bodies. Nuclear speckles and paraspeckles are dynamic nuclear 
subdomains, enriched for serine- and arginine-rich (SR) proteins that comprise the 
mRNA-splicing machinery 19. The distinct paraspeckles are located in close proximity to 
the nuclear speckles, hence the name 20. Both nuclear speckle and paraspeckle bodies 
are known to associate with long noncoding (lnc)RNAs21,22. In a screen for nuclear 
transcripts associated with the SR-rich splicing machinery, two lncRNAs, nuclear 
enriched abundant transcripts (NEAT), NEAT2 an NEAT1 were identified 21. The same 
study demonstrated, using RNA fluorescence in situ hybridization (FISH), that NEAT2 
localizes to the nuclear speckles while NEAT2 localizes to their periphery21, now a 
distinct domain called paraspeckles. It is well-accepted now that paraspeckle formation 
proceeds in conjugation with the biogenesis of lncRNA NEAT123,24. Genetic Loss of 
NEAT2 has been recently associated with slower tumor growth and reduction in 
metastasis in mammary tumors25. Both NEAT1 and NEAT2 expression levels were 
reported to increase in response to viral infection26,27 implying a role in viral infection. 
Recently, lncRNA NEAT2 and NEAT1 were shown to physically interact with proteins that 
are resident components of the nuclear speckles and paraspeckles, respectively, thereby 
confirming their structural role in the organization of these nuclear bodies 10. Our mass-




Given the capacity of HBc to bind RNA6, I hypothesized that HBc associates with lncRNAs 
that are part of these nuclear complexes. Ribonucleoprotein immunoprecipitation (RIP) 
of HBc confirmed that HBc associated with NEAT1 and NEAT2 in cellular models of HBc 
replication and infection.  
5.2 Results 
5.2.1 Identification of HBc interacting proteins by AP-MS 
Assembly competent strep-tagged HBc protein was expressed from an HBc 
expressing HepaRG cell line (HepaRG-TR-HBc). Affinity purified and processed HBc was 
subjected to mass spec analysis. I compared the HBc interactome from this study with 
HBc interactomes curated from the literature in a previous study16 (Fig. 1). Among the 
previously reported interacting partners, Serine/Arginine-rich protein-specific kinase 1 
(SRPK1)28, PDZ domain-containing protein GIPC117, nucleophosmin29, Phosphatase 2A 
inhibitor (I2PP2A)/protein SET30 and Cyclin-dependent kinase inhibitor 1 (CDKN1A)31 
were also identified in my study. My study also identified additional putative HBc 
interacting proteins (Table 1). In addition to identifying SRPK1, a well-documented HBc 
binding partner 28,32,33, I also identified several proteins that are known to interact with 
SRPK1 namely SRSF134, SRSF9, DHX9, CDKN2A, DDX21 and DDX50 (BioGRID3.4 database). 
A complex of these proteins generally known as serine arginine rich protein (SR-rich) 
complexes with SRPK1 play key roles in alternative RNA splicing and contribute 
pleiotropically to regulation of gene expression 35. Interestingly, SR-rich proteins are also 
known to serve as adaptor proteins for mRNA- and ribonucleoprotein- export factor 




genomic RNA (pgRNA) may exploit NFX-1/TAP machinery for nuclear exit 37, my studies 
have likely identified additional factors involved in this process and they deserve 
biochemical validation.  
5.2.2 An overlap between interactomes of HBV core protein and HIV-1 Rev 
protein 
Both HBV and HIV have common routes of transmission (blood borne) and 
persons at high risk for infection of HIV are also likely to be at high risk for HBV 
infection. Remarkably, there is evidence of prior HBV infection in approximately 90% of 
HIV-infected persons38, 5-15 % among whom are chronic carriers of HBV. This 
observation suggests that some of the cellular pathways hijacked by both viruses may 
be common. I noticed a notable degree of overlap in high confidence interactors 
between HIV-1 Rev8 and HBc with a common group of 32 proteins (Fig. 2). These 
common interacting proteins are likely involved in cellular processes broadly exploited 
by viruses for purposes of their replication or evasion from host immunity regardless of 
how distinct these viruses are in their pathobiology. Further study of these proteins and 
associated pathways promises to expand our understanding of such pathways.   
5.2.3 STRING network analysis reveals paraspeckle proteins as HBc interacting 
partners 
To gain a global understanding of the human HBc interactome and to identify 
novel complexes and pathways hijacked by HBc, I performed a STRING network analysis, 
which provided a global map of HBc interactome (Fig. 3) as well as gene ontology (GO) 




and paraspeckle complexes. In particular, I identified heterogeneous nuclear 
ribonucleoprotein M HNRNPM, splicing factor proline/glutamine-rich (SFPQ) and non-
POU domain containing protein (NONO) as HBc binding proteins; all are resident 
components of paraspeckle nuclear bodies 20,23. Of the proteins that localize to the 
nuclear specks, I found peptidyl prolyl cis-trans isomerase 1 (PIN1), RNA binding motif 
protein 39 (RBM39) and DEAD box polypeptide 3, X-linked RNA helicase (DDX3X) of 
particular interest, as they have also been identified independently by colleagues in 
France (Durantel, personal communication) as HBc interacting partners. Other newly 
identified HBc binding proteins, although not biochemically validated, such as 
HNRNPA1, HNRNPF, HNRNPH, HNRNPU, FUS and RBM14 that localize both to nuclear 
speckle and paraspeckle bodies were also identified. Interestingly, these proteins were 
recently identified as interacting partners for lncRNAs NEAT1 and NEAT2 in a pull-down 
study of these lncRNAs using specific oligonucleotides followed by MS analysis (Table 2) 
22. Whether HBc physically associated with all these proteins and/or lncRNAs is yet to be 
determined.  
5.2.4 HBc associates with lncRNAs NEAT1 and NEAT2 
MS analysis implicated a novel association between HBc and proteins that are 
structural components of the nuclear speckle and paraspeckle bodies as well as proteins 
that localize to both nuclear subdomains. Therefore, it was intriguing to test whether 
HBc also associated with NEAT1 and NEAT2 in vivo. I performed ribonucleoprotein 
immunopericipitation (RIP) assays to pull down HBc from lysates of HBc expressing liver 




NEAT1 and NEAT2 associated with the core protein (Fig. 4). This indirectly supports a 
model where HBc associates or localizes at nuclear speckles and paraspeckles. However, 
this point is yet to be demonstrated by direct co-immunoprecipitation (co-IP) or co-
immunofluorescence experiments.  
5.2.5 HBc binds lncRNAs NEAT1 and NEAT2 during HBV replication and 
infection 
Since the HBc interactome / MS analysis (Table 1) and HBc RIP experiments (Fig. 
4) were performed in the absence of viral replication, to gain more insights into HBc 
function in the context of the viral machinery, I performed HBc-RIP experiments using 
HBV replicating hepatoblastoma cells (HepAD38)39 as well as HBV-infected HepG2hNTCP 
cells. In both models of HBV replication and infection, HBc associated with NEAT1 and 
NEAT2 implying a role for NEAT1 and NEAT2 in HBV pathogenesis (Fig. 5). Interestingly, 
no change in NEAT1 or NEAT2 expression level was observed upon HBV infection in 
HepG2hNTCP cells (Fig. 6). 
5.2.6 Phosphorylation status of HBc regulates interaction with lncRNAs 
Phosphorylation of HBc is a key regulator of HBc-mediated RNA encapsidation40 
and is particularly essential for facilitating HBc nucleic acid chaperone activity41. I 
wondered if HBc phosphorylation influences HBc binding to NEAT1 and NEAT2. To 
investigate this hypothesis, I performed RIP experiments with HBc variants carrying the 
following substitution mutations: HBc-3AP with 3 Ser/Ala substitutions at the 3 SP sites, 
HBc-3DP with 3 Ser/Asp substitutions at the 3 SP sites, HBc-3DP/3A with 3 Ser/Asp 




sites 176, 178 and 181 and finally HBc 4A with 4 Ser/Ala substitutions at sites 168, 176, 
178 and 181 in addition to HBc WT. While no significant difference was observed among 
the different HBc variants with regards to their ability to bind NEAT1 and NEAT2, a 
consistent decrease with the HBc-3DP/3A binding to NEAT1 was observed when 
compared to WT or 3DP (Fig. 7). I interpret this to mean that loss of Plk1 
phosphorylation may regulate HBc binding to NEAT1, although additional studies are 
required in support of this preliminary finding. 
5.3 Discussion 
This study provides the first global analysis of HBc human interactome. Using 
affinity-purification and mass spectrometry, I identified HBc interacting partners that 
have been previously described as well as novel putative one. In particular, I observed 
several SR-rich proteins as potential HBc interacting partners. Previous studies have 
identified SR-rich proteins such as SRSF1 as regulators of viral biogenesis42–45. While 
SRPK1 is an established interacting partner of HBc 28,33, the significance of this 
interaction seems ambiguous and probably secondary for the viral life cycle- since the 
kinase activity has no impact on viral replication32. To our interest, SRSF1, which is a 
canonical SRPK1 phosphorylation substrate, could shed more light on the significance of 
HBc-SRPK1 interaction. While SPRK1-HBc interaction may seem redundant, HBc could 
simply function as a competitive inhibitor of SRPK1 substrates. Other viral proteins such 
as Human papillomavirus type 1 E1^E4 protein is a documented example of such case46. 
Interaction between HBc and SRSF1, a canonical substrate of SRPK1, could also be 




proteins not only modulates their splicing activity and subcellular localization but also 
regulates their interaction with NFX-1/TAP complex 47. Remarkably, NEAT2 is another 
key regulator of SR-rich protein phosphorylation 48; whether NEAT2-HBc interaction is 
an additional regulatory layer  for SR-rich protein functions remains to be investigated. A 
more comprehensive analysis of all such players and how HBc affects/regulates their 
function will certainly further expand our understanding of the pathobiology of HBV 
infection.  
Only a subset of previously reported HBc interacting proteins was identified by my 
MS analysis. In my study, I only used immuno-purified HBc protein in absence of other 
viral components. The presence of other HBV replication intermediates may be required 
for HBc interaction with certain host molecules. Future MS studies using HBV infection 
and replication cellular models will facilitate the identification and future 
characterization of such molecules. It is also important to note that some of these 
protein-protein interactions are transient in nature and may therefore fall outside the 
range of MS based detection methods. To enrich for week and transient interactions, it 
may be useful to specifically enrich for certain subcellular domains and/or use 
synchronized cell cultures.  
Study of virus-host interaction during infection using host cells with replication 
competent-virus is optimal for the identification of critical host factors. Yet, such 
approach is not always practical. Alternatively, the use of ectopically expressed epitope-
tagged individual viral proteins has proven valuable particularly when trying to decipher 




is noteworthy to remember that this approach does not recapitulate the viral 
pathogenesis in its entirety. In order to assess the in vivo relevance of such interactions 
in the context of HBV infection, future analysis using loss of function genetic approach 
will be useful. A knockdown or knockout of the different protein or RNA components 
will help characterize their significance for the viral life cycle. While no change in NEAT1 
and NEAT2 expression was observed with HBV infection, HBV infection may result in 
other changes with regards to localization of HBc and/or HBV mini-chromosome inside 
the nucleus. The use of RNA FISH and other intracellular imaging techniques may help 
elucidate any changes in HBc and NEAT1/NEAT2 localization during infection.   
Flavivirus infection- either by Japanese encephalitis virus or West Nile virus- 
reportedly caused elevated NEAT2 expression in mammalian cells26. Similarly, NEAT1 
levels were elevated upon viral infection including influenza virus and herpes simplex 
virus as well as poly I:C 27. Notably, induction of NEAT1 was associated with enlarged 
paraspeckles and involved binding of NEAT1 to SFPQ, displacing the latter from the IL-8 
promoter region. This resulted in the activation of IL-8 as well as IL-8 dependent innate-
immunity genes 27.My studies show that HBc associates with NEAT1 and potentially with 
SFPQ so it is reasonable to envisage a similar mechanism taking place during HBV 
infection. 
5.4 Materials and Methods 
5.4.1 Chemicals, antibodies, and others reagents 
All chemicals were purchased from Sigma Aldrich unless otherwise specified. 




magnetic beads were from (IBA, 2-4090-002). Protein G Dynabeads® were purchased 
from Thermo (10003D). 10X cell lysis buffer (Cell Signaling #9803) was prepared 
according to manufacturer protocol. Ambion Purelink DNase (12-185-010) kit was 
purchased from Thermo. Proteinase K (EO0492) was purchased from Thermo. Purelink 
RNA Mini Kit (12183018A) from Thermo was used to isolate RNA. iScript cDNA Synthesis 
Kit (170-8891; Bio-Rad) was used to synthesize cDNA.    
5.4.2 Cell culture 
Strep-tagged HBc protein was overexpressed in a HepaRG cell line (HepaRG-TR-
HBc) in a tetracycline-regulated fashion. Culture and maintenance of HepaRG cells was 
performed as previously described 1. Cells were collected in CST lysis buffer 
supplemented with protease inhibitor cocktail (sigma) following manufacturer protocol. 
After brief sonication, lysates were cleared by centrifugation at 14000 rpm at 4°C. 
Expression of strep-HBc was confirmed by western blotting of whole cell extracts 
obtained 2-3 days after tetracycline treatment. HepAD38 cells, HepG2hNTCP cells and 
HEK293T cells were all maintained as described previously 53,54.  
5.4.3 Affinity purification and Protein Digestion 
Cleared lysates were incubated overnight at 4°C with 50 µL of MagStrep XT 
beads. Beads were washed 3x with cold lysis buffer then once with PBS. Proteins were 
denatured and reduced in 50 mM trimethyl ammounium bicarbonate containing 8M 
Urea and 5 mM dithiothreitol for 30 min at 37 °C. The proteins were further alkylated in 
15 mM iodoacetamide for 1 h in the dark at room temperature and digested with 




was added to the peptide mix to lower the pH below 3 and loaded onto a Stage-Tip 55 to 
efficiently  remove buffer and small molecules. The peptides were eluted with 0.1% TFA 
in 80% acetonitrile and dried completely using a SpeedVac. 
5.4.4 LC-MS/MS Analysis 
Peptides were dissolved in 4 µL of 0.3% formic acid (FA) with 3% acetonitrile (ACN) 
and injected into an Easy-nLC 1000 (Thermo Fisher Scientific). Peptides were separated 
on a 45 cm in-house packed column (360 µm OD × 75 µm ID) containing C18 resin (2.2 
µm, 100Å, Michrom Bioresources) with a 30 cm column heater (Analytical Sales and 
Services) and the temperature was set at 50 °C. The mobile phase buffer consisted of 0.1% 
FA in ultra-pure water (buffer A) with an eluting buffer of 0.1% FA in 80% ACN (buffer B) 
run over either with a linear 45 min gradient of 6%-30% buffer B at flow rate of 250 nL/min. 
The Easy-nLC 1000 was coupled online with a Velos LTQ-Orbitrap mass spectrometer 
(Thermo Fisher Scientific). The mass spectrometer was operated in the data-dependent 
mode in which a full-scan MS (from m/z 350-1500 with the resolution of 30,000 at m/z 
400). The 10 most intense ions were subjected to collision-induced dissociation (CID) 
fragmentation (normalized collision energy (NCE) 30%, AGC 3e4, max injection time 100 
ms).  
5.4.5 Data analysis 
Data analysis was performed with SEQUEST algorithms using Proteome 
Discoverer software V2.0 (ThermoFisher Scientific, San Jose, CA, USA). RAW files were 
searched against Homo sapiens database with no redundant entries and manual added 




tolerance was set at 0.8 Da (0.05 Da for HCD data). Search criteria included a static 
modification of cysteine residues of +57.0214 Da, variable modifications of +15.9949 Da 
to include potential oxidation of methionines. Search was performed with Trypsin/P 
digestion and allowed a maximum of two missed cleavages on the peptides analyzed 
from the sequence database. The false discovery rates of proteins, peptides and 
phosphosites were set at 0.01. The minimum peptide length was six amino acids, and a 
minimum Andromeda score was set at 40 for modified peptides. 
 
5.4.6 Bioinformatics 
Common contaminants and non-specific binders (including keratins, actin, 
myosin, IgG etc…) were removed manually and the list was further filtered using the 
Crapome (Contaminant Repository for Affinity Purification and Mass Spectrometry) 
online platform 56. I obtained protein-protein interaction information using the STRING 
database v.10.0 57 which includes direct (physical) as well as indirect (functional) 
associations. I used STRING in protein mode, the Homo sapiens interactome and only 
high confidence interactions (>0.7) were taken into consideration. Data was visualized 
using the STRING platform and high-resolution confidence views were downloaded and 
saved.  
5.4.7 Ribonucleoprotein Immunoprecipitation (RNP-IP) 
Cells were grown in 100mm cell culture plates. Cells were washed once with cold 
PBS and 1 mL of cold PBS was added to each plate. Cells were then cross-linked by UV-




were then resuspended in 600 µL of CST lysis buffer, briefly sonicated before 
centrifugation at 14000 rpm for 15 minutes at 4°C. 
Cleared lysates were incubated with protein G beads conjugated with HBc 
antibody or rabbit IgG. 5 µL of antibody were used for every 20 µL of bead slurry. 1 % of 
whole cell lysates were kept as input for RNA extraction. After overnight incubation with 
the beads, RIP buffer (150 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.5 mM DTT, 0.5% 
NP40) was used to wash beads 3X. The RNP complexes (on beads) were incubated with 
30 units of RNase free DNase (Thermo) for 15 minutes at room temperature and further 
incubated with 0.1% SDS and 0.5 mg/mL proteinase K (Thermo) for 15 minutes at 55°C 
to degrade DNA and proteins respectively.  
RNA was isolated from the immunoprecipitated material using Purelink RNA Mini 
Kit as per manufacturer’s protocol. Primers for lncRNAs NEAT1, NEAT2 and HOTAIR 
were used to assess RNA levels by RT-qPCR. Analysis was performed using input 
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5.6 Figure Legends 
Figure 1: Interactome analysis identifies previously known and novel HBc interacting 
partners. V- diagrams showing overlap between newly identified potential HBc 
interacting partners and previously reported HBV interacting proteins. 
Figure 2: Overlap between HIV-1 Rev and HBc interactomes. A list of 32 different 
proteins that showed up as both HBc and HIV-1 REV interacting proteins. 
Figure 3: Global map of HBc interactome. Map was created using STRING online 
platform using 226 top scoring HBV interacting partners. 
Figure 4: HBc binds lncRNAs NEAT1 and NEAT2 in HepaRG-TR-HBc cells. HBc-RIP analysis 
shows binding of HBc to lncRNAs NEAT1 and NEAT2, HOTAIR is a control lncRNA. % input 
method was used relative to IgG. 
Figure 5: HBc binds lncRNAs NEAT1 and NEAT2 in HBV replication and infection. HBc-RIP 
analysis in HepAD38 cells (A, B and C) after 5 days of HBV replication (n=2) and 
HepG2hNTCP cells (E, F and G) as shown in D. 
Figure 6: HBV infection does not induce NEAT1 and NEAT2. RT-qPCR analysis of NEAT1 
and NEAT2 expression in HepG2hNTCP cells with and without infection (n=7). 
Figure 7: HBc mutants bind lncRNAs NEAT1 and NEAT2. HBc-RIP analysis in HEK293T 
cells over-expressing different HBc mutants or WT. 3AP has 3 Ala substitutions at SP 
sites, 3DP has 3 Asp substitutions at SP sites, 3DP 3A has additional 3 Ala substitutions at 
Plk1 sites 168, 176 and 178 and finally WT 4A has 4 Ala substitutions at sites 168, 176, 




































Table 2: HBc interactome raw table 
Protein FDR 
Confidence 
Accession Description Exp. q-
value 
High P35579 Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 
SV=4 
0 
High Q15149 Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3 0 
High Q13813 Spectrin alpha chain, non-erythrocytic 1 
OS=Homo sapiens GN=SPTAN1 PE=1 SV=3 
0 
High Q01082 Spectrin beta chain, non-erythrocytic 1 
OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 
0 
High P35580 Myosin-10 OS=Homo sapiens GN=MYH10 PE=1 
SV=3 
0 
High Q13085 Acetyl-CoA carboxylase 1 OS=Homo sapiens 
GN=ACACA PE=1 SV=2 
0 
High Q96RQ3 Methylcrotonoyl-CoA carboxylase subunit alpha, 
mitochondrial OS=Homo sapiens GN=MCCC1 
PE=1 SV=3 
0 
High O43707 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 
PE=1 SV=2 
0 
High P11498 Pyruvate carboxylase, mitochondrial OS=Homo 
sapiens GN=PC PE=1 SV=2 
0 
High Q9HCC0 Methylcrotonoyl-CoA carboxylase beta chain, 
mitochondrial OS=Homo sapiens GN=MCCC2 
PE=1 SV=1 
0 
High P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
0 
High P05165 Propionyl-CoA carboxylase alpha chain, 
mitochondrial OS=Homo sapiens GN=PCCA PE=1 
SV=4 
0 
High A0A087WVQ6 Clathrin heavy chain OS=Homo sapiens GN=CLTC 
PE=3 SV=1 
0 
High P12814 Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 
PE=1 SV=2 
0 
High O00763 Acetyl-CoA carboxylase 2 OS=Homo sapiens 
GN=ACACB PE=1 SV=3 
0 
High E9PMS6 LIM domain only protein 7 OS=Homo sapiens 
GN=LMO7 PE=1 SV=1 
0 
High P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 
0 
High F8WD26 LIM domain only protein 7 OS=Homo sapiens 
GN=LMO7 PE=1 SV=2 
0 
High E9PDR0 Propionyl-CoA carboxylase beta chain, 






High E9PMT2 LIM domain only protein 7 OS=Homo sapiens 
GN=LMO7 PE=1 SV=1 
0 
High P05787 Keratin, type II cytoskeletal 8 OS=Homo sapiens 
GN=KRT8 PE=1 SV=7 
0 
High Q6WCQ1 Myosin phosphatase Rho-interacting protein 
OS=Homo sapiens GN=MPRIP PE=1 SV=3 
0 
High O00159 Unconventional myosin-Ic OS=Homo sapiens 
GN=MYO1C PE=1 SV=4 
0 
High O75369 Filamin-B OS=Homo sapiens GN=FLNB PE=1 
SV=2 
0 
High P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens 
GN=KRT9 PE=1 SV=3 
0 
High Q92614 Unconventional myosin-XVIIIa OS=Homo sapiens 
GN=MYO18A PE=1 SV=3 
0 
High Q15746 Myosin light chain kinase, smooth muscle 
OS=Homo sapiens GN=MYLK PE=1 SV=4 
0 
High P35908 Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 SV=2 
0 
High O94929 Actin-binding LIM protein 3 OS=Homo sapiens 
GN=ABLIM3 PE=1 SV=3 
0 
High P05783 Keratin, type I cytoskeletal 18 OS=Homo sapiens 
GN=KRT18 PE=1 SV=2 
0 
High P08727 Keratin, type I cytoskeletal 19 OS=Homo sapiens 
GN=KRT19 PE=1 SV=4 
0 
High P68032 Actin, alpha cardiac muscle 1 OS=Homo sapiens 
GN=ACTC1 PE=1 SV=1 
0 
High P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 
0 
High A0A0A0MRL6 Actin-binding LIM protein 1 OS=Homo sapiens 
GN=ABLIM1 PE=4 SV=1 
0 
High O14639 Actin-binding LIM protein 1 OS=Homo sapiens 
GN=ABLIM1 PE=1 SV=3 
0 
High P21333 Filamin-A OS=Homo sapiens GN=FLNA PE=1 
SV=4 
0 
High A0A0A0MRM8 Unconventional myosin-VI OS=Homo sapiens 
GN=MYO6 PE=4 SV=1 
0 
High Q7Z406 Myosin-14 OS=Homo sapiens GN=MYH14 PE=1 
SV=2 
0 
High H0Y2S9 Myosin phosphatase Rho-interacting protein 
(Fragment) OS=Homo sapiens GN=MPRIP PE=1 
SV=3 
0 
High P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB 
PE=1 SV=2 
0 
High P68371 Tubulin beta-4B chain OS=Homo sapiens 





High O43795 Unconventional myosin-Ib OS=Homo sapiens 
GN=MYO1B PE=1 SV=3 
0 
High O00515 Ladinin-1 OS=Homo sapiens GN=LAD1 PE=1 
SV=2 
0 
High P25705 ATP synthase subunit alpha, mitochondrial 
OS=Homo sapiens GN=ATP5A1 PE=1 SV=1 
0 
High O15042 U2 snRNP-associated SURP motif-containing 
protein OS=Homo sapiens GN=U2SURP PE=1 
SV=2 
0 
High A0A087WWU8 Tropomyosin alpha-3 chain OS=Homo sapiens 
GN=TPM3 PE=1 SV=1 
0 
High P02538 Keratin, type II cytoskeletal 6A OS=Homo 
sapiens GN=KRT6A PE=1 SV=3 
0 
High P09493 Tropomyosin alpha-1 chain OS=Homo sapiens 
GN=TPM1 PE=1 SV=2 
0 
High P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens 
GN=KRT14 PE=1 SV=4 
0 
High P67936 Tropomyosin alpha-4 chain OS=Homo sapiens 
GN=TPM4 PE=1 SV=3 
0 
High Q9UPQ0 LIM and calponin homology domains-containing 
protein 1 OS=Homo sapiens GN=LIMCH1 PE=1 
SV=4 
0 
High Q9ULV4 Coronin-1C OS=Homo sapiens GN=CORO1C PE=1 
SV=1 
0 
High P04259 Keratin, type II cytoskeletal 6B OS=Homo 
sapiens GN=KRT6B PE=1 SV=5 
0 
High O95425 Supervillin OS=Homo sapiens GN=SVIL PE=1 
SV=2 
0 
High Q6ZN40 Tropomyosin 1 (Alpha), isoform CRA_f 
OS=Homo sapiens GN=TPM1 PE=2 SV=1 
0 
High J3QSX6 Actin-binding LIM protein 1 OS=Homo sapiens 
GN=ABLIM1 PE=1 SV=2 
0 
High Q16643 Drebrin OS=Homo sapiens GN=DBN1 PE=1 SV=4 0 
High H7BYY1 Tropomyosin 1 (Alpha), isoform CRA_m 
OS=Homo sapiens GN=TPM1 PE=3 SV=1 
0 
High Q96I24 Far upstream element-binding protein 3 
OS=Homo sapiens GN=FUBP3 PE=1 SV=2 
0 
High J3KN67 Tropomyosin alpha-3 chain OS=Homo sapiens 
GN=TPM3 PE=1 SV=1 
0 
High O15020 Spectrin beta chain, non-erythrocytic 2 
OS=Homo sapiens GN=SPTBN2 PE=1 SV=3 
0 
High P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens 
GN=KRT5 PE=1 SV=3 
0 
High I3L204 Unconventional myosin-Ic (Fragment) OS=Homo 





High P11021 78 kDa glucose-regulated protein OS=Homo 
sapiens GN=HSPA5 PE=1 SV=2 
0 
High K7EJH8 Alpha-actinin-4 (Fragment) OS=Homo sapiens 
GN=ACTN4 PE=1 SV=1 
0 
High Q9Y2D5 A-kinase anchor protein 2 OS=Homo sapiens 
GN=AKAP2 PE=1 SV=3 
0 
High Q13045 Protein flightless-1 homolog OS=Homo sapiens 
GN=FLII PE=1 SV=2 
0 
High J3QRS3 Myosin regulatory light chain 12A OS=Homo 
sapiens GN=MYL12A PE=4 SV=1 
0 
High H0YK48 Tropomyosin alpha-1 chain OS=Homo sapiens 
GN=TPM1 PE=1 SV=1 
0 
High O94832 Unconventional myosin-Id OS=Homo sapiens 
GN=MYO1D PE=1 SV=2 
0 
High J3KND3 Myosin light polypeptide 6 OS=Homo sapiens 
GN=MYL6 PE=1 SV=1 
0 
High Q9ULV0 Unconventional myosin-Vb OS=Homo sapiens 
GN=MYO5B PE=1 SV=3 
0 
High P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens 
GN=KRT16 PE=1 SV=4 
0 
High G8JLA2 Myosin light polypeptide 6 OS=Homo sapiens 
GN=MYL6 PE=1 SV=1 
0 
High J3KN01 Afadin OS=Homo sapiens GN=MLLT4 PE=1 SV=1 0 
High B1AK88 Capping protein (Actin filament) muscle Z-line, 
beta, isoform CRA_d OS=Homo sapiens 
GN=CAPZB PE=1 SV=1 
0 
High Q8N3V7 Synaptopodin OS=Homo sapiens GN=SYNPO 
PE=1 SV=2 
0 
High P38646 Stress-70 protein, mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 SV=2 
0 
High P15144 Aminopeptidase N OS=Homo sapiens 
GN=ANPEP PE=1 SV=4 
0 
High Q9NS25 Sperm protein associated with the nucleus on 
the X chromosome B/F OS=Homo sapiens 
GN=SPANXB1 PE=2 SV=1 
0 
High J3QK89 Calcium homeostasis endoplasmic reticulum 
protein OS=Homo sapiens GN=CHERP PE=1 SV=1 
0 
High P49411 Elongation factor Tu, mitochondrial OS=Homo 
sapiens GN=TUFM PE=1 SV=2 
0 
High P68363 Tubulin alpha-1B chain OS=Homo sapiens 
GN=TUBA1B PE=1 SV=1 
0 
High P11142 Heat shock cognate 71 kDa protein OS=Homo 
sapiens GN=HSPA8 PE=1 SV=1 
0 






High O00571 ATP-dependent RNA helicase DDX3X OS=Homo 
sapiens GN=DDX3X PE=1 SV=3 
0 
High Q9Y2W1 Thyroid hormone receptor-associated protein 3 
OS=Homo sapiens GN=THRAP3 PE=1 SV=2 
0 
High Q69YQ0 Cytospin-A OS=Homo sapiens GN=SPECC1L PE=1 
SV=2 
0 
High E9PGZ1 Caldesmon OS=Homo sapiens GN=CALD1 PE=1 
SV=1 
0 
High O95782 AP-2 complex subunit alpha-1 OS=Homo sapiens 
GN=AP2A1 PE=1 SV=3 
0 
High P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo 
sapiens GN=TRIM21 PE=1 SV=1 
0 
High Q96PK6 RNA-binding protein 14 OS=Homo sapiens 
GN=RBM14 PE=1 SV=2 
0 
High Q562R1 Beta-actin-like protein 2 OS=Homo sapiens 
GN=ACTBL2 PE=1 SV=2 
0 
High Q05682 Caldesmon OS=Homo sapiens GN=CALD1 PE=1 
SV=3 
0 
High P05141 ADP/ATP translocase 2 OS=Homo sapiens 
GN=SLC25A5 PE=1 SV=7 
0 
High P47755 F-actin-capping protein subunit alpha-2 
OS=Homo sapiens GN=CAPZA2 PE=1 SV=3 
0 
High P06576 ATP synthase subunit beta, mitochondrial 
OS=Homo sapiens GN=ATP5B PE=1 SV=3 
0 
High Q9UHB6 LIM domain and actin-binding protein 1 
OS=Homo sapiens GN=LIMA1 PE=1 SV=1 
0 
High P68366 Tubulin alpha-4A chain OS=Homo sapiens 
GN=TUBA4A PE=1 SV=1 
0 
High P52907 F-actin-capping protein subunit alpha-1 
OS=Homo sapiens GN=CAPZA1 PE=1 SV=3 
0 
High O94875 Sorbin and SH3 domain-containing protein 2 
OS=Homo sapiens GN=SORBS2 PE=1 SV=3 
0 
High Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 
SV=2 
0 
High P07355 Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 
SV=2 
0 
High Q9NYL9 Tropomodulin-3 OS=Homo sapiens GN=TMOD3 
PE=1 SV=1 
0 
High Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens 
GN=KRT17 PE=1 SV=2 
0 
High P62269 40S ribosomal protein S18 OS=Homo sapiens 
GN=RPS18 PE=1 SV=3 
0 
High A0A0A0MR36 Unconventional myosin-Vb (Fragment) 





High G3V1L9 Tight junction protein 1 (Zona occludens 1), 
isoform CRA_a OS=Homo sapiens GN=TJP1 PE=4 
SV=1 
0 
High H7BXR3 Sorbin and SH3 domain-containing protein 2 
(Fragment) OS=Homo sapiens GN=SORBS2 PE=1 
SV=1 
0 
High Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 
SV=1 
0 
High P68104 Elongation factor 1-alpha 1 OS=Homo sapiens 
GN=EEF1A1 PE=1 SV=1 
0 
High P78386 Keratin, type II cuticular Hb5 OS=Homo sapiens 
GN=KRT85 PE=1 SV=1 
0 
High P36578 60S ribosomal protein L4 OS=Homo sapiens 
GN=RPL4 PE=1 SV=5 
0 
High P23246 Splicing factor, proline- and glutamine-rich 
OS=Homo sapiens GN=SFPQ PE=1 SV=2 
0 
High P28799 Granulins OS=Homo sapiens GN=GRN PE=1 SV=2 0 
High F8WE88 Unconventional myosin-Va OS=Homo sapiens 
GN=MYO5A PE=1 SV=2 
0 
High Q96C19 EF-hand domain-containing protein D2 
OS=Homo sapiens GN=EFHD2 PE=1 SV=1 
0 
High Q9BX66 Sorbin and SH3 domain-containing protein 1 
OS=Homo sapiens GN=SORBS1 PE=1 SV=3 
0 
High P46783 40S ribosomal protein S10 OS=Homo sapiens 
GN=RPS10 PE=1 SV=1 
0 
High Q9Y4K1 Absent in melanoma 1 protein OS=Homo 
sapiens GN=AIM1 PE=1 SV=3 
0 
High Q13425 Beta-2-syntrophin OS=Homo sapiens GN=SNTB2 
PE=1 SV=1 
0 
High P02545 Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 
SV=1 
0 
High P11137 Microtubule-associated protein 2 OS=Homo 
sapiens GN=MAP2 PE=1 SV=4 
0 
High D3DTX6 Neurabin-2 OS=Homo sapiens GN=PPP1R9B 
PE=4 SV=1 
0 
High P62136 Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit OS=Homo sapiens 
GN=PPP1CA PE=1 SV=1 
0 
High O43790 Keratin, type II cuticular Hb6 OS=Homo sapiens 
GN=KRT86 PE=1 SV=1 
0 
High Q06830 Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 
PE=1 SV=1 
0 
High Q7Z5L9 Interferon regulatory factor 2-binding protein 2 
OS=Homo sapiens GN=IRF2BP2 PE=1 SV=2 
0 
High O95678 Keratin, type II cytoskeletal 75 OS=Homo 





High P04406 Glyceraldehyde-3-phosphate dehydrogenase 
OS=Homo sapiens GN=GAPDH PE=1 SV=3 
0 
High P63010 AP-2 complex subunit beta OS=Homo sapiens 
GN=AP2B1 PE=1 SV=1 
0 
High P06748 Nucleophosmin OS=Homo sapiens GN=NPM1 
PE=1 SV=2 
0 
High P14373 Zinc finger protein RFP OS=Homo sapiens 
GN=TRIM27 PE=1 SV=1 
0 
High P62979 Ubiquitin-40S ribosomal protein S27a OS=Homo 
sapiens GN=RPS27A PE=1 SV=2 
0 
High P14618 Pyruvate kinase PKM OS=Homo sapiens 
GN=PKM PE=1 SV=4 
0 
High P23396 40S ribosomal protein S3 OS=Homo sapiens 
GN=RPS3 PE=1 SV=2 
0 
High Q9BY89 Uncharacterized protein KIAA1671 OS=Homo 
sapiens GN=KIAA1671 PE=1 SV=2 
0 
High P33121 Long-chain-fatty-acid--CoA ligase 1 OS=Homo 
sapiens GN=ACSL1 PE=1 SV=1 
0 
High A0A087X130 Ig kappa chain C region OS=Homo sapiens 
GN=IGKC PE=4 SV=1 
0 
High P62701 40S ribosomal protein S4, X isoform OS=Homo 
sapiens GN=RPS4X PE=1 SV=2 
0 
High Q14677 Clathrin interactor 1 OS=Homo sapiens 
GN=CLINT1 PE=1 SV=1 
0 
High P29590 Protein PML OS=Homo sapiens GN=PML PE=1 
SV=3 
0 
High P61247 40S ribosomal protein S3a OS=Homo sapiens 
GN=RPS3A PE=1 SV=2 
0 
High P35222 Catenin beta-1 OS=Homo sapiens GN=CTNNB1 
PE=1 SV=1 
0 
High P62987 Ubiquitin-60S ribosomal protein L40 OS=Homo 
sapiens GN=UBA52 PE=1 SV=2 
0 
High E7EMB3 Calmodulin OS=Homo sapiens GN=CALM2 PE=1 
SV=1 
0 
High Q02878 60S ribosomal protein L6 OS=Homo sapiens 
GN=RPL6 PE=1 SV=3 
0 
High P36542 ATP synthase subunit gamma, mitochondrial 
OS=Homo sapiens GN=ATP5C1 PE=1 SV=1 
0 
High O00151 PDZ and LIM domain protein 1 OS=Homo 
sapiens GN=PDLIM1 PE=1 SV=4 
0 
High P12235 ADP/ATP translocase 1 OS=Homo sapiens 
GN=SLC25A4 PE=1 SV=4 
0 
High Q15233 Non-POU domain-containing octamer-binding 
protein OS=Homo sapiens GN=NONO PE=1 SV=4 
0 
High O94973 AP-2 complex subunit alpha-2 OS=Homo sapiens 





High Q9Y608 Leucine-rich repeat flightless-interacting protein 
2 OS=Homo sapiens GN=LRRFIP2 PE=1 SV=1 
0 
High P48047 ATP synthase subunit O, mitochondrial 
OS=Homo sapiens GN=ATP5O PE=1 SV=1 
0 
High P35221 Catenin alpha-1 OS=Homo sapiens GN=CTNNA1 
PE=1 SV=1 
0 
High Q00839 Heterogeneous nuclear ribonucleoprotein U 
OS=Homo sapiens GN=HNRNPU PE=1 SV=6 
0 
High P18124 60S ribosomal protein L7 OS=Homo sapiens 
GN=RPL7 PE=1 SV=1 
0 
High P16402 Histone H1.3 OS=Homo sapiens GN=HIST1H1D 
PE=1 SV=2 
0 
High P62249 40S ribosomal protein S16 OS=Homo sapiens 
GN=RPS16 PE=1 SV=2 
0 
High P62851 40S ribosomal protein S25 OS=Homo sapiens 
GN=RPS25 PE=1 SV=1 
0 
High P38159 RNA-binding motif protein, X chromosome 
OS=Homo sapiens GN=RBMX PE=1 SV=3 
0 
High P62424 60S ribosomal protein L7a OS=Homo sapiens 
GN=RPL7A PE=1 SV=2 
0 
High F5GYR0 Actin-binding LIM protein 2 OS=Homo sapiens 
GN=ABLIM2 PE=4 SV=2 
0 
High Q13501 Sequestosome-1 OS=Homo sapiens GN=SQSTM1 
PE=1 SV=1 
0 
High P06733 Alpha-enolase OS=Homo sapiens GN=ENO1 
PE=1 SV=2 
0 
High P50395 Rab GDP dissociation inhibitor beta OS=Homo 
sapiens GN=GDI2 PE=1 SV=2 
0 
High P62140 Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit OS=Homo sapiens GN=PPP1CB 
PE=1 SV=3 
0 
High Q12792 Twinfilin-1 OS=Homo sapiens GN=TWF1 PE=1 
SV=3 
0 
High E9PFW3 AP-2 complex subunit mu OS=Homo sapiens 
GN=AP2M1 PE=1 SV=1 
0 
High P22626 Heterogeneous nuclear ribonucleoproteins 
A2/B1 OS=Homo sapiens GN=HNRNPA2B1 PE=1 
SV=2 
0 
High H3BLZ8 Probable ATP-dependent RNA helicase DDX17 
OS=Homo sapiens GN=DDX17 PE=1 SV=1 
0 
High Q08380 Galectin-3-binding protein OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 
0 
High Q86X51 Uncharacterized protein CXorf67 OS=Homo 
sapiens GN=CXorf67 PE=2 SV=1 
0 
High P62241 40S ribosomal protein S8 OS=Homo sapiens 





High J3KS54 Protein flightless-1 homolog OS=Homo sapiens 
GN=FLII PE=1 SV=1 
0 
High G8JLB6 Heterogeneous nuclear ribonucleoprotein H 
OS=Homo sapiens GN=HNRNPH1 PE=1 SV=1 
0 
High Q02543 60S ribosomal protein L18a OS=Homo sapiens 
GN=RPL18A PE=1 SV=2 
0 
High P26373 60S ribosomal protein L13 OS=Homo sapiens 
GN=RPL13 PE=1 SV=4 
0 
High P62753 40S ribosomal protein S6 OS=Homo sapiens 
GN=RPS6 PE=1 SV=1 
0 
High P35268 60S ribosomal protein L22 OS=Homo sapiens 
GN=RPL22 PE=1 SV=2 
0 
High Q6ZRV2 Protein FAM83H OS=Homo sapiens 
GN=FAM83H PE=1 SV=3 
0 
High P52272 Heterogeneous nuclear ribonucleoprotein M 
OS=Homo sapiens GN=HNRNPM PE=1 SV=3 
0 
High J3KTA4 Probable ATP-dependent RNA helicase DDX5 
OS=Homo sapiens GN=DDX5 PE=1 SV=1 
0 
High E9PKC0 Pleckstrin homology domain-containing family A 
member 7 OS=Homo sapiens GN=PLEKHA7 PE=1 
SV=1 
0 
High Q9NS26 Sperm protein associated with the nucleus on 
the X chromosome A OS=Homo sapiens 
GN=SPANXA1 PE=2 SV=1 
0 
High O14974 Protein phosphatase 1 regulatory subunit 12A 
OS=Homo sapiens GN=PPP1R12A PE=1 SV=1 
0 
High P98082 Disabled homolog 2 OS=Homo sapiens 
GN=DAB2 PE=1 SV=3 
0 
High P06396 Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 0 
High Q08431 Lactadherin OS=Homo sapiens GN=MFGE8 PE=1 
SV=2 
0 
High P61313 60S ribosomal protein L15 OS=Homo sapiens 
GN=RPL15 PE=1 SV=2 
0 
High U3KQK0 Histone H2B OS=Homo sapiens GN=HIST1H2BN 
PE=3 SV=1 
0 
High A0A0A0MRV0 Ribosome-binding protein 1 OS=Homo sapiens 
GN=RRBP1 PE=4 SV=1 
0 
High O60941 Dystrobrevin beta OS=Homo sapiens GN=DTNB 
PE=1 SV=1 
0 
High P62937 Peptidyl-prolyl cis-trans isomerase A OS=Homo 
sapiens GN=PPIA PE=1 SV=2 
0 
High P62913 60S ribosomal protein L11 OS=Homo sapiens 
GN=RPL11 PE=1 SV=2 
0 
High P62829 60S ribosomal protein L23 OS=Homo sapiens 





High O43166 Signal-induced proliferation-associated 1-like 
protein 1 OS=Homo sapiens GN=SIPA1L1 PE=1 
SV=4 
0 
High P09496 Clathrin light chain A OS=Homo sapiens 
GN=CLTA PE=1 SV=1 
0 
High Q5VWP3 Muscular LMNA-interacting protein OS=Homo 
sapiens GN=MLIP PE=1 SV=3 
0 
High P04908 Histone H2A type 1-B/E OS=Homo sapiens 
GN=HIST1H2AB PE=1 SV=2 
0 
High Q9P266 Junctional protein associated with coronary 
artery disease OS=Homo sapiens GN=KIAA1462 
PE=1 SV=3 
0 
High Q96E39 RNA binding motif protein, X-linked-like-1 
OS=Homo sapiens GN=RBMXL1 PE=1 SV=1 
0 
High Q99569 Plakophilin-4 OS=Homo sapiens GN=PKP4 PE=1 
SV=2 
0 
High P21397 Amine oxidase [flavin-containing] A OS=Homo 
sapiens GN=MAOA PE=1 SV=1 
0 
High P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A 
PE=1 SV=2 
0 
High Q6FI13 Histone H2A type 2-A OS=Homo sapiens 
GN=HIST2H2AA3 PE=1 SV=3 
0 
High A0A087X2I6 Keratin, type I cuticular Ha3-II OS=Homo sapiens 
GN=KRT33B PE=3 SV=1 
0 
High P60866 40S ribosomal protein S20 OS=Homo sapiens 
GN=RPS20 PE=1 SV=1 
0 
High Q15323 Keratin, type I cuticular Ha1 OS=Homo sapiens 
GN=KRT31 PE=2 SV=3 
0 
High P62280 40S ribosomal protein S11 OS=Homo sapiens 
GN=RPS11 PE=1 SV=3 
0 
High Q4KMQ1 Taperin OS=Homo sapiens GN=TPRN PE=1 SV=2 0 
High J3KQN4 60S ribosomal protein L36a OS=Homo sapiens 
GN=RPL36A PE=3 SV=1 
0 
High P62917 60S ribosomal protein L8 OS=Homo sapiens 
GN=RPL8 PE=1 SV=2 
0 
High P39019 40S ribosomal protein S19 OS=Homo sapiens 
GN=RPS19 PE=1 SV=2 
0 
High P19013 Keratin, type II cytoskeletal 4 OS=Homo sapiens 
GN=KRT4 PE=1 SV=4 
0 
High Q969Q0 60S ribosomal protein L36a-like OS=Homo 
sapiens GN=RPL36AL PE=1 SV=3 
0 
High Q71DI3 Histone H3.2 OS=Homo sapiens GN=HIST2H3A 
PE=1 SV=3 
0 
High P27348 14-3-3 protein theta OS=Homo sapiens 





High A0A0A0PLW7 Core protein (Fragment) OS=Hepatitis B virus 
GN=C PE=4 SV=1 
0 
High Q01105 Protein SET OS=Homo sapiens GN=SET PE=1 
SV=3 
0 
High P84090 Enhancer of rudimentary homolog OS=Homo 
sapiens GN=ERH PE=1 SV=1 
0 
High J3QQ67 60S ribosomal protein L18 (Fragment) OS=Homo 
sapiens GN=RPL18 PE=1 SV=1 
0 
High P27105 Erythrocyte band 7 integral membrane protein 
OS=Homo sapiens GN=STOM PE=1 SV=3 
0 
High P55795 Heterogeneous nuclear ribonucleoprotein H2 
OS=Homo sapiens GN=HNRNPH2 PE=1 SV=1 
0 
High A0A0A6YYJ8 Putative RNA-binding protein Luc7-like 2 
OS=Homo sapiens GN=LUC7L2 PE=4 SV=1 
0 
High P63173 60S ribosomal protein L38 OS=Homo sapiens 
GN=RPL38 PE=1 SV=2 
0 
High P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 
PE=1 SV=4 
0 
High M0R2L9 40S ribosomal protein S19 (Fragment) OS=Homo 
sapiens GN=RPS19 PE=1 SV=1 
0 
High O60701 UDP-glucose 6-dehydrogenase OS=Homo 
sapiens GN=UGDH PE=1 SV=1 
0 
High Q8TA86 Retinitis pigmentosa 9 protein OS=Homo 
sapiens GN=RP9 PE=1 SV=2 
0 
High Q6KC79 Nipped-B-like protein OS=Homo sapiens 
GN=NIPBL PE=1 SV=2 
0 
High P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 
PE=1 SV=1 
0 
High P06899 Histone H2B type 1-J OS=Homo sapiens 
GN=HIST1H2BJ PE=1 SV=3 
0 
High P62263 40S ribosomal protein S14 OS=Homo sapiens 
GN=RPS14 PE=1 SV=3 
0 
High P39023 60S ribosomal protein L3 OS=Homo sapiens 
GN=RPL3 PE=1 SV=2 
0 
High P84243 Histone H3.3 OS=Homo sapiens GN=H3F3A PE=1 
SV=2 
0 
High O75494 Serine/arginine-rich splicing factor 10 OS=Homo 
sapiens GN=SRSF10 PE=1 SV=1 
0 
High P0CW22 40S ribosomal protein S17-like OS=Homo 
sapiens GN=RPS17L PE=1 SV=1 
0 
High P08238 Heat shock protein HSP 90-beta OS=Homo 
sapiens GN=HSP90AB1 PE=1 SV=4 
0 
High Q6NZI2 Polymerase I and transcript release factor 
OS=Homo sapiens GN=PTRF PE=1 SV=1 
0 
High P09651 Heterogeneous nuclear ribonucleoprotein A1 





High H0Y2W2 ATPase family AAA domain-containing protein 
3A (Fragment) OS=Homo sapiens GN=ATAD3A 
PE=1 SV=1 
0 
High Q9NQX4 Unconventional myosin-Vc OS=Homo sapiens 
GN=MYO5C PE=1 SV=2 
0 
High P30050 60S ribosomal protein L12 OS=Homo sapiens 
GN=RPL12 PE=1 SV=1 
0 
High P09497 Clathrin light chain B OS=Homo sapiens 
GN=CLTB PE=1 SV=1 
0 
High Q9NSY1 BMP-2-inducible protein kinase OS=Homo 
sapiens GN=BMP2K PE=1 SV=2 
0 
High P45880 Voltage-dependent anion-selective channel 
protein 2 OS=Homo sapiens GN=VDAC2 PE=1 
SV=2 
0 
High Q9NWB6 Arginine and glutamate-rich protein 1 OS=Homo 
sapiens GN=ARGLU1 PE=1 SV=1 
0 
High Q6NYC8 Phostensin OS=Homo sapiens GN=PPP1R18 
PE=1 SV=1 
0 
High P62266 40S ribosomal protein S23 OS=Homo sapiens 
GN=RPS23 PE=1 SV=3 
0 
High P61158 Actin-related protein 3 OS=Homo sapiens 
GN=ACTR3 PE=1 SV=3 
0 
High P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 
SV=3 
0 
High P10809 60 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPD1 PE=1 SV=2 
0 
High P62879 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 OS=Homo sapiens 
GN=GNB2 PE=1 SV=3 
0 
High H0Y8C2 60S ribosomal protein L22-like 1 (Fragment) 
OS=Homo sapiens GN=RPL22L1 PE=4 SV=1 
0 
High P46776 60S ribosomal protein L27a OS=Homo sapiens 
GN=RPL27A PE=1 SV=2 
0 
High O43734 Adapter protein CIKS OS=Homo sapiens 
GN=TRAF3IP2 PE=1 SV=3 
0 
High P62854 40S ribosomal protein S26 OS=Homo sapiens 
GN=RPS26 PE=1 SV=3 
0 
High F8W1S1 Keratin, type II cytoskeletal 74 OS=Homo 
sapiens GN=KRT74 PE=1 SV=1 
0 
High Q15637 Splicing factor 1 OS=Homo sapiens GN=SF1 PE=1 
SV=4 
0 
High P04899 Guanine nucleotide-binding protein G(i) subunit 
alpha-2 OS=Homo sapiens GN=GNAI2 PE=1 SV=3 
0 
High G1E7Q7 External core antigen OS=Hepatitis B virus PE=3 
SV=1 
0 




High P61254 60S ribosomal protein L26 OS=Homo sapiens 
GN=RPL26 PE=1 SV=1 
0 
High P80297 Metallothionein-1X OS=Homo sapiens GN=MT1X 
PE=1 SV=1 
0 
High A0A0A6YYL6 Protein RPL17-C18orf32 OS=Homo sapiens 
GN=RPL17-C18orf32 PE=4 SV=1 
0 
High P00338 L-lactate dehydrogenase A chain OS=Homo 
sapiens GN=LDHA PE=1 SV=2 
0 
High P05388 60S acidic ribosomal protein P0 OS=Homo 
sapiens GN=RPLP0 PE=1 SV=1 
0 
High Q92804 TATA-binding protein-associated factor 2N 
OS=Homo sapiens GN=TAF15 PE=1 SV=1 
0 
High P04792 Heat shock protein beta-1 OS=Homo sapiens 
GN=HSPB1 PE=1 SV=2 
0 
High H0Y449 Nuclease-sensitive element-binding protein 1 
(Fragment) OS=Homo sapiens GN=YBX1 PE=1 
SV=1 
0 
High M0R0R2 40S ribosomal protein S5 OS=Homo sapiens 
GN=RPS5 PE=1 SV=1 
0 
High Q92764 Keratin, type I cuticular Ha5 OS=Homo sapiens 
GN=KRT35 PE=2 SV=5 
0 
High P15880 40S ribosomal protein S2 OS=Homo sapiens 
GN=RPS2 PE=1 SV=2 
0 
High Q9H477 Ribokinase OS=Homo sapiens GN=RBKS PE=1 
SV=1 
0 
High P51991 Heterogeneous nuclear ribonucleoprotein A3 
OS=Homo sapiens GN=HNRNPA3 PE=1 SV=2 
0 
High P62277 40S ribosomal protein S13 OS=Homo sapiens 
GN=RPS13 PE=1 SV=2 
0 
High Q9NR12 PDZ and LIM domain protein 7 OS=Homo 
sapiens GN=PDLIM7 PE=1 SV=1 
0 
High P83731 60S ribosomal protein L24 OS=Homo sapiens 
GN=RPL24 PE=1 SV=1 
0 
High L0H7I3 Core protein OS=Hepatitis B virus GN=C PE=4 
SV=1 
0 
High P23284 Peptidyl-prolyl cis-trans isomerase B OS=Homo 
sapiens GN=PPIB PE=1 SV=2 
0 
High Q6UWP8 Suprabasin OS=Homo sapiens GN=SBSN PE=2 
SV=2 
0 
High Q9BR76 Coronin-1B OS=Homo sapiens GN=CORO1B 
PE=1 SV=1 
0 
High P02795 Metallothionein-2 OS=Homo sapiens GN=MT2A 
PE=1 SV=1 
0 






High P01023 Alpha-2-macroglobulin OS=Homo sapiens 
GN=A2M PE=1 SV=3 
0 
High B1ALY0 Protein PALM2-AKAP2 (Fragment) OS=Homo 
sapiens GN=PALM2-AKAP2 PE=4 SV=1 
0 
High P46781 40S ribosomal protein S9 OS=Homo sapiens 
GN=RPS9 PE=1 SV=3 
0 
High E9PR17 CD59 glycoprotein OS=Homo sapiens GN=CD59 
PE=1 SV=1 
0 
High Q9UDY2 Tight junction protein ZO-2 OS=Homo sapiens 
GN=TJP2 PE=1 SV=2 
0 
High O76031 ATP-dependent Clp protease ATP-binding 
subunit clpX-like, mitochondrial OS=Homo 
sapiens GN=CLPX PE=1 SV=2 
0 
High Q9UGI8 Testin OS=Homo sapiens GN=TES PE=1 SV=1 0 
High P01891 HLA class I histocompatibility antigen, A-68 
alpha chain OS=Homo sapiens GN=HLA-A PE=1 
SV=4 
0 
High Q9Y6N5 Sulfide:quinone oxidoreductase, mitochondrial 
OS=Homo sapiens GN=SQRDL PE=1 SV=1 
0 
High H7BY58 Protein-L-isoaspartate O-methyltransferase 
OS=Homo sapiens GN=PCMT1 PE=1 SV=1 
0 
High A0A0A0MTH9 TATA-binding protein-associated factor 172 
OS=Homo sapiens GN=BTAF1 PE=4 SV=1 
0 
High Q9Y5B9 FACT complex subunit SPT16 OS=Homo sapiens 
GN=SUPT16H PE=1 SV=1 
0 
High F8VVM2 Phosphate carrier protein, mitochondrial 
OS=Homo sapiens GN=SLC25A3 PE=1 SV=1 
0 
High A0A871 External core antigen OS=Hepatitis B virus 
GN=PreC/C PE=3 SV=1 
0 
High M0QYS1 60S ribosomal protein L13a (Fragment) 
OS=Homo sapiens GN=RPL13A PE=1 SV=2 
0 
High E9PB61 THO complex subunit 4 OS=Homo sapiens 
GN=ALYREF PE=1 SV=1 
0 
High Q9P0K7 Ankycorbin OS=Homo sapiens GN=RAI14 PE=1 
SV=2 
0 
High Q08211 ATP-dependent RNA helicase A OS=Homo 
sapiens GN=DHX9 PE=1 SV=4 
0 
High E7EVA0 Microtubule-associated protein OS=Homo 
sapiens GN=MAP4 PE=1 SV=1 
0 
High Q8NC51 Plasminogen activator inhibitor 1 RNA-binding 
protein OS=Homo sapiens GN=SERBP1 PE=1 
SV=2 
0 
High H0Y948 Afadin (Fragment) OS=Homo sapiens GN=MLLT4 
PE=1 SV=1 
0 
High P46940 Ras GTPase-activating-like protein IQGAP1 





High P84098 60S ribosomal protein L19 OS=Homo sapiens 
GN=RPL19 PE=1 SV=1 
0 
High H3BN98 Uncharacterized protein (Fragment) OS=Homo 
sapiens PE=4 SV=2 
0 
High Q9UNX3 60S ribosomal protein L26-like 1 OS=Homo 
sapiens GN=RPL26L1 PE=1 SV=1 
0 
High H3BPE7 RNA-binding protein FUS OS=Homo sapiens 
GN=FUS PE=1 SV=1 
0 
High P31946 14-3-3 protein beta/alpha OS=Homo sapiens 
GN=YWHAB PE=1 SV=3 
0 
High P05387 60S acidic ribosomal protein P2 OS=Homo 
sapiens GN=RPLP2 PE=1 SV=1 
0 
High P02751 Fibronectin OS=Homo sapiens GN=FN1 PE=1 
SV=4 
0 
High Q16527 Cysteine and glycine-rich protein 2 OS=Homo 
sapiens GN=CSRP2 PE=1 SV=3 
0 
High O76021 Ribosomal L1 domain-containing protein 1 
OS=Homo sapiens GN=RSL1D1 PE=1 SV=3 
0 
High P14649 Myosin light chain 6B OS=Homo sapiens 
GN=MYL6B PE=1 SV=1 
0 
High O75367 Core histone macro-H2A.1 OS=Homo sapiens 
GN=H2AFY PE=1 SV=4 
0 
High Q9NYF8 Bcl-2-associated transcription factor 1 OS=Homo 
sapiens GN=BCLAF1 PE=1 SV=2 
0 
High P61978 Heterogeneous nuclear ribonucleoprotein K 
OS=Homo sapiens GN=HNRNPK PE=1 SV=1 
0 
High P48735 Isocitrate dehydrogenase [NADP], mitochondrial 
OS=Homo sapiens GN=IDH2 PE=1 SV=2 
0 
High P62906 60S ribosomal protein L10a OS=Homo sapiens 
GN=RPL10A PE=1 SV=2 
0 
High Q16666 Gamma-interferon-inducible protein 16 
OS=Homo sapiens GN=IFI16 PE=1 SV=3 
0 
High A0A087WXF8 Nucleolar protein of 40 kDa OS=Homo sapiens 
GN=ZCCHC17 PE=1 SV=1 
0 
High P60842 Eukaryotic initiation factor 4A-I OS=Homo 
sapiens GN=EIF4A1 PE=1 SV=1 
0 
High I3XMW9 External core antigen OS=Hepatitis B virus GN=C 
PE=3 SV=1 
0 
High O14908 PDZ domain-containing protein GIPC1 OS=Homo 
sapiens GN=GIPC1 PE=1 SV=2 
0 
High Q9NSB4 Keratin, type II cuticular Hb2 OS=Homo sapiens 
GN=KRT82 PE=1 SV=3 
0 
High A0A075B6K9 Ig lambda-2 chain C regions (Fragment) 
OS=Homo sapiens GN=IGLC2 PE=4 SV=1 
0 
High P61981 14-3-3 protein gamma OS=Homo sapiens 





High G3V4C1 Heterogeneous nuclear ribonucleoproteins 
C1/C2 OS=Homo sapiens GN=HNRNPC PE=1 
SV=1 
0 
High P62750 60S ribosomal protein L23a OS=Homo sapiens 
GN=RPL23A PE=1 SV=1 
0 
High Q6YHK3 CD109 antigen OS=Homo sapiens GN=CD109 
PE=1 SV=2 
0 
High Q95604 HLA class I histocompatibility antigen, Cw-17 
alpha chain OS=Homo sapiens GN=HLA-C PE=1 
SV=1 
0 
High P07900 Heat shock protein HSP 90-alpha OS=Homo 
sapiens GN=HSP90AA1 PE=1 SV=5 
0 
High Q14247 Src substrate cortactin OS=Homo sapiens 
GN=CTTN PE=1 SV=2 
0 
High O00567 Nucleolar protein 56 OS=Homo sapiens 
GN=NOP56 PE=1 SV=4 
0 
High Q6J326 External core antigen OS=Hepatitis B virus PE=3 
SV=1 
0 
High P23141 Liver carboxylesterase 1 OS=Homo sapiens 
GN=CES1 PE=1 SV=2 
0 
High K7QJE2 External core antigen OS=Hepatitis B virus GN=C 
PE=3 SV=1 
0 
High H6V5L5 HBcAg OS=Hepatitis B virus PE=4 SV=1 0 
High P02787 Serotransferrin OS=Homo sapiens GN=TF PE=1 
SV=3 
0 
High P31040 Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial OS=Homo 
sapiens GN=SDHA PE=1 SV=2 
0 
High P09874 Poly [ADP-ribose] polymerase 1 OS=Homo 
sapiens GN=PARP1 PE=1 SV=4 
0 
High Q8IUE6 Histone H2A type 2-B OS=Homo sapiens 
GN=HIST2H2AB PE=1 SV=3 
0 
High L8B1Z8 External core antigen OS=Hepatitis B virus 
GN=PC-C PE=3 SV=1 
0 
High P52597 Heterogeneous nuclear ribonucleoprotein F 
OS=Homo sapiens GN=HNRNPF PE=1 SV=3 
0 
High P0C0L4 Complement C4-A OS=Homo sapiens GN=C4A 
PE=1 SV=2 
0 
High B4Z2V2 Core protein (Fragment) OS=Hepatitis B virus 
GN=C PE=4 SV=1 
0 
High P61513 60S ribosomal protein L37a OS=Homo sapiens 
GN=RPL37A PE=1 SV=2 
0 
High P04080 Cystatin-B OS=Homo sapiens GN=CSTB PE=1 
SV=2 
0 




High P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 
SV=2 
0 
High Q9Y3U8 60S ribosomal protein L36 OS=Homo sapiens 
GN=RPL36 PE=1 SV=3 
0 
High Q9Y3Y2 Chromatin target of PRMT1 protein OS=Homo 
sapiens GN=CHTOP PE=1 SV=2 
0 
High K7ELC2 40S ribosomal protein S15 OS=Homo sapiens 
GN=RPS15 PE=1 SV=1 
0 
High P62888 60S ribosomal protein L30 OS=Homo sapiens 
GN=RPL30 PE=1 SV=2 
0 
High H7BYT1 Casein kinase I isoform delta OS=Homo sapiens 
GN=CSNK1D PE=1 SV=2 
0 
High Q5JSZ5 Protein PRRC2B OS=Homo sapiens GN=PRRC2B 
PE=1 SV=2 
0 
High H0YMV8 40S ribosomal protein S27 OS=Homo sapiens 
GN=RPS27L PE=1 SV=1 
0 
High P04732 Metallothionein-1E OS=Homo sapiens GN=MT1E 
PE=1 SV=1 
0 
High Q8TF72 Protein Shroom3 OS=Homo sapiens 
GN=SHROOM3 PE=1 SV=2 
0 
High P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 
SV=3 
0 
High E0ZS18 Core protein OS=Hepatitis B virus GN=C PE=4 
SV=1 
0 
High H0YKD8 60S ribosomal protein L28 OS=Homo sapiens 
GN=RPL28 PE=1 SV=1 
0 
High P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 
SV=2 
0 
High Q9Y281 Cofilin-2 OS=Homo sapiens GN=CFL2 PE=1 SV=1 0 
High Q0VF96 Cingulin-like protein 1 OS=Homo sapiens 
GN=CGNL1 PE=1 SV=2 
0 
High P47914 60S ribosomal protein L29 OS=Homo sapiens 
GN=RPL29 PE=1 SV=2 
0 
High Q96Q07 BTB/POZ domain-containing protein 9 OS=Homo 
sapiens GN=BTBD9 PE=2 SV=2 
0 
High Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo 
sapiens GN=KRT80 PE=1 SV=2 
0 
High P38936 Cyclin-dependent kinase inhibitor 1 OS=Homo 
sapiens GN=CDKN1A PE=1 SV=3 
0 
High P53007 Tricarboxylate transport protein, mitochondrial 
OS=Homo sapiens GN=SLC25A1 PE=1 SV=2 
0 
High Q9Y2X3 Nucleolar protein 58 OS=Homo sapiens 
GN=NOP58 PE=1 SV=1 
0 
High P46778 60S ribosomal protein L21 OS=Homo sapiens 





High O14773 Tripeptidyl-peptidase 1 OS=Homo sapiens 
GN=TPP1 PE=1 SV=2 
0 
High P04183 Thymidine kinase, cytosolic OS=Homo sapiens 
GN=TK1 PE=1 SV=2 
0 
High Q14498 RNA-binding protein 39 OS=Homo sapiens 
GN=RBM39 PE=1 SV=2 
0 
High H7C0V5 Protein ANKHD1-EIF4EBP3 (Fragment) OS=Homo 
sapiens GN=ANKHD1-EIF4EBP3 PE=4 SV=1 
0 
High F8W727 60S ribosomal protein L32 OS=Homo sapiens 
GN=RPL32 PE=1 SV=1 
0 
High P06702 Protein S100-A9 OS=Homo sapiens GN=S100A9 
PE=1 SV=1 
0 
High Q66PJ3 ADP-ribosylation factor-like protein 6-interacting 
protein 4 OS=Homo sapiens GN=ARL6IP4 PE=1 
SV=2 
0 
High P22087 rRNA 2'-O-methyltransferase fibrillarin 
OS=Homo sapiens GN=FBL PE=1 SV=2 
0 
High A0A096ZUQ1 Core protein (Fragment) OS=Hepatitis B virus 
PE=4 SV=1 
0 
High Q03135 Caveolin-1 OS=Homo sapiens GN=CAV1 PE=1 
SV=4 
0 
High P24539 ATP synthase F(0) complex subunit B1, 
mitochondrial OS=Homo sapiens GN=ATP5F1 
PE=1 SV=2 
0 
High P62857 40S ribosomal protein S28 OS=Homo sapiens 
GN=RPS28 PE=1 SV=1 
0 
High P49207 60S ribosomal protein L34 OS=Homo sapiens 
GN=RPL34 PE=1 SV=3 
0 
High Q9BWE0 Replication initiator 1 OS=Homo sapiens 
GN=REPIN1 PE=1 SV=1 
0 
High Q9E0S7 Core protein (Fragment) OS=Hepatitis B virus 
GN=prec/C PE=4 SV=1 
0 
High C7AYN4 Core protein OS=Hepatitis B virus GN=C PE=4 
SV=1 
0 
High Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 
OS=Homo sapiens GN=ITIH3 PE=1 SV=2 
0 
High Q13151 Heterogeneous nuclear ribonucleoprotein A0 
OS=Homo sapiens GN=HNRNPA0 PE=1 SV=1 
0 
High P00966 Argininosuccinate synthase OS=Homo sapiens 
GN=ASS1 PE=1 SV=2 
0 
High P50914 60S ribosomal protein L14 OS=Homo sapiens 
GN=RPL14 PE=1 SV=4 
0 
High B1AHD1 NHP2-like protein 1 OS=Homo sapiens 
GN=NHP2L1 PE=1 SV=1 
0 
High A0A087WYJ9 Ig mu chain C region OS=Homo sapiens 





High C9JWC3 Sorbin and SH3 domain-containing protein 2 
(Fragment) OS=Homo sapiens GN=SORBS2 PE=1 
SV=1 
0 
High Q9NZT1 Calmodulin-like protein 5 OS=Homo sapiens 
GN=CALML5 PE=1 SV=2 
0 
High P63096 Guanine nucleotide-binding protein G(i) subunit 
alpha-1 OS=Homo sapiens GN=GNAI1 PE=1 SV=2 
0 
High Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5 
OS=Homo sapiens GN=FKBP5 PE=1 SV=2 
0 
High P19823 Inter-alpha-trypsin inhibitor heavy chain H2 
OS=Homo sapiens GN=ITIH2 PE=1 SV=2 
0 
High Q96C36 Pyrroline-5-carboxylate reductase 2 OS=Homo 
sapiens GN=PYCR2 PE=1 SV=1 
0 
High S5N100 External core antigen OS=Hepatitis B virus GN=C 
PE=3 SV=1 
0 
High Q14444 Caprin-1 OS=Homo sapiens GN=CAPRIN1 PE=1 
SV=2 
0 
High P04179 Superoxide dismutase [Mn], mitochondrial 
OS=Homo sapiens GN=SOD2 PE=1 SV=2 
0 
High Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 1 OS=Homo sapiens GN=PIN1 PE=1 
SV=1 
0 
High P27635 60S ribosomal protein L10 OS=Homo sapiens 
GN=RPL10 PE=1 SV=4 
0 
High E7EX29 14-3-3 protein zeta/delta (Fragment) OS=Homo 
sapiens GN=YWHAZ PE=1 SV=1 
0 
High Q02978 Mitochondrial 2-oxoglutarate/malate carrier 
protein OS=Homo sapiens GN=SLC25A11 PE=1 
SV=3 
0 
High Q53HC5 Kelch-like protein 26 OS=Homo sapiens 
GN=KLHL26 PE=1 SV=2 
0 
High O15511 Actin-related protein 2/3 complex subunit 5 
OS=Homo sapiens GN=ARPC5 PE=1 SV=3 
0 
High Q14764 Major vault protein OS=Homo sapiens GN=MVP 
PE=1 SV=4 
0 
High P30837 Aldehyde dehydrogenase X, mitochondrial 
OS=Homo sapiens GN=ALDH1B1 PE=1 SV=3 
0 
High E9PAU2 Ribonucleoprotein PTB-binding 1 OS=Homo 
sapiens GN=RAVER1 PE=4 SV=1 
0 
High Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 
SV=2 
0 
High U5JI55 External core antigen (Fragment) OS=Hepatitis B 
virus GN=C PE=3 SV=1 
0 
High Q5T4U5 Acyl-Coenzyme A dehydrogenase, C-4 to C-12 
straight chain, isoform CRA_a OS=Homo sapiens 





High P42766 60S ribosomal protein L35 OS=Homo sapiens 
GN=RPL35 PE=1 SV=2 
0 
High P01024 Complement C3 OS=Homo sapiens GN=C3 PE=1 
SV=2 
0 
High P22695 Cytochrome b-c1 complex subunit 2, 
mitochondrial OS=Homo sapiens GN=UQCRC2 
PE=1 SV=3 
0 
High Q9J1L7 Core protein OS=Hepatitis B virus PE=4 SV=1 0 
High A0A0A6YYG9 Protein ARPC4-TTLL3 OS=Homo sapiens 
GN=ARPC4-TTLL3 PE=4 SV=1 
0 
High P62314 Small nuclear ribonucleoprotein Sm D1 
OS=Homo sapiens GN=SNRPD1 PE=1 SV=1 
0 
High Q5VTI5 Pleckstrin homology domain-containing family A 
member 6 OS=Homo sapiens GN=PLEKHA6 PE=1 
SV=1 
0 
High Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo 
sapiens GN=KRT78 PE=2 SV=2 
0 
High P50402 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 0 
High P01594 Ig kappa chain V-I region AU OS=Homo sapiens 
PE=1 SV=1 
0 
High Q96QZ7 Membrane-associated guanylate kinase, WW 
and PDZ domain-containing protein 1 OS=Homo 
sapiens GN=MAGI1 PE=1 SV=3 
0 
High Q92522 Histone H1x OS=Homo sapiens GN=H1FX PE=1 
SV=1 
0 
High P35754 Glutaredoxin-1 OS=Homo sapiens GN=GLRX 
PE=1 SV=2 
0 
High P61353 60S ribosomal protein L27 OS=Homo sapiens 
GN=RPL27 PE=1 SV=2 
0 
High P11413 Glucose-6-phosphate 1-dehydrogenase 
OS=Homo sapiens GN=G6PD PE=1 SV=4 
0 
High Q9BU76 Multiple myeloma tumor-associated protein 2 
OS=Homo sapiens GN=MMTAG2 PE=1 SV=1 
0 
High P20930 Filaggrin OS=Homo sapiens GN=FLG PE=1 SV=3 0 
High O75190 DnaJ homolog subfamily B member 6 OS=Homo 
sapiens GN=DNAJB6 PE=1 SV=2 
0 
High Q5M775 Cytospin-B OS=Homo sapiens GN=SPECC1 PE=1 
SV=1 
0 
High Q01844 RNA-binding protein EWS OS=Homo sapiens 
GN=EWSR1 PE=1 SV=1 
0 
High B8PTF7 External core antigen OS=Hepatitis B virus GN=C 
PE=3 SV=1 
0 
High Q04837 Single-stranded DNA-binding protein, 






High Q9BXS6 Nucleolar and spindle-associated protein 1 
OS=Homo sapiens GN=NUSAP1 PE=1 SV=1 
0 
High F8VWL3 FYVE, RhoGEF and PH domain-containing 
protein 4 OS=Homo sapiens GN=FGD4 PE=4 
SV=1 
0 
High B4DPQ0 Complement C1r subcomponent OS=Homo 
sapiens GN=C1R PE=2 SV=1 
0 
High P32969 60S ribosomal protein L9 OS=Homo sapiens 
GN=RPL9 PE=1 SV=1 
0 
High P11387 DNA topoisomerase 1 OS=Homo sapiens 
GN=TOP1 PE=1 SV=2 
0 
High Q07065 Cytoskeleton-associated protein 4 OS=Homo 
sapiens GN=CKAP4 PE=1 SV=2 
0 
High P40261 Nicotinamide N-methyltransferase OS=Homo 
sapiens GN=NNMT PE=1 SV=1 
0 
High O15235 28S ribosomal protein S12, mitochondrial 
OS=Homo sapiens GN=MRPS12 PE=1 SV=1 
0 
High Q5R363 SRSF protein kinase 1 OS=Homo sapiens 
GN=SRPK1 PE=1 SV=2 
0 
High Q6YN16 Hydroxysteroid dehydrogenase-like protein 2 
OS=Homo sapiens GN=HSDL2 PE=1 SV=1 
0.000621 
High P36957 Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial OS=Homo sapiens 
GN=DLST PE=1 SV=4 
0.000621 
High B7Z4C8 60S ribosomal protein L31 OS=Homo sapiens 
GN=RPL31 PE=2 SV=1 
0.000621 
High Q9C0C2 182 kDa tankyrase-1-binding protein OS=Homo 
sapiens GN=TNKS1BP1 PE=1 SV=4 
0.000621 
High W0SK71 Core protein OS=Hepatitis B virus GN=C PE=4 
SV=1 
0.000621 
High P62891 60S ribosomal protein L39 OS=Homo sapiens 
GN=RPL39 PE=1 SV=2 
0.000621 
High O14976 Cyclin-G-associated kinase OS=Homo sapiens 
GN=GAK PE=1 SV=2 
0.000621 
High P57721 Poly(rC)-binding protein 3 OS=Homo sapiens 
GN=PCBP3 PE=2 SV=2 
0.000621 
High Q12959 Disks large homolog 1 OS=Homo sapiens 
GN=DLG1 PE=1 SV=2 
0.000621 
High P01602 Ig kappa chain V-I region HK102 (Fragment) 
OS=Homo sapiens GN=IGKV1-5 PE=4 SV=1 
0.000621 
High Q9NZR1 Tropomodulin-2 OS=Homo sapiens GN=TMOD2 
PE=1 SV=1 
0.000621 
High P43490 Nicotinamide phosphoribosyltransferase 





High A0A0A0MT30 Aldo-keto reductase family 1 member C1 
OS=Homo sapiens GN=AKR1C1 PE=4 SV=1 
0.000621 
High O75947 ATP synthase subunit d, mitochondrial 
OS=Homo sapiens GN=ATP5H PE=1 SV=3 
0.000621 
High Q9NR30 Nucleolar RNA helicase 2 OS=Homo sapiens 
GN=DDX21 PE=1 SV=5 
0.000621 
High P62081 40S ribosomal protein S7 OS=Homo sapiens 
GN=RPS7 PE=1 SV=1 
0.000621 
High Q15293 Reticulocalbin-1 OS=Homo sapiens GN=RCN1 
PE=1 SV=1 
0.000621 
High P04196 Histidine-rich glycoprotein OS=Homo sapiens 
GN=HRG PE=1 SV=1 
0.000621 
High P20700 Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 
SV=2 
0.000621 
High D4I4S1 C protein OS=Hepatitis B virus GN=C PE=4 SV=1 0.000621 
High P01613 Ig kappa chain V-I region Ni OS=Homo sapiens 
PE=1 SV=1 
0.000621 
High P20073 Annexin A7 OS=Homo sapiens GN=ANXA7 PE=1 
SV=3 
0.000621 
High P19022 Cadherin-2 OS=Homo sapiens GN=CDH2 PE=1 
SV=4 
0.000621 
High P25398 40S ribosomal protein S12 OS=Homo sapiens 
GN=RPS12 PE=1 SV=3 
0.000621 
High P13639 Elongation factor 2 OS=Homo sapiens GN=EEF2 
PE=1 SV=4 
0.000621 
High P61160 Actin-related protein 2 OS=Homo sapiens 
GN=ACTR2 PE=1 SV=1 
0.000621 
High P05452 Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 
SV=3 
0.000621 
High P13797 Plastin-3 OS=Homo sapiens GN=PLS3 PE=1 SV=4 0.000621 
High Q16698 2,4-dienoyl-CoA reductase, mitochondrial 
OS=Homo sapiens GN=DECR1 PE=1 SV=1 
0.000621 
High P62995 Transformer-2 protein homolog beta OS=Homo 
sapiens GN=TRA2B PE=1 SV=1 
0.000621 
High B4DLN1 Uncharacterized protein OS=Homo sapiens PE=2 
SV=1 
0.000621 
High O75964 ATP synthase subunit g, mitochondrial 
OS=Homo sapiens GN=ATP5L PE=1 SV=3 
0.000621 
High P00450 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 
SV=1 
0.000621 
High O76013 Keratin, type I cuticular Ha6 OS=Homo sapiens 
GN=KRT36 PE=1 SV=1 
0.000621 
High D0EZ03 Core protein OS=Hepatitis B virus GN=C PE=4 
SV=1 
0.000621 
High S5TQ29 External core antigen (Fragment) OS=Hepatitis B 





High Q5T5U3 Rho GTPase-activating protein 21 OS=Homo 
sapiens GN=ARHGAP21 PE=1 SV=1 
0.000621 
High P0C0S5 Histone H2A.Z OS=Homo sapiens GN=H2AFZ 
PE=1 SV=2 
0.000621 
High P78527 DNA-dependent protein kinase catalytic subunit 
OS=Homo sapiens GN=PRKDC PE=1 SV=3 
0.000621 
High P27169 Serum paraoxonase/arylesterase 1 OS=Homo 
sapiens GN=PON1 PE=1 SV=3 
0.000621 
High P30481 HLA class I histocompatibility antigen, B-44 
alpha chain OS=Homo sapiens GN=HLA-B PE=1 
SV=1 
0.000621 
High D2U640 External core antigen OS=Hepatitis B virus PE=4 
SV=1 
0.000621 
High G1E7X4 Core protein OS=Hepatitis B virus PE=4 SV=1 0.000621 
High P53621 Coatomer subunit alpha OS=Homo sapiens 
GN=COPA PE=1 SV=2 
0.000621 
High J3KQL8 Apolipoprotein L2 OS=Homo sapiens GN=APOL2 
PE=1 SV=2 
0.000621 
High Q86SQ0 Pleckstrin homology-like domain family B 
member 2 OS=Homo sapiens GN=PHLDB2 PE=1 
SV=2 
0.000621 
High E9PRY8 Elongation factor 1-delta OS=Homo sapiens 
GN=EEF1D PE=1 SV=1 
0.000621 
High P21980 Protein-glutamine gamma-glutamyltransferase 2 
OS=Homo sapiens GN=TGM2 PE=1 SV=2 
0.000621 
High Q1MSW4 External core antigen (Fragment) OS=Hepatitis B 
virus GN=preC/C PE=3 SV=1 
0.000621 
High P01604 Ig kappa chain V-I region Kue OS=Homo sapiens 
PE=1 SV=1 
0.000621 
High Q86V48 Leucine zipper protein 1 OS=Homo sapiens 
GN=LUZP1 PE=1 SV=2 
0.000621 
High H7C3D8 COX assembly mitochondrial protein homolog 
(Fragment) OS=Homo sapiens GN=CMC1 PE=1 
SV=1 
0.000621 
High Q16629 Serine/arginine-rich splicing factor 7 OS=Homo 
sapiens GN=SRSF7 PE=1 SV=1 
0.000621 
High F5H6S0 Keratin-associated protein 2-2 OS=Homo 
sapiens GN=KRTAP2-2 PE=4 SV=1 
0.000621 
High Q86X95 Corepressor interacting with RBPJ 1 OS=Homo 
sapiens GN=CIR1 PE=1 SV=1 
0.000621 
High P31944 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 
SV=2 
0.000621 
High Q92828 Coronin-2A OS=Homo sapiens GN=CORO2A 
PE=2 SV=2 
0.000621 
High Q92499 ATP-dependent RNA helicase DDX1 OS=Homo 





High A6MGA7 Core protein OS=Hepatitis B virus GN=C PE=4 
SV=1 
0.000621 
High Q7Z417 Nuclear fragile X mental retardation-interacting 
protein 2 OS=Homo sapiens GN=NUFIP2 PE=1 
SV=1 
0.000621 
High P29401 Transketolase OS=Homo sapiens GN=TKT PE=1 
SV=3 
0.000621 
High Q8WWM7 Ataxin-2-like protein OS=Homo sapiens 
GN=ATXN2L PE=1 SV=2 
0.000621 
High E7ETY2 Treacle protein OS=Homo sapiens GN=TCOF1 
PE=1 SV=1 
0.000621 
High Q9NZN4 EH domain-containing protein 2 OS=Homo 
sapiens GN=EHD2 PE=1 SV=2 
0.000621 
High A0A075B6I1 Protein IGLV4-60 (Fragment) OS=Homo sapiens 
GN=IGLV4-60 PE=4 SV=1 
0.000621 
High J3QRU1 Non-specific protein-tyrosine kinase OS=Homo 
sapiens GN=YES1 PE=1 SV=1 
0.000621 
High Q96HS1 Serine/threonine-protein phosphatase PGAM5, 
mitochondrial OS=Homo sapiens GN=PGAM5 
PE=1 SV=2 
0.000621 
High Q8IUC1 Keratin-associated protein 11-1 OS=Homo 
sapiens GN=KRTAP11-1 PE=1 SV=1 
0.000621 
High B3KS98 Eukaryotic translation initiation factor 3 subunit 
H OS=Homo sapiens GN=EIF3S3 PE=2 SV=1 
0.000621 
High Q13867 Bleomycin hydrolase OS=Homo sapiens 
GN=BLMH PE=1 SV=1 
0.000621 
High Q9BZE4 Nucleolar GTP-binding protein 1 OS=Homo 
sapiens GN=GTPBP4 PE=1 SV=3 
0.000621 
High Q96IX5 Up-regulated during skeletal muscle growth 
protein 5 OS=Homo sapiens GN=USMG5 PE=1 
SV=1 
0.000621 
High P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 
SV=1 
0.000621 
High P60953 Cell division control protein 42 homolog 
OS=Homo sapiens GN=CDC42 PE=1 SV=2 
0.000621 
High Q10589 Bone marrow stromal antigen 2 OS=Homo 
sapiens GN=BST2 PE=1 SV=1 
0.000621 
High P14174 Macrophage migration inhibitory factor 
OS=Homo sapiens GN=MIF PE=1 SV=4 
0.000621 
High O43852 Calumenin OS=Homo sapiens GN=CALU PE=1 
SV=2 
0.000621 
High G3V2S9 SRA stem-loop-interacting RNA-binding protein, 
mitochondrial OS=Homo sapiens GN=SLIRP PE=1 
SV=1 
0.000621 
High E9PR30 40S ribosomal protein S30 OS=Homo sapiens 





High P49458 Signal recognition particle 9 kDa protein 
OS=Homo sapiens GN=SRP9 PE=1 SV=2 
0.000621 
High Q14974 Importin subunit beta-1 OS=Homo sapiens 
GN=KPNB1 PE=1 SV=2 
0.000621 
High P01605 Ig kappa chain V-I region Lay OS=Homo sapiens 
PE=1 SV=1 
0.000621 
High Q14151 Scaffold attachment factor B2 OS=Homo sapiens 
GN=SAFB2 PE=1 SV=1 
0.000621 
High P62316 Small nuclear ribonucleoprotein Sm D2 
OS=Homo sapiens GN=SNRPD2 PE=1 SV=1 
0.000621 
High P29508 Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 
SV=2 
0.000621 
High O00479 High mobility group nucleosome-binding 
domain-containing protein 4 OS=Homo sapiens 
GN=HMGN4 PE=1 SV=3 
0.000621 
High P02788 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 
SV=6 
0.000621 
High Q14160 Protein scribble homolog OS=Homo sapiens 
GN=SCRIB PE=1 SV=4 
0.000621 
High P02042 Hemoglobin subunit delta OS=Homo sapiens 
GN=HBD PE=1 SV=2 
0.000621 
High A0A087WUD1 Zinc finger protein 787 OS=Homo sapiens 
GN=ZNF787 PE=1 SV=1 
0.000621 
High Q9UM22 Mammalian ependymin-related protein 1 
OS=Homo sapiens GN=EPDR1 PE=1 SV=2 
0.000621 
High P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A 
OS=Homo sapiens GN=FKBP1A PE=1 SV=2 
0.000621 
High Q5T749 Keratinocyte proline-rich protein OS=Homo 
sapiens GN=KPRP PE=1 SV=1 
0.000621 
High P52943 Cysteine-rich protein 2 OS=Homo sapiens 
GN=CRIP2 PE=1 SV=1 
0.000621 
High Q68073 External core antigen OS=Hepatitis B virus 
GN=core PE=3 SV=1 
0.000621 
High Q9Y2Q3 Glutathione S-transferase kappa 1 OS=Homo 
sapiens GN=GSTK1 PE=1 SV=3 
0.000621 
High P13010 X-ray repair cross-complementing protein 5 
OS=Homo sapiens GN=XRCC5 PE=1 SV=3 
0.000621 
High O75400 Pre-mRNA-processing factor 40 homolog A 
OS=Homo sapiens GN=PRPF40A PE=1 SV=2 
0.000621 
High Q7Z4L5 Tetratricopeptide repeat protein 21B OS=Homo 
sapiens GN=TTC21B PE=1 SV=2 
0.000621 
High P53597 Succinyl-CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial OS=Homo sapiens 
GN=SUCLG1 PE=1 SV=4 
0.000621 
High Q9Y6C9 Mitochondrial carrier homolog 2 OS=Homo 





High Q96I25 Splicing factor 45 OS=Homo sapiens GN=RBM17 
PE=1 SV=1 
0.000621 
High P07305 Histone H1.0 OS=Homo sapiens GN=H1F0 PE=1 
SV=3 
0.000621 
High P62258 14-3-3 protein epsilon OS=Homo sapiens 
GN=YWHAE PE=1 SV=1 
0.000621 
High P49748 Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial OS=Homo 
sapiens GN=ACADVL PE=1 SV=1 
0.001848 
High P18859 ATP synthase-coupling factor 6, mitochondrial 
OS=Homo sapiens GN=ATP5J PE=1 SV=1 
0.001848 
High P07858 Cathepsin B OS=Homo sapiens GN=CTSB PE=1 
SV=3 
0.001848 
High P56182 Ribosomal RNA processing protein 1 homolog A 
OS=Homo sapiens GN=RRP1 PE=1 SV=1 
0.001848 
High O14949 Cytochrome b-c1 complex subunit 8 OS=Homo 
sapiens GN=UQCRQ PE=1 SV=4 
0.001848 
High Q92576 PHD finger protein 3 OS=Homo sapiens 
GN=PHF3 PE=1 SV=3 
0.002443 
High P62847 40S ribosomal protein S24 OS=Homo sapiens 
GN=RPS24 PE=1 SV=1 
0.002443 
High P55084 Trifunctional enzyme subunit beta, 
mitochondrial OS=Homo sapiens GN=HADHB 
PE=1 SV=3 
0.002642 
High Q12797 Aspartyl/asparaginyl beta-hydroxylase 
OS=Homo sapiens GN=ASPH PE=1 SV=3 
0.002642 
High O00443 Phosphatidylinositol 4-phosphate 3-kinase C2 
domain-containing subunit alpha OS=Homo 
sapiens GN=PIK3C2A PE=1 SV=2 
0.002642 
High Q9HAV7 GrpE protein homolog 1, mitochondrial 
OS=Homo sapiens GN=GRPEL1 PE=1 SV=2 
0.002642 
High Q96EV2 RNA-binding protein 33 OS=Homo sapiens 
GN=RBM33 PE=1 SV=3 
0.002642 
High H7C4P4 U2 snRNP-associated SURP motif-containing 
protein (Fragment) OS=Homo sapiens 
GN=U2SURP PE=1 SV=1 
0.002642 
High C7DNM0 External core antigen OS=Hepatitis B virus GN=C 
PE=3 SV=1 
0.002642 
High P63244 Guanine nucleotide-binding protein subunit 
beta-2-like 1 OS=Homo sapiens GN=GNB2L1 
PE=1 SV=3 
0.002642 
High Q14331 Protein FRG1 OS=Homo sapiens GN=FRG1 PE=1 
SV=1 
0.002642 
High Q96G21 U3 small nucleolar ribonucleoprotein protein 





High E0ZNI6 Core protein (Fragment) OS=Hepatitis B virus 
PE=4 SV=1 
0.002642 
High P01603 Ig kappa chain V-I region Ka OS=Homo sapiens 
PE=1 SV=1 
0.002642 
High Q15773 Myeloid leukemia factor 2 OS=Homo sapiens 
GN=MLF2 PE=1 SV=1 
0.002642 
High P21796 Voltage-dependent anion-selective channel 
protein 1 OS=Homo sapiens GN=VDAC1 PE=1 
SV=2 
0.002642 
High H7C0N4 Splicing factor 1 (Fragment) OS=Homo sapiens 
GN=SF1 PE=1 SV=1 
0.003225 
High Q4KMP7 TBC1 domain family member 10B OS=Homo 
sapiens GN=TBC1D10B PE=1 SV=3 
0.003225 
High O60884 DnaJ homolog subfamily A member 2 OS=Homo 
sapiens GN=DNAJA2 PE=1 SV=1 
0.006108 
High G3V325 Protein ATP5J2-PTCD1 OS=Homo sapiens 
GN=ATP5J2-PTCD1 PE=4 SV=1 
0.006108 
High Q01081 Splicing factor U2AF 35 kDa subunit OS=Homo 
sapiens GN=U2AF1 PE=1 SV=3 
0.006108 
High P08473 Neprilysin OS=Homo sapiens GN=MME PE=1 
SV=2 
0.006108 
High P19338 Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 0.006108 
High P62273 40S ribosomal protein S29 OS=Homo sapiens 
GN=RPS29 PE=1 SV=2 
0.006108 
High Q99959 Plakophilin-2 OS=Homo sapiens GN=PKP2 PE=1 
SV=2 
0.006108 
High P27708 CAD protein OS=Homo sapiens GN=CAD PE=1 
SV=3 
0.006108 
High P30048 Thioredoxin-dependent peroxide reductase, 
mitochondrial OS=Homo sapiens GN=PRDX3 
PE=1 SV=3 
0.006108 
High Q9Y5J1 U3 small nucleolar RNA-associated protein 18 
homolog OS=Homo sapiens GN=UTP18 PE=1 
SV=3 
0.006108 
High D3J5Z4 Precore/core protein (Fragment) OS=Hepatitis B 
virus GN=C PE=4 SV=1 
0.006108 
High P27658 Collagen alpha-1(VIII) chain OS=Homo sapiens 
GN=COL8A1 PE=1 SV=2 
0.006108 
High P28290 Sperm-specific antigen 2 OS=Homo sapiens 
GN=SSFA2 PE=1 SV=3 
0.006108 
High P18206 Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 0.006108 
High Q7Z7G8 Vacuolar protein sorting-associated protein 13B 
OS=Homo sapiens GN=VPS13B PE=1 SV=2 
0.006648 
High Q9Y3I0 tRNA-splicing ligase RtcB homolog OS=Homo 





High Q9P2D8 Protein unc-79 homolog OS=Homo sapiens 
GN=UNC79 PE=2 SV=4 
0.006648 
High P51114 Fragile X mental retardation syndrome-related 
protein 1 OS=Homo sapiens GN=FXR1 PE=1 SV=3 
0.007434 
High A0A0A0MRM9 Nucleolar and coiled-body phosphoprotein 1 
(Fragment) OS=Homo sapiens GN=NOLC1 PE=4 
SV=1 
0.007434 
High P49761 Dual specificity protein kinase CLK3 OS=Homo 
sapiens GN=CLK3 PE=1 SV=3 
0.007434 
High Q8TDN6 Ribosome biogenesis protein BRX1 homolog 
OS=Homo sapiens GN=BRIX1 PE=1 SV=2 
0.007434 
High A0A075B6S8 Ig kappa chain V-I region HK102 (Fragment) 
OS=Homo sapiens GN=IGKV1-5 PE=4 SV=1 
0.007434 
High P00387 NADH-cytochrome b5 reductase 3 OS=Homo 
sapiens GN=CYB5R3 PE=1 SV=3 
0.008199 
High Q6UN15 Pre-mRNA 3'-end-processing factor FIP1 
OS=Homo sapiens GN=FIP1L1 PE=1 SV=1 
0.008199 
High H0YIV9 Uncharacterized protein (Fragment) OS=Homo 
sapiens PE=3 SV=1 
0.008199 
High Q1MSQ5 External core antigen (Fragment) OS=Hepatitis B 
virus GN=preC/C PE=3 SV=1 
0.008199 
High Q52LJ0 Protein FAM98B OS=Homo sapiens GN=FAM98B 
PE=1 SV=1 
0.008199 
High Q6P1L8 39S ribosomal protein L14, mitochondrial 
OS=Homo sapiens GN=MRPL14 PE=1 SV=1 
0.008199 
High P14854 Cytochrome c oxidase subunit 6B1 OS=Homo 
sapiens GN=COX6B1 PE=1 SV=2 
0.008199 
High P37802 Transgelin-2 OS=Homo sapiens GN=TAGLN2 
PE=1 SV=3 
0.008199 
High E7EPK1 Septin-7 OS=Homo sapiens GN=SEPT7 PE=1 
SV=2 
0.008199 
High B9ZVT1 RNA-binding protein 12B OS=Homo sapiens 
GN=RBM12B PE=1 SV=2 
0.008199 
High P13497 Bone morphogenetic protein 1 OS=Homo 
sapiens GN=BMP1 PE=1 SV=2 
0.008465 
Medium H3BLT4 Baculoviral IAP repeat-containing protein 5 
OS=Homo sapiens GN=BIRC5 PE=1 SV=1 
0.011147 
Medium Q93052 Lipoma-preferred partner OS=Homo sapiens 
GN=LPP PE=1 SV=1 
0.011147 
Medium Q9Y4P3 Transducin beta-like protein 2 OS=Homo sapiens 
GN=TBL2 PE=1 SV=1 
0.013137 
Medium Q96DI7 U5 small nuclear ribonucleoprotein 40 kDa 






Medium Q9Y277 Voltage-dependent anion-selective channel 
protein 3 OS=Homo sapiens GN=VDAC3 PE=1 
SV=1 
0.013137 
Medium Q9UQ35 Serine/arginine repetitive matrix protein 2 
OS=Homo sapiens GN=SRRM2 PE=1 SV=2 
0.013137 
Medium P18077 60S ribosomal protein L35a OS=Homo sapiens 
GN=RPL35A PE=1 SV=2 
0.013137 
Medium P00390 Glutathione reductase, mitochondrial OS=Homo 
sapiens GN=GSR PE=1 SV=2 
0.013137 
Medium Q9H0D6 5'-3' exoribonuclease 2 OS=Homo sapiens 
GN=XRN2 PE=1 SV=1 
0.013137 
Medium P03973 Antileukoproteinase OS=Homo sapiens GN=SLPI 
PE=1 SV=2 
0.013137 
Medium O15143 Actin-related protein 2/3 complex subunit 1B 
OS=Homo sapiens GN=ARPC1B PE=1 SV=3 
0.013137 
Medium H0Y300 Haptoglobin OS=Homo sapiens GN=HP PE=1 
SV=4 
0.013137 
Medium P14923 Junction plakoglobin OS=Homo sapiens GN=JUP 
PE=1 SV=3 
0.013137 
Medium X6RAL5 Histone deacetylase complex subunit SAP18 
OS=Homo sapiens GN=SAP18 PE=1 SV=1 
0.013137 
Medium Q9H444 Charged multivesicular body protein 4b 
OS=Homo sapiens GN=CHMP4B PE=1 SV=1 
0.013137 
Medium B3VAK2 Core protein OS=Hepatitis B virus PE=4 SV=1 0.013137 
Medium M0QYZ2 AP-2 complex subunit sigma OS=Homo sapiens 
GN=AP2S1 PE=1 SV=1 
0.013137 
Medium Q8ND56 Protein LSM14 homolog A OS=Homo sapiens 
GN=LSM14A PE=1 SV=3 
0.013351 
Medium P0C263 Serine/threonine-protein kinase SBK2 OS=Homo 
sapiens GN=SBK2 PE=3 SV=2 
0.013351 
Medium P35232 Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 0.013351 
Medium E9PI68 Signal peptidase complex subunit 2 OS=Homo 
sapiens GN=SPCS2 PE=1 SV=1 
0.013351 
Medium Q9UJC5 SH3 domain-binding glutamic acid-rich-like 
protein 2 OS=Homo sapiens GN=SH3BGRL2 PE=1 
SV=2 
0.01356 
Medium Q96T37 Putative RNA-binding protein 15 OS=Homo 
sapiens GN=RBM15 PE=1 SV=2 
0.01356 
Medium P01608 Ig kappa chain V-I region Roy OS=Homo sapiens 
PE=1 SV=1 
0.01356 
Medium Q8TC07 TBC1 domain family member 15 OS=Homo 
sapiens GN=TBC1D15 PE=1 SV=2 
0.01356 
Medium P22735 Protein-glutamine gamma-glutamyltransferase K 
OS=Homo sapiens GN=TGM1 PE=1 SV=4 
0.01356 
Medium P69905 Hemoglobin subunit alpha OS=Homo sapiens 





Medium P01612 Ig kappa chain V-I region Mev OS=Homo sapiens 
PE=1 SV=1 
0.01356 
Medium P05187 Alkaline phosphatase, placental type OS=Homo 
sapiens GN=ALPP PE=1 SV=2 
0.01356 
Medium Q9NWH9 SAFB-like transcription modulator OS=Homo 
sapiens GN=SLTM PE=1 SV=2 
0.014308 
Medium Q93074 Mediator of RNA polymerase II transcription 
subunit 12 OS=Homo sapiens GN=MED12 PE=1 
SV=4 
0.014308 
Medium P11940 Polyadenylate-binding protein 1 OS=Homo 
sapiens GN=PABPC1 PE=1 SV=2 
0.014308 
Medium Q70EL1 Inactive ubiquitin carboxyl-terminal hydrolase 
54 OS=Homo sapiens GN=USP54 PE=1 SV=4 
0.014737 
Medium U5JMW5 External core antigen (Fragment) OS=Hepatitis B 
virus GN=C PE=3 SV=1 
0.014737 
Medium P12268 Inosine-5'-monophosphate dehydrogenase 2 
OS=Homo sapiens GN=IMPDH2 PE=1 SV=2 
0.014737 
Medium Q92734 Protein TFG OS=Homo sapiens GN=TFG PE=1 
SV=2 
0.015441 
Medium Q9BZL4 Protein phosphatase 1 regulatory subunit 12C 
OS=Homo sapiens GN=PPP1R12C PE=1 SV=1 
0.015441 
Medium H0YL18 Beta-2-microglobulin OS=Homo sapiens 
GN=B2M PE=1 SV=1 
0.016441 
Medium Q8WXE9 Stonin-2 OS=Homo sapiens GN=STON2 PE=1 
SV=1 
0.016441 
Medium P01611 Ig kappa chain V-I region Wes OS=Homo sapiens 
PE=1 SV=1 
0.016441 
Medium J3KNN5 Probable ATP-dependent RNA helicase DDX41 
(Fragment) OS=Homo sapiens GN=DDX41 PE=1 
SV=1 
0.016499 
Medium Q14774 H2.0-like homeobox protein OS=Homo sapiens 
GN=HLX PE=1 SV=3 
0.016499 
Medium Q9H0E2 Toll-interacting protein OS=Homo sapiens 
GN=TOLLIP PE=1 SV=1 
0.016499 
Medium Q4L180 Filamin A-interacting protein 1-like OS=Homo 
sapiens GN=FILIP1L PE=1 SV=2 
0.016499 
Medium Q96L91 E1A-binding protein p400 OS=Homo sapiens 
GN=EP400 PE=1 SV=4 
0.016499 
Medium Q12830 Nucleosome-remodeling factor subunit BPTF 
OS=Homo sapiens GN=BPTF PE=1 SV=3 
0.016499 
Medium Q9H6R4 Nucleolar protein 6 OS=Homo sapiens GN=NOL6 
PE=1 SV=2 
0.016499 
Medium Q8N9E0 Protein FAM133A OS=Homo sapiens 
GN=FAM133A PE=2 SV=1 
0.016499 
Medium Q8N9Q2 Protein SREK1IP1 OS=Homo sapiens 





Medium B4DKF8 PH and SEC7 domain-containing protein 3 
OS=Homo sapiens GN=PSD3 PE=2 SV=1 
0.016499 
Medium Q8WUH2 Transforming growth factor-beta receptor-
associated protein 1 OS=Homo sapiens 
GN=TGFBRAP1 PE=1 SV=1 
0.016731 
Medium A0A060CND0 External core antigen OS=Hepatitis B virus GN=C 
PE=3 SV=1 
0.016871 
Medium O75083 WD repeat-containing protein 1 OS=Homo 
sapiens GN=WDR1 PE=1 SV=4 
0.016871 
Medium F5H423 Uncharacterized protein OS=Homo sapiens PE=3 
SV=1 
0.016871 
Medium Q96T51 RUN and FYVE domain-containing protein 1 
OS=Homo sapiens GN=RUFY1 PE=1 SV=2 
0.016871 
Medium Q96JI7 Spatacsin OS=Homo sapiens GN=SPG11 PE=1 
SV=3 
0.016871 
Medium Q8N8E3 Centrosomal protein of 112 kDa OS=Homo 
sapiens GN=CEP112 PE=1 SV=2 
0.016871 
Medium P57740 Nuclear pore complex protein Nup107 
OS=Homo sapiens GN=NUP107 PE=1 SV=1 
0.016871 
Medium P00734 Prothrombin OS=Homo sapiens GN=F2 PE=1 
SV=2 
0.016871 
Medium P13073 Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial OS=Homo sapiens GN=COX4I1 
PE=1 SV=1 
0.016871 
Medium Q5VZ46 Uncharacterized protein KIAA1614 OS=Homo 
sapiens GN=KIAA1614 PE=2 SV=3 
0.016871 
Medium Q96CN9 GRIP and coiled-coil domain-containing protein 
1 OS=Homo sapiens GN=GCC1 PE=1 SV=1 
0.018135 
Medium P0C7P4 Putative cytochrome b-c1 complex subunit 
Rieske-like protein 1 OS=Homo sapiens 
GN=UQCRFS1P1 PE=5 SV=1 
0.018135 
Medium P00747 Plasminogen OS=Homo sapiens GN=PLG PE=1 
SV=2 
0.018344 
Medium P01011 Alpha-1-antichymotrypsin OS=Homo sapiens 
GN=SERPINA3 PE=1 SV=2 
0.018344 
Medium Q96QR8 Transcriptional activator protein Pur-beta 
OS=Homo sapiens GN=PURB PE=1 SV=3 
0.019309 
Medium P30536 Translocator protein OS=Homo sapiens 
GN=TSPO PE=1 SV=3 
0.019309 
Medium P13584 Cytochrome P450 4B1 OS=Homo sapiens 
GN=CYP4B1 PE=1 SV=2 
0.019309 
Medium P51397 Death-associated protein 1 OS=Homo sapiens 
GN=DAP PE=1 SV=3 
0.019309 
Medium Q3ZCV2 Uncharacterized protein C1orf177 OS=Homo 





Medium Q9Y2F5 Little elongation complex subunit 1 OS=Homo 
sapiens GN=ICE1 PE=1 SV=5 
0.019309 
Medium P50416 Carnitine O-palmitoyltransferase 1, liver isoform 
OS=Homo sapiens GN=CPT1A PE=1 SV=2 
0.019543 
Medium Q8WXW3 Progesterone-induced-blocking factor 1 
OS=Homo sapiens GN=PIBF1 PE=1 SV=2 
0.019543 
Medium Q9BRX2 Protein pelota homolog OS=Homo sapiens 
GN=PELO PE=1 SV=2 
0.020807 
Medium Q05516 Zinc finger and BTB domain-containing protein 
16 OS=Homo sapiens GN=ZBTB16 PE=1 SV=2 
0.022025 
Medium Q08554 Desmocollin-1 OS=Homo sapiens GN=DSC1 PE=1 
SV=2 
0.022025 
Medium Q8WWY7 WAP four-disulfide core domain protein 12 
OS=Homo sapiens GN=WFDC12 PE=2 SV=1 
0.022025 
Medium Q13492 Phosphatidylinositol-binding clathrin assembly 
protein OS=Homo sapiens GN=PICALM PE=1 
SV=2 
0.022025 
Medium O75762 Transient receptor potential cation channel 
subfamily A member 1 OS=Homo sapiens 
GN=TRPA1 PE=1 SV=3 
0.022025 
Medium Q9UJS0 Calcium-binding mitochondrial carrier protein 
Aralar2 OS=Homo sapiens GN=SLC25A13 PE=1 
SV=2 
0.02225 
Medium H0Y8C6 Importin-5 (Fragment) OS=Homo sapiens 
GN=IPO5 PE=1 SV=1 
0.022603 
Medium B3VAK0 Core protein OS=Hepatitis B virus PE=4 SV=1 0.022603 
Medium Q6IQ22 Ras-related protein Rab-12 OS=Homo sapiens 
GN=RAB12 PE=1 SV=3 
0.022603 
Medium P20062 Transcobalamin-2 OS=Homo sapiens GN=TCN2 
PE=1 SV=3 
0.022603 
Medium Q8NAT2 Tudor domain-containing protein 5 OS=Homo 
sapiens GN=TDRD5 PE=1 SV=3 
0.022603 
Medium Q9H1K1 Iron-sulfur cluster assembly enzyme ISCU, 
mitochondrial OS=Homo sapiens GN=ISCU PE=1 
SV=2 
0.022603 
Medium Q16613 Serotonin N-acetyltransferase OS=Homo sapiens 
GN=AANAT PE=1 SV=1 
0.023543 
Medium P51636 Caveolin-2 OS=Homo sapiens GN=CAV2 PE=1 
SV=2 
0.02377 
Medium Q96B01 RAD51-associated protein 1 OS=Homo sapiens 
GN=RAD51AP1 PE=1 SV=1 
0.027193 
Medium A0A087WYC5 Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 
0.027193 
Medium C9JVQ0 Small nuclear ribonucleoprotein G OS=Homo 





Medium P27797 Calreticulin OS=Homo sapiens GN=CALR PE=1 
SV=1 
0.028571 
Medium K7ELL7 Glucosidase 2 subunit beta OS=Homo sapiens 
GN=PRKCSH PE=1 SV=1 
0.029946 
Medium Q01484 Ankyrin-2 OS=Homo sapiens GN=ANK2 PE=1 
SV=4 
0.030867 
Medium O00483 Cytochrome c oxidase subunit NDUFA4 
OS=Homo sapiens GN=NDUFA4 PE=1 SV=1 
0.030867 
Medium P53355 Death-associated protein kinase 1 OS=Homo 
sapiens GN=DAPK1 PE=1 SV=6 
0.031272 
Medium P17096 High mobility group protein HMG-I/HMG-Y 
OS=Homo sapiens GN=HMGA1 PE=1 SV=3 
0.031272 
Medium A0A0A0MS20 Leukocyte immunoglobulin-like receptor 
subfamily B member 4 OS=Homo sapiens 
GN=LILRB4 PE=4 SV=1 
0.031272 
Medium Q5VTL8 Pre-mRNA-splicing factor 38B OS=Homo sapiens 
GN=PRPF38B PE=1 SV=1 
0.031705 
Medium P30793 GTP cyclohydrolase 1 OS=Homo sapiens 
GN=GCH1 PE=1 SV=1 
0.031705 
Medium Q8TAP9 M-phase-specific PLK1-interacting protein 
OS=Homo sapiens GN=MPLKIP PE=1 SV=1 
0.031705 
Medium Q9Y2G3 Probable phospholipid-transporting ATPase IF 
OS=Homo sapiens GN=ATP11B PE=1 SV=2 
0.031705 
Medium O96000 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10 OS=Homo sapiens 
GN=NDUFB10 PE=1 SV=3 
0.032084 
Medium E7EX17 Eukaryotic translation initiation factor 4B 
OS=Homo sapiens GN=EIF4B PE=1 SV=1 
0.032084 
Medium Q05823 2-5A-dependent ribonuclease OS=Homo sapiens 
GN=RNASEL PE=1 SV=2 
0.032281 
Medium Q14257 Reticulocalbin-2 OS=Homo sapiens GN=RCN2 
PE=1 SV=1 
0.032581 
Medium Q5JU67 Uncharacterized protein C9orf117 OS=Homo 
sapiens GN=C9orf117 PE=2 SV=1 
0.032581 
Medium Q9HCD5 Nuclear receptor coactivator 5 OS=Homo 
sapiens GN=NCOA5 PE=1 SV=2 
0.032581 
Medium Q5SVJ8 Calcium-activated potassium channel subunit 
alpha-1 OS=Homo sapiens GN=KCNMA1 PE=4 
SV=2 
0.032581 
Medium Q6ZVX7 F-box only protein 50 OS=Homo sapiens 
GN=NCCRP1 PE=1 SV=1 
0.032581 
Medium Q9Y490 Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 0.032806 
Medium Q9GZW8 Membrane-spanning 4-domains subfamily A 






Medium H3BTQ9 Coiled-coil domain-containing protein C16orf93 






CHAPTER 6. CONCLUSION & FUTURE DIRECTIONS 
As chronic HBV infection continues to pose a major health threat worldwide due to 
the lack of effective therapy regimens, more research efforts are geared towards finding 
novel and efficient therapeutics. This is why it is so critical to understand the basic 
molecular mechanisms that drives HBV biology and pathogenesis in order to develop 
targeted therapeutics. With this objective in mind, I undertook this study by combining 
a global approach to study HBc interactome as well as biochemical analysis to 
characterize the role of PLK1 in HBV infection.  
Firstly, I was able to demonstrate that PLK1 is a positive effector of HBV replication using 
specific chemical inhibitors both in vitro and in vivo. This finding comes in agreement 
with previous work from our lab highlighting the positive role of PLK1 in cellular HBV 
replication models 1,2. Using biological gain of function –over-expression- as well as loss 
of function –siRNA-mediated- approaches, I further confirmed the positive role of PLK1 
in HBV infection. Significantly, I also demonstrated that HBc served as phosphorylation 
substrate for PLK1 in vitro and I was able to map the phosphorylation residues to the 
serines 168, 176 and 178. Collectively, my studies suggest that PLK1 inhibitors could 
potentially serve as novel anti-HBV therapeutics.  
It remains to be discerned, however, if PLK1 is the kinase responsible for HBc 




specific antibodies targeting the residues 168, 176 and 178 would help answer this 
question. While the importance of PLK1 for efficient HBV replication is evident, the 
mechanism by which PLK1 is involved remains an enigma. Direct phosphorylation of HBc 
by PLK1, thereby regulating capsid assembly or viral DNA synthesis, is a very attractive 
hypothesis given that HBc is a robust PLK1 in vitro substrate. My preliminary studies 
showed that alanine substitutions at the 3 identified in vitro PLK1 phosphorylation sites 
(168, 176 and 178) in the 3DP background resulted in almost 50% decrease in cccDNA 
production in a trans-complementation assay for HBV replication. These preliminary 
findings support the hypothesis that PLK1 is acting directly by phosphorylating HBc. As 
HBc contributes pleiotropically to HBV replication, the exact function of HBc affected by 
PLK1 phosphorylation is yet to be determined. Functional analysis using the HBc 
phosphorylation mutants is a powerful tool to address such question. 
Alternatively, PlK1 may be phosphorylating other/additional targets, either viral 
(HBV polymerase) or host proteins, that in turn regulate viral replication. In a previous 
study, we have already shown that PLK1 phosphorylates chromatin modifying proteins 
SUZ12 and ZNF198, targeting them for proteosomal degradation. Both proteins are 
components of chromatin modifying complexes that repress transcription3. Given that 
viral cccDNA is modified by host chromatin modifying enzymes4,5, it is reasonable to 
envision a mechanism by which down regulation of SUZ12 and ZNF198 by PLK1 
phosphorylation results in activation of viral transcription. Indeed, siRNA mediated 
knockdown of PLK1 not only reduced viral replication (total viral DNA) but also viral 




In addition to characterizing the role of PLK1 as a positive effector of HBV replication 
possibly via HBc phosphorylation, I sought to identify new host molecules usurped by 
HBc. Our understanding of HBc as a multi-functional protein in HBV replication is 
expanding. Aside from the structural role as the building block of the viral capsids, HBc 
plays a role in encapsidation of viral pgRNA, reverse transcription, subcellular 
localization and potentially cccDNA regulation5,6. HBc also interacts with a wide array of 
host proteins enabling HBV to replicate efficiently as well as to suppress/evade host 
immunity. To gain more insights into HBc biology, I undertook a global mass 
spectrometry-based approach to identify novel HBc interacting partners. Of marked 
interest, I identified host nuclear speckle and paraspeckle proteins as potential HBc 
interacting partners. Furthermore, I established a novel link between HBc and lncRNAs 
NEAT1 and NEAT2; a link that merits further investigation as it promises to expand our 
understanding of how lncRNAs NEAT1 and NEAT2 are involved in host immune response 
to viral insults. These findings, albeit preliminary in nature, open the floor for future 
investigation. For example, it is intriguing to determine if nuclear speckle or paraspeckle 
proteins regulate HBV replication. Specifically, the question whether HBV cccDNA 
localizes to these nuclear loci is an interesting one. More broadly, does HBc 
phosphorylation status and more specifically PLK1 mediated phosphorylation regulate 
such a process. All such questions promise to bridge many gaps of our understanding of 
HBV pathogenesis, host immunity and lncRNA biology. The potential clinical significance 






1.  Studach L, Wang W-H, Weber G, et al. Polo-like kinase 1 activated by the hepatitis 
B virus X protein attenuates both the DNA damage checkpoint and DNA repair 
resulting in partial polyploidy. J. Biol. Chem. 2010;285:30282–93. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2943266&tool=pmc
entrez&rendertype=abstract [Accessed March 14, 2012]. 
2.  Studach LL, Rakotomalala L, Wang W-H, et al. Polo-like kinase 1 inhibition 
suppresses hepatitis B virus X protein-induced transformation in an in vitro model 
of liver cancer progression. Hepatology 2009;50:414–423. Available at: 
http://doi.wiley.com/10.1002/hep.22996. 
3.  Zhang H, Diab A, Fan H, et al. PLK1 and HOTAIR Accelerate Proteasomal 
Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver 
Carcinogenesis. Cancer Res. 2015;75:2363–2374. 
4.  Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the 
acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. 
Gastroenterology 2006;130:823–837. 
5.  Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA - The holy grail to 
hepatitis B cure. J. Hepatol. 2016;64:S41-8. 
6.  Zlotnick A, Venkatakrishnan B, Tan Z, et al. Core protein: A pleiotropic keystone in 
















PhD, Cancer Biology, Department of Basic Medical Sciences, West Lafayette, IN, USA.  
Title: Molecular Regulatory Mechanisms In Hepatitis B Virus Pathogenesis 
Co-supervisors: Ourania Andrisani, Fabien Zoulim                       08/2011-12-2016 
Master of Science in Biosciences, King Abdullah University of Science and Technology 
(KAUST), Kingdom of Saudi Arabia.  
     GPA: 3.79/4.00                   08/2010-12/2011 
Bachelor of Science with High Honors in Biology (Magna Cum Laude), The American 
University in Cairo (AUC), Egypt.          




Postdoctoal Fellow, Mendez Lab. Clinical Research Division, Fred Hutchinson Cancer 
Research Center, Seattle, WA.             09/2016-present 
 Studying the role of HPV16 E6 in DNA Repair in head and neck squamous cell 
carcinoma. 
PhD Candidate, Andrisani Lab. Department of Basic Medical Sciences, Purdue 
University, IN, USA                                                       06/2012-08/2016 
 Studying the role of PLK1 in HBV mediated HCC and in viral replication. 
Chateaubriand Visiting Fellow, Zoulim/Durantel Group, Department: Immunity, 
Microenvironment and Virus, Center for Cancer Research of Lyon, INSERM 1052, France,         
 Studying the proviral role of PLK1 in HBV replication.       12/2013-08-2014 
Visiting Research Scholar, Plant Physiology Lab, Department of Applied Biology, 
University of Perugia, Italy.             06/2011-07/2011 
 Assessing the expression level of atDGK4 in different plant tissues and under 
different biotic and abiotic stress stimuli. 
Graduate Research Assistant, Biomolecular Lab, Bioscience Division, KAUST.              
 Assessing the potential adenylyl cyclase activity of AtDGK4 & the guanylyl cyclase 
activity of K+ transporter AtKUP5.             01/2011-05/2011 
Undergraduate Thesis Project, Biology Department-AUC & Theodor Bilharz Research 
Institute, Cairo Egypt.             09/2009- 05/2010 
 Examined the efficacy of Praziquantel, Furoxan & Auranofin as antischistosomal 
drugs on fresh S. mansoni worms. 
 Conducted an enzyme assay to examine the inhibitory activity of these drugs on 




Summer Intern, Department of Microbiology & Immunology, Rush University Medical 
Center, Chicago, IL.                 06/2009-08/2009 
 Cloned, expressed and purified Schistosomal peroxiredoxins (prx I, II) -potential 
drug targets for Schistosomiasis. 
Trainee, Gene Expression Lab, Agricultural Genetic Engineering Research Institute 
(AGERI), Cairo, Egypt.                                07/2007-08/2007 
 
Academic Honors/ Awards: 
 
Best Poster Award, 2nd place, Purdue Health and Disease Poster Competition   Spring 16 
Young Scientist Travel Grant, Hepatitis B Foundation                 Fall 15 
Purdue Graduate Student Government Travel gran, Purdue Graduate School        Fall 15 
Miles Graduate Scholarship Award, Purdue Center for Cancer Research       Summer 15 
Young Investigator Bursary, European Association for the Study of the Liver     Spring 15 
Graduate Student Travel Award, Purdue Center for Cancer Research          Spring 15 
Chateaubriand Fellowship, French Embassy in Washington, USA       Summer 13  
PULSe Graduate Assistantship- PhD in Interdisciplinary Life Sciences, Purdue    Spring 11 
KAUST Fellowship- for academic excellence. M. S in Biosciences- KAUST, KSA Summer10 
Plate for highest GPA- Junior Class, Biology Department, AUC, Egypt              Spring 09 
KAUST Discovery Scholarship- Full tuition merit scholarship with stipend, AUC,     Fall 08 




Zhang, H; Diab, A; Fan, H; Mani, S; Hullinger, R; Merle P & Andrisani O. PLK1 and HOTAIR 
accelerate proteasomal degradation of SUZ12 and ZNF198 during hepatitis B virus-
induced liver carcinogenesis. Cancer Research, 2015 doi: 10.1158/0008-5472. 
Mani, S; Zhang, H; Diab, A; Pascuzzi, P; Fares, N; Bancel B; Merle P & Andrisani O. 
EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene 
signature in hepatitis B virus-infected hepatocytes. Journal of Hepatology, May 
2016. doi: 10.1016/j.jhep.2016.05.022. 
Fan, H; Cui, Zhibin; Zhang, H; Mani, S; Diab, A; Lefrancois, L; Fares, N; Merle P & 
Andrisani O. DNA demethylation induces SALL4 gene re-expression in subgroups of 
hepatocellular carcinoma associated with Hepatitis B or C virus infection. Oncogene, 
in press. 
Diab, A; Foca, A; Jalaguier, P; N’Guyen, L; Isorce, N; Zoulim, F; Andrisani O & Durantel, D. 
Polo-like-kinase 1, a positive effector in hepatitis B virus replication: therapeutic 
implications. In preparation.  
Diab, A; Zoulim, F; Durantel, D & Andrisani O. Hepatitis B virus (HBV) core antigen (HBc): 












Molecular Regulatory Mechanisms in Hepatitis B Virus Pathogenesis and liver 
transformation. Fred Hutchinson Cancer Center, Seattle           May 2016 
Targeting Plk1 for Hepatitis B Virus Treatment. Department of Basic Medical Science, 
Purdue University                       April 2015 
Understanding the Role of PLK1 Phosphorylation of Chromatin Regulators in pX-
Mediated Liver Cancer. INSERM, Lyon                February 2014 
 
Poster presentations:  
 
Diab, A; Durantel, D; Zoulim, F & Andrisani, O. M. Targeting Plk1 for Hepatitis B Virus 
Treatment. Purdue Health & Disease Poster Competition.          March 2016 
Diab, A; Foca, A; Jalaguier, P; N’Guyen, L; Isorce, N; Zoulim, F; Andrisani, O. M & 
Durantel, D. Polo-like-kinase 1, a positive effector in hepatitis B virus replication. 
Hepatitis B Meeting, Poster, Bad Nauheim, German                                  October 2015 
Diab, A; Foca, A; Jalaguier, P; N’Guyen, L; Isorce, N; Zoulim, F; Andrisani, O. M & 
Durantel, D. Polo-like-kinase 1, a positive effector in hepatitis B virus replication. The 
International Liver Congress, E-Poster, Vienna, Austria.         April 2015 
Diab, A; Foca, A; Jalaguier, P; N’Guyen, L; Isorce, N; Zoulim, F; Andrisani, O. M & 
Durantel, D. Oral Presentation. Polo-like-kinase 1, a positive effector in hepatitis B 
virus replication: therapeutic implications. Oral Presentation. ANRS Hepatitis 
meeting. Paris, France.                                January 2015 
Diab, A & Andrisani, O. M. Targeting Plk1 for Hepatitis B Virus Treatment. Purdue 
University Center for Cancer Research. Poster, West Lafayette, IN.    November 2014 
Diab, A & Andrisani, O. M. The nuclear proteins SUZ12 and ZNF198 in Hepatitis B Virus 
(HBV) replication. Phi Zeta Poster Session, College of Veterinary Medicine, Purdue 
University West Lafayette, IN.             April 2013 
Diab, A & Andrisani, O. M. Understanding the Role of PLK1 Phosphorylation of 
Chromatin Regulators in pX-Mediated Liver Cancer. Purdue University Center for 
Cancer Research, Poster, West Lafayette, IN.            September 2012 
Diab, A & Andrisani, O. M. Understanding the Role of PLK1 Phosphorylation of 
Chromatin Regulators in pX-Mediated Liver Cancer. Purdue Interdisciplinary 
Graduate Program Spring Reception, Poster, West Lafayette, IN.                  April 2012 
Diab, A & Andrisani, O. M. Understanding the Role of PLK1 Phosphorylation of 
Chromatin Regulators in pX-Mediated Liver Cancer. Chronic Disease Research Poster 
Session, Purdue University College of Human and Health Sciences             March 2012 
Diab, A & Zada S. The efficacy of Praziquantel, Furoxan & Auranofin as antischistosomal 
drugs on fresh S. mansoni worms. Poster and Oral Presentation. Sixth Annual Biology 
Senior Thesis Conference, AUC, Cairo, Egypt.                                                      May 2010 
 
Language Skills:  
Languages: Arabic (mother tongue), English (native speaker), French (working 









Model United Nations Coach for high-school students in Algeria,       Dec 2009- Jan 2010 
 Selected by the U.S. Embassy of Algiers- Cultural Affairs section to train and coach 
a delegation of 6 MUN participants. 
Human Resources Director and Upper Board Member, AYB (Alashanek Ya Balady), AUC 
Egypt.                                                                                                  Sep 2009- May 2012 
 Alashanek Ya Balady is and NGO that aims at sustainable development of the 
under-privileged community of Ain El Seera in Cairo. 
English Teacher for youth in the underprivileged Old Cairo area, Help Club, Egypt    2009 
Co-organizer. Youth Leadership Initiative, Vodafone HR Directory. 3, 10, 17, 24 Oct 2009 
• Recruited 30 AUC students to attend the sessions on Leadership. 
•     Attended the leadership sessions as a participant. 
 
Delegate. 1st Lebanon International Model United Nations (LEBIMUN 2009), Beirut, 
Lebanon,                   26-31 July 2009 
 
Participant. Middle East Partnership Initiative (MEPI) Student Leaders Alumni 
Conference. Cairo, Egypt, organized by US Department of State.  3-7 March 2009  
Volunteer, children program- HSC pediatric center- Washington DC. USA,          July 2008  
• Organized and coached soccer trainings and tournaments for patients. 
 
MEPI Leadership Training, Georgetown University, Washington DC., USA,  July-August 
08 
 Nominated by the American Embassy to represent Egypt in a youth leadership 
program including political, community service and leadership aspects. 
 Enrolled in summer courses at Georgetown studying Middle East and American 
politics. 
 Interacted with young Arab leaders from 20 Middle East countries and increased 
my multi-culturally- diverse exposure. 
